Exploring low molecular weight molecules produced by hookworms (Ancylostoma caninum) and their use as anti-inflammatory agents by Shepherd, Catherine
ResearchOnline@JCU 
This file is part of the following work:
Shepherd, Catherine (2017) Exploring low molecular weight molecules produced
by hookworms (Ancylostoma caninum) and their use as anti-inflammatory agents.
PhD Thesis, James Cook University. 
Access to this file is available from:
https://doi.org/10.25903/5be0cf4ac8546
Copyright © 2017 Catherine Shepherd
The author has certified to JCU that they have made a reasonable effort to gain
permission and acknowledge the owners of any third party copyright material
included in this document. If you believe that this is not the case, please email
researchonline@jcu.edu.au
i 
 
JAMES COOK UNIVERSITY 
 
 
Exploring low molecular weight 
molecules produced by hookworms 
(Ancylostoma caninum) and their use as 
anti-inflammatory agents 
PhD Thesis 
November 2017 
 
 
 
 
Catherine Shepherd 
College of Public Health, Medical and Veterinary Sciences 
Australian Institute of Tropical Health and Medicine 
James Cook University 
  
 
Supervisors 
Primary Supervisor: Professor Alex Loukas 
Professor Norelle Daly 
Doctor David Wilson 
Doctor Phurpa Wangchuk 
ii 
 
Acknowledgements 
Support comes in many forms; intellectual, emotional and substantive and there are many 
to mention and thank on the journey to a thesis. It is impossible to name them all 
individually, so I will not try. 
I would like to thank my supervisorial team who have brought their diverse and broad range 
of skills to the yard. Without exception they have provided encouragement and direction to 
my project. It is reflection on them the great teams they have gathered around them; they 
have unfailingly provided advice and guidance to me. Without them this project would not 
have been possible. Thank you. 
I would like to take a little space to thank the assistance of the JCU Cohort program. The 
hard work of a few dedicated individuals has provided a supportive framework and 
encouragement to others and me when milestones seemed so far away. They were able to 
provide support in ways other bodies could not. Thank you. 
Particular thanks go to the vets that have assisted with my work. Dr Owen Lavers and his 
team at Earlville Vets were able to help at a particularly difficult time in the project and this 
was appreciated. The assistance of Dr Con Constainanou from the Veterinary School, JCU 
Townsville has been crucial to my research and the ongoing collaboration that has resulted 
will no doubt result in many fruitful research projects. Thank you. 
I would like to thank my life partner David. The last four years have not been an easy path 
and I would like to thank him for forgiving my forgetfulness, frustration, my generally 
annoying behaviour, as well as whispering in my ear, “A good thesis is a submitted thesis”. 
He has provided support in ways that are difficult to list here and probably endless. Thank 
you. 
Thanks to various friends and hangers on you know who you are. Doctoral studies run in 
part on coffee, wine, and whinging. Thank you for providing fuel. 
Finally, I would like to acknowledge the animals that have contributed to this study without 
whom this thesis would not been possible. Bene vale canis. 
Thank you. 
 
 
 
 
iii 
 
Statement of the Contributions of 
Others 
Every reasonable effort has been made to gain permission and acknowledge the owners of 
copyright material. I would be pleased to hear from any copyright owner who has been 
omitted or incorrectly acknowledged. 
I acknowledge the help of the following people/institutions: 
Nature of assistance Contribution 
(this list is not exhaustive) 
Name, Affiliation 
Intellectual Support Proposal Writing 
 
Ethics Application 
 
Experimental Design and 
Supervision 
 
 
 
Misc. Project input 
Prof Alex Loukas, JCU 
 
Prof Alex Loukas, Dr 
Severine Navarro, JCU 
Prof Alex Loukas, JCU 
Prof Norelle Daly, JCU 
Dr David Wilson, JCU 
Dr Phurpa Wangchuk, JCU 
Dr Paul Giacomin, JCU 
Dr Kate Miller, JCU 
Dr Severine Navarro, JCU 
Dr Javi Sotillo, JCU 
Financial Support Australian Postgraduate Award 
Top-up Scholarship 
Stipend Support 
Federal Government 
James Cook University 
Prof Alex Loukas, JCU 
Data 
Collection/Technical 
Support 
Animal Handling Training, TNBS 
colitis model training 
 
Animal care 
 
Quarantine Facility Training 
Collection of hookworms 
 
 
HPLC and MS/MS Training 
Polar Metabolite Analysis 
NMR Analysis 
Dr Severine Navarro, Dr 
Ivana Ferreria, JCU 
 
Mr Atik Susianto, Mr 
Bjoernar Hauge, JCU 
Luke Becker, JCU 
Dr Con Constantinoiu, JCU 
Dr Owen Lavers, Earlville 
Veterinary Practice 
Dr David Wilson 
Bio21 Institute, Melbourne 
Prof Norelle Daly, JCU 
Data Analysis LCMS Data analysis 
 
Polar Metabolite GCMS  
 
PCR-RT Data analysis 
NMR Data analysis 
Dr David Wilson, JCU 
Dr Javi Sotillo 
Mr Kon Kouremenos, Bio21 
Institute, Melbourne 
Ms Martha Cooper, JCU 
Prof Norelle Daly, JCU 
iv 
 
Abstract 
The dog hookworm, Ancylostoma caninum is an experimental model for human hookworm. 
Relying on the ancient association of hookworms and their host and guided by the 
observations of the “Old friend’s Theory” these parasites may be a valuable source for 
therapeutic discovery. This thesis is designed to study the small molecules produced by the 
adult hookworm with particular emphasis on identifying molecules with anti-inflammatory 
potential using experimental techniques not applied to any helminth previously.  
To achieve this primary, aim the small molecular component of hookworm 
excretory/secretory fluid was extracted and separated. These fractions were separated 
using the small molecule techniques commonly employed in the study of ethnobotanicals. 
These extracts were tested in a mouse chemical colitis model known to exhibit Th1/Th17 
responses, Th2 type hypertrophy, and innate immune response. This model is employed 
here as a broad-based bioactivity screen for immunomodulatory potential. Using these 
combined techniques, it was possible to identify several small molecule fractions exhibit a 
protective effect in TNBS mouse model of intestinal inflammation. These fractions have the 
potential to reveal therapeutic candidates for inflammatory disease. 
During this study it was also possible to characterise the small molecule secretome of A. 
caninum using gas chromatography/ mass spectroscopy. This characterisation has been able 
to describe over 300 features never described for A. caninum. The majority of the molecules 
have no currently described immunomodulatory activity. This includes low-molecular 
weight molecules hereto undescribed. In addition to this, a number of metabolites were 
identified, and these could be assigned to the described pathways of the human hookworm 
Necator americanus. 
It was possible to demonstrate that the small molecule milieu produced by adult dog 
hookworm is complex. Dog hookworm excretory/secretory material contains small molecule 
components that when administered to mice can prevent chemical colitis. These molecules 
present a novel pool of small molecules that have the potential to be used to treat 
inflammatory disease. 
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Chapter 1 
Introduction 
1.1 Ancient associations meeting modern therapeutic needs: 
Inflammatory bowel disease – increasing incidence and burden drives a 
need for new therapeutics 
The autoimmune, allergic, or immune-mediated diseases resulting from chronic 
inflammation are typified by altered immune responses that can adversely affect any part of 
the body. Triggers of inflammatory diseases have revealed dysregulated immune response 
with an underlying genetic propensity. The incidence of inflammatory disease is on the rise 
globally and expected to be a significant global health burden by 2025 [1]. Specifically, 
Inflammatory Bowel Disease (IBD) has the highest prevalence in developed nations and is 
increasing as countries change their socio-economic make up and urbanise [2]. With the 
advent of newer therapeutics, better outcomes for patients have been achieved but the 
cost of treatment has increased considerably [3]. My research interests lie in the discovery 
of helminth-derived therapeutics which could be targeted for the treatment of IBD, with 
particular emphasis on small molecules that are easier to administer and likely more cost 
effective than many of the current protein therapeutics (biologics). 
1.2 Treatments for IBD – treatments not cures 
IBDs are the group of inflammatory diseases of the alimentary tract that include both 
ulcerative colitis (UC) and Crohn’s disease (CD). Individuals that suffer from UC and CD 
experience a variety of debilitating symptoms including diarrhoea, cramping, pain, 
malabsorption, bloody stools, septic episodes, and increased risk of carcinoma. The 
economic burden (both direct and indirect) for these individuals and society is considerable 
[4]. While the clinical presentation of these two diseases can be similar the immunological 
profile of CD and UC is quite different, as summarised in Table 1.1. Essentially CD is a T 
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helper (Th) 1/Th17 dysfunction while UC is a modified-Th2 type hypertrophy. It is 
worthwhile highlighting that the TNBS colitis model utilised as a screening platform here 
clinically presents as an acute bout of UC. However, the cytokine response is a mix of 
Th1/Th17 with a Th2 type patchy hypertrophy (Table 1.1) reflecting neither the cytokine 
profile of UC or CD. This reduces the utility of TNBS as a mechanistic model but provides a 
broad-based screening for a large number of therapeutic targets. 
 
Ulcerative 
Colitis (UC) 
Crohn’s Disease 
(CD) 
TNBS Colitis 
TNBS/Ethanol 
Ref 
Immunological Basis 
Atypical Th2 
response 
Th1/Th17 
mediated disease 
with implicated 
innate immune 
responses 
Th1/Th17 with a 
Th2 type patchy 
hypertrophy 
[5, 6] 
Disease ameliorated 
by 
Blocking T cell 
responses 
Blocking IL-12p40 
or TNF 
Anti-IL-12, Anti-
TNF and IL-10 
[7, 8] 
Cytokine response     
Il-1β    [9] 
IL-2    [5, 10] 
IL-4 ±   [10] 
IL-5 ±   [10] 
IL-6   ± [5, 9, 11] 
IL-8    [12] 
IL-9    [13] 
IL-10    [11] 
IL-12p40    [5, 9, 11] 
IL-13    [14] 
IL-17A    (chronic) [5, 11, 15] 
IL-18    [9] 
IL-21  ±  [11] 
IL-22     
IL-23 ±   [9, 11] 
IL-27  ±   
IL-33     
IFN-γ    [5, 7, 11] 
TNF    [9, 11] 
TGF-β    [11] 
Table 1.1 Comparison of cytokine responses in the inflammatory bowel diseases 
Ulcerative Colitis and Crohn’s Disease, and the TNBS chemical colitis mouse model. 
Arrows indicate increased (upwards facing) or decreased (downwards) expression of the 
cytokine in the respective human conditions and mouse model. 
Current treatments for IBD include non-specific anti-inflammatory drugs (aminosalicylates 
and corticosteroids), immunosuppressant drugs (Azathioprine, Cyclosporine, Methotrexate), 
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and monoclonal antibody biologics (proteins) that dampen inflammatory responses by 
targeting tumour necrosis factor (TNF) such as infliximab, adalimumab and golimumab, or 
anti-integrin biologics such as natalizumab and vedolizumab. In addition, antibiotics, 
nutritional supplements, and pain relief are used to manage the symptoms of IBD. The final 
treatment option presented to patients is surgical removal of the affected section of colon. 
It is worth noting that none of these options are curative. Ideal treatments would be well 
tolerated, easy to administer and have low complication rates. 
Indications are that the initiation of IBD is multi-faceted; involving environmental factors, 
genes and immune status with a growing recognition that due to this complexity, 
individualised treatment is the most effective approach in management of IBD [16]. It is due 
to this complex interplay that IBD can be refractive and treatment can have serious side 
effects. For example, anti-TNF biologics are contraindicated in individuals with tuberculosis, 
fungal infections and hepatitis B as well as being implicated in the formation lymphomas 
and cancers because they alter the ability of the patients’ immune system to respond 
appropriately when faced with infections, as well as the ability of the adaptive immune 
system to function effectively. 
Better understanding of the underlying pathological processes of IBD has meant that newer 
therapies can be designed to target upstream initiators of inflammation. The focus on the T 
cell family cytokines, leukotrienes and signalling molecules associated with IBD have 
produced a number of therapeutic options [16]. For example, targeting the IL-12 family, 
specifically the p40 subunit of IL-12/23 is associated with reduction in Th1/Th17 driven pro-
inflammatory responses which can be used to treat both UC and CD [17]. Currently, a phase 
3 trial is recruiting for moderate to severe UC using ustekinumab which specifically targets 
IL-12/23p40 (https://clinicaltrials.gov/ct2/show/NCT02407236) and phase II trials for CD are 
being conducted [18]. There is considerable effort to generate biologics that can ameliorate 
inflammatory disease that in turn can be tailored to an individual’s cytokine/immune 
dysfunction. 
There are a number of issues with biologics. Infusion reactions to biologic therapeutics are 
considered a significant risk of therapy [19, 20]. Treatment regimens are expensive and 
difficult to administer; generally, patients have to be admitted to hospital for treatment. 
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These drugs must be administered by injection and closely monitored by highly trained 
individuals. Biologics are expensive to make and must be stored and transported 
appropriately. Comparing current cost of treatment of Crohn’s disease, biologics cost 45 
USD/day compared with 2 USD/day for traditional treatments [21]. This is seen for 
treatments of other inflammatory bowel diseases with costs in the thousands per year for 
biologics and hundreds of dollars for traditional treatments like steroidal drugs and 
methotrexate [22]. In Europe, biosimilars used for the treatment of luminal Crohn’s disease 
such as infliximab can cost €34,500-€77,062 for five years of treatment per quality adjusted 
life years while a combined therapy of infliximab-adalimumab can cost up to €206,226-
€363,232 for the same period [23]. The characteristics of biologics do not make them 
suitable for use in developing nations or remote regions. As such, the specific focus of this 
thesis is the discovery of targeted immunomodulatory small molecules tailored for safety 
and efficacy by millennia of host-parasite co-evolution that could be developed as novel, 
cost effective, and efficacious treatments for IBD. 
1.3 Drug discovery – ancient associations outclass modern drug discovery 
methodologies 
Small molecules are good candidates for drugs. According to Lipinski’s rule of five [24] there 
is a sweet spot of size, solubility, acidity and permeability which determines maximum 
bioavailability of a molecule, or it’s “druggability”. Biologics fail miserably on the Lipinski 
rule; they are very large hydrophobic molecules that have low bioavailability [25]. Ideal 
treatments for IBD would be orally available, well tolerated and targeted to the specific 
tissues affected. With this aim, my research explores the potential of novel small molecules 
sourced from ancient associations. Using a mouse colitis model as a bioactivity screen it is 
possible to rapidly assess crude extracts, sub-fractions of mixtures and individual molecules 
for their immunomodulatory potential. 
Modern drug discovery methods have proven to have low success rates. In silico 
computational drug design is limited due to convergent algorithms that are partly based on 
Lipinski, as well as our understanding of structure-activity-relationships (SAR) and the 
pathogenesis of the disease process. The result is a limited palate of chemical structures 
from which therapeutics are generated and a very low conversion rate from predicted 
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structure to drug candidate [26]. These molecules when generated can prove to be toxic 
and have low bio-acceptance [27]. To counter these problems ad hoc screening of small 
molecules sourced from biological sources (plants, animals, sponges, fungi etc.) has been 
attempted. Molecules from biological sources have highly diverse and novel structures. The 
downside is that novel molecules may be difficult to synthesise. Unsurprisingly, using an 
untargeted approach has resulted in very few candidates that have been successfully 
developed as drugs. 
Pools of molecules of proven bioactivity are the ethnobotanicals. Traditional herbal 
medicines have been rich sources of small molecules. There are many examples of small 
molecules that have been developed as therapeutics. Traditional herbal medicines have 
been by far the richest source of small molecule therapeutics represented in the modern 
pharmacopeia [28]. Ethnobotanicals have an added advantage in that their bio-acceptability 
and toxicity has been assessed at least at a crude level. Isolating individual components and 
screening for specific activity can be guided by the traditional use of the herb.  
There are dozens of examples of traditional herbal medicines which have yielded modern 
drugs, often linked with their traditional use [29, 30]. Examples include; the Chincona spp. - 
Quinine (treatment for malaria); Ephedra sinica - Ephedrine; Melilotus officinalis – 
Coumadin; Papaver somniferum – Codeine; Taxus brevifolia - Paclitaxel; Salix alba – Aspirin 
and Camelia sinensis – Theophylline. The ethnobotanicals are a considered a fruitful source 
of novel therapeutics compared to untargeted screening of plant material or screening of 
molecules synthesised from in silico prediction [29]. Screening is often guided by the 
traditional use of the herbal medicine.  
In this thesis I aim to exploit the techniques used to isolate and identify bioactive molecules 
from plants and apply them to the small molecules produced by hookworms. I have shown 
that capnoidine, isolated from Corydalis dubia, is able to prevent many of the pathological 
changes associated with Trinitrobenzene sulphonic acid (TNBS)-induced chemical colitis in 
mice [31]. This proof of concept screening of a small molecule ethnobotanical supports the 
use of a bioactivity screen to demonstrate the immunomodulatory potential of natural and 
ancient associations. 
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1.4 Parasites – Humans oldest friendship 
Ancient associations are not limited to ethnobotanicals; parasites are the most enduring and 
ancient association that humans have. The soil transmitted helminths (STH), particularly the 
hookworms, have such a long association with humans that they are considered “heirloom 
parasites” [32]. It is certain that hookworms have been associated with humans since they 
were hominids, with an intimate evolutionary relationship that harks back at least two 
million years. Observations of the co-evolutionary relationship between humans and their 
parasites has resulted in the theoretical basis of much of the following research and is 
encapsulated in the “Old friends’ theory”. 
In 2002, Graham Rook coined the term “Old friends” theory to describe the requirement for 
exposure to organisms like hookworms, microbes, and environmental factors to drive 
correct immune development during childhood. Absence of exposure to organisms like 
hookworms is associated with immune dysfunction and the development of inflammatory 
responses later in life [33, 34]. The epidemiological evidence supports the “Old Friends” 
theory and the observation that the elimination of helminths increases the risk of 
inflammatory disease and immune dysfunction. In 1989 David Strachan postulated the 
“Hygiene Hypothesis” to explain the increase in inflammatory and allergic disease due to 
urbanisation [35]. This has evolved into a complex multi-pronged theory with a core position 
which states that a healthy and functioning immune system is reliant on early exposure to 
diverse factors [36, 37]. A refinement of this is the “Old Friends” theory [38] where the 
significance of exposure to parasites in this process should be not be underestimated. 
The hookworms, like many STH, actively induce tolerance by producing molecules that 
interact with the host immune system at the site of their parasitism. In the case of 
hookworms, it is their adult stage that attaches to the gut wall for feeding and breeding that 
is of most interest for developing IBD therapeutics. In my review [39] of the 
immunomodulatory components produced by helminths, I discuss the theme of altered host 
immune response in the context of the molecules that helminths produce. It is apparent 
that the excretory/secretory (ES) component produced by helminths is a complex mix of 
small organic molecules, proteins, peptides, glycans and lipids. We currently know little 
about the immunomodulatory function of the low molecular weight component of ES (LES) 
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however, we know that successful helminths, particularly the hookworms, induce a 
“modified Th2” response. Due to the limitations of omics databases and bioinformatics 
workflows [39], it is necessary to screen LES for defined bioactivities to identify its 
immunomodulatory components. In the research that follows, I present evidence that LES 
from hookworms contains immunomodulatory small molecules. These molecules may 
contribute to host tolerance and may be candidates for therapeutic development. 
Additionally, characterisation of hookworm LES builds upon both secretome and 
metabolomics databases and will hopefully trigger similar endeavours for other helminth 
parasites. 
 
Figure 1.1. This figure shows the global distribution of autoimmune disorders (left) 
versus the distribution of hookworm endemic areas (right). From Molodecky et al. 2012 [2]. 
It has been noted that the incidence of inflammatory disease is highest in countries where 
endemic exposure to helminth is at its’ lowest (Figure 1.1.) [2, 33, 40, 41]. There is 
epidemiological evidence to support the observation that the removal of helminths results 
in a dysregulation of the immune system. Large studies show that as a population urbanises 
and exposure to helminths is reduced, an increase in the incidence of inflammatory disease 
is observed [42, 43]. The implication of helminths in this process is documented in mass 
drug administration programs, where removal of helminths is soon followed by an increase 
in allergic and autoimmune disorders [44]. In a study by Kabeerdoss et al. of Crohn’s 
patients in India, patients who were negative for hookworm were more likely to have 
Crohn’s disease than uninfected patients [45]. In South Africa childhood exposure to 
helminths was shown to be protective against IBD [46], and in Papua New Guinea exposure 
to intestinal parasites protects against the development of allergic rhinitis [47]. These 
observations support a growing body of experimental evidence that helminths actively 
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produce immunomodulatory molecules that may be useful therapeutics in the treatment of 
allergic and autoimmune disease. 
While helminth parasites are identified as a significant neglected tropical disease (NTD), 
with soil transmitted helminths (STH) estimated to affect over 2.2 billion people [48, 49], 
their effect is considered more in terms of morbidity than mortality [48]. This is because the 
vast majority of human helminth infections are typified by a partial activation of both the 
adaptive and innate arms of the immune system termed a ‘modified Th2” response. That 
modified Th2 response consists of typical Th2 cytokines and associated cell types (IL-4, IL-5, 
IL-9, IL-13, mastocytosis and eosinophilia), but also features immunoregulatory components 
such as IL-10, TGF-, regulatory T cells and M2 macrophages). A successful parasite is 
benchmarked by its ability to actively skew its host’s immune system to prevent elimination 
and development of immunity [50]. 
This immune skewing results in suppression of the Th1/Th17 axis and induction of a 
‘modified Th2’ response [51] characterised by expansion of both Th2 cells and inducible 
Treg expressing FOXP3, increased IL-10 levels and production of polyclonal IgE by B cells 
[52]. Classical Th1/17 inflammatory responses can damage worms, but at a substantial cost 
in collateral damage to host tissues [53, 54]. Thus, in evolutionary terms, Th2 immunity is 
thought to have arisen from our innate response to tissue damage, with repair responses 
isolating and encapsulating helminths through fibrotic processes while simultaneously 
resolving localised damage. Indeed, hookworms are one of the most adept infectious agents 
at driving regulatory responses. These strategies mean that individual parasites can colonise 
a host for many years while preventing the development of sterilising protective immunity 
and suppressing the onset of inappropriate immune responses to innocuous antigens [52, 
55]. 
1.5 Ancylostoma caninum, a model for human-hookworm interaction 
The dog hookworm, A. caninum, has been used as an animal model for the human 
hookworms. Phylogenetic studies highlight the close relationship between A. caninum and 
the anthropophilic hookworms Necator americanus and Ancylostoma duodenale [56-59]. In 
addition, the lifecycles of A. caninum and A. duodenale are very similar [60] - both have a 
latent stage, faecal-oral transmission, larval hypobiosis and mammary-oral infection. 
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Moreover, hookworms, humans, and dogs present a unique triad that makes the parasites 
of dogs an excellent proxy for human hookworm interaction. This is discussed at length in 
my review of A. caninum and is part of the following literature review. Due to the 
complicated nature of the hookworm lifecycle it is not possible to culture this parasite 
through all stages in vitro. Instead, hookworms must be harvested from the gut of the host 
animal for study. These parasites are then cultured in a supportive media and the ES is 
collected for analysis. I have been able to show herein that LES from A. caninum can prevent 
TNBS-induced colitis, but the in vitro culture conditions are important, and require attention 
if a small molecule research program is proposed. 
Previous culture methods for parasites have focussed on studying parasite physiology and 
the effects of various anthelmintics and used a buffer-based culturing system supplemented 
with dog sera. Using this system it is possible to successfully sustain adult hookworms for 
over 80 days in vitro [61]. However, with the revolution in proteomics and the desire to 
profile ES proteinaceous components, the addition of dog sera became problematic. 
Removal of dog sera led to the addition of a multi-component supplement, RPMI. This 
supplement contains a large number of small molecules as listed in Table 2, and while 
suitable for the culture of hookworms and the harvesting of ES products for proteomic 
study; RPMI-based culturing methods are unsuitable for small molecule profiling. Individual 
ingredients present in RPMI are known to possess immunomodulatory activity (see Table 2). 
It was due to these reasons that a new culture method for the collection of ES was 
formulated for my research program. 
Interestingly, in establishing a new culture system for hookworm omics studies, I showed 
that LES obtained using different minimal media displayed very different levels of anti-colitic 
properties in vivo. Changes in the small molecule milieu produced by these hookworms 
under different culturing conditions inferred considerable metabolic plasticity. 
Understanding the small molecules that hookworms produce during their gut feeding stage 
will enable researchers to not only understand the biology of the host-parasite interaction 
but also has the potential to identify immunomodulatory molecules of potential therapeutic 
value. From the data produced herein, I have been able to build a database of small 
molecules secreted by A. caninum that can be incorporated into other hookworm omics 
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databases and confirm (or refute) the existence of metabolic pathways inferred from 
gene/protein datasets. 
1.6 TNBS chemical colitis in mice – a bioactivity screen for small molecule 
immunomodulatory activity 
Chemical colitis is induced in mice by Trinitrobenzene sulphonic acid (TNBS) administered in 
an ethanoic solution by rectal enema [6]. The ethanol acts to strip the mucosa and disrupts 
the cells, commensal bacteria and gut contents; TNBS, a highly reactive compound, reacts 
with these gut components and haptenizes them. These haptens are then presented to the 
mouse immune system. This initiates a pro-inflammatory cytokine response involving both 
the innate and adaptive immune systems (Table 1.2). An acute model of TNBS – the model 
that is utilised here - clinically presents as an acute bout of UC, however the cytokine 
response is constituted of Th1/Th17 and Th2 pro-inflammatory responses as well as innate 
immune responses. While this broad immunopathologic profile is disadvantageous when 
trying to unpack mechanistic detail, it does present as a valuable platform to screen for 
immunomodulatory activity of small molecules [15]. Additional advantages of the acute 
TNBS colitis model are that it uses small quantities of screening material and has a rapid 
turnaround time of only four days. 
As demonstrated throughout this thesis, the TNBS chemical colitis model provides a means 
of detecting immunomodulatory activity in crude LES from A. caninum. Using small molecule 
separation techniques, it is possible to determine which fractions of LES display anti-colitic 
protection. 
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RPMI Constituent Reported Bioactivity Reference 
Niacinamide Anti-inflammatory [62, 63] 
D-Pantothenic Acid ND - 
Vitamin B12 Anti-inflammatory [64] 
Choline Chloride ND - 
Cyanocobalamin Anti-inflammatory [64] 
D-Biotin ND - 
D-Glucose Pro-inflammatory [65] 
Folic Acid ND - 
Glutathione (reduced) Pro-inflammatory [66] 
Glycine Inhibitory neurotransmitter [67-69] 
Hydroxy-L-Proline ND - 
L-Arginine 
Nitrogen donor for NO2 synthesis, signal 
transduction 
[70] 
L-Asparagine ND - 
L-Aspartic Acid NMDA receptor agonist [71] 
L-Cystine ND - 
L-Glutamic Acid 
Non selective agonist, nutritive 
supplementation 
[72, 73] 
L-Glutamine Anti-inflammatory [74] 
L-Histidine ND - 
L-Isoleucine ND - 
L-Leucine ND - 
L-Lysine Anti-inflammatory [75] 
L-Methionine ND - 
L-Phenylalanine ND - 
L-Proline Induces differentiation [76] 
L-Threonine ND - 
L-Tryptophan Bioactivity - antidepressant  
L-Tyrosine ND - 
L-Valine ND - 
myo-Inositol Improves insulin sensitivity [77] 
p-Aminobenzoic acid Mild anti-inflammatory [78] 
Phenol Red ND - 
Pyridoxine ND - 
Riboflavin Anti-inflammatory [79, 80] 
Thiamine Anti-inflammatory [81, 82] 
L-Glutamax™ – L-alanyl-L-
glutamine† 
ND - 
Table 1.2. The literature-reported bioactivity of RPMI components. Bioactivity in this 
case is defined as pharmacological activity and not biomolecular interactions or pathways. 
Searches were carried out on both NCBI and Chemspider databases. ND – not reported 
† Glutamax™ is included as part of RPMI complete media. 
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1.7 This Study  
Interest in host-parasite interactions was initially borne from the extensive morbidity and 
mortality caused by parasites. It has become apparent that parasite success, principally gut 
dwelling parasites, is due to their ability to actively induce immune tolerance at the site of 
attachment. In this body of research, I focused on identifying a pool of small molecules of 
parasite origin that are derived from ancient associations of humans and hookworms. As 
proof-of-concept that the proposed model was valid for identifying anti-colitic small 
molecules, I turned to ethnobotanical compounds that were available in my lab and utilized 
the TNBS colitis mouse model as a bioactivity-screening tool.  
Hypothesis underpinning this thesis: 
The dog hookworm, Ancylostoma caninum, secretes low molecular weight compounds 
that have anti-inflammatory properties. 
The first aim of this research was to assess whether the low molecular weight ES (LES) 
obtained from the dog hookworm, A. caninum, confers protection in the murine TNBS 
chemical colitis model. To do this a suitable culture method had to be devised for the 
screening of small molecules. Further to this, the nature of the protection needed to be 
determined by assessment of cytokine profiles. Using small molecule techniques, 
components of LES were extracted and purified and assessed for protective potential. I was 
also able to demonstrate the utility of the TNBS colitis model for determining anti-colitic 
efficacy of individual small molecules, as demonstrated using the plant-derived 
isoquinolone, capnoidine. Finally, using small molecule metabolomic techniques, the LES 
from A. caninum was characterised and annotated into known metabolic pathways. 
1.8 Primary experimental aims of this research 
 
1
• Isolate LES from A. caninum and show protection in a TNBS 
colitis model.
2
• Gain insights into how these molecules interact with the immune 
system.
3
• Separate LES into fractions and determine which of these confer 
protection in TNBS colitis.
4
• Characterise molecular components of protective fraction.
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Chapter 2 
Literature Review 
Preamble 
This chapter situates this thesis in the current research agenda and primarily draws on two 
review articles produced during the course of this investigation. 
The first article explores the relevance of the dog hookworm as a suitable model for 
translational research (manuscript under peer review at Parasites and Vectors). 
The second article explores the interest in parasite molecules as immunomodulators and as 
sources of therapeutic agents [39]. 
These articles have been edited to allow for ease of reading. Portions of these articles have 
been moved to relevant chapters (as indicated). 
 
Outputs from this chapter 
Of dogs and hookworms: man’s best friend and his parasites as a model for translational 
biomedical research. Shepherd C, Wangchuk P, Loukas A. ACCEPTED FOR PUBLICATION; 
Parasites & Vectors 
Identifying the immunomodulatory components of helminths. Shepherd C, Navarro S, 
Wangchuk P, Wilson D, Daly NL, Loukas A: Parasite Immunology 2015, 37(6):293-303. 
PUBLISHED WORK 
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The following writing has been submitted to the journal Parasites and Vectors. Of dogs and 
hookworms: man’s best friend and his parasites as a model for translational biomedical 
research. Shepherd C, Wangchuk P, Loukas A. ACCEPTED FOR PUBLICATION: Parasites and 
Vectors. Permission to publish here has been obtained. 
2.1 Outline 
I present evidence that the dog hookworm (Ancylostoma caninum) is underutilised in the 
study of host-parasite interactions, particularly as a proxy for the human-hookworm 
relationship. The inability to passage hookworms through all life stages in vitro means that 
adult stage hookworms must be harvested from the gut of their definitive hosts for ex vivo 
research. This makes study of the human-hookworm interface difficult for technical and 
ethical reasons. The historical association of humans, dogs, and hookworms presents a 
unique triad of positive evolutionary pressure to drive the A. caninum-canine interaction to 
reflect that of the human-hookworm relationship. Here I discuss A. caninum as a proxy for 
human hookworm infection and situate this hookworm model within the current research 
agenda, including the various omics applications and the search for next generation 
biologics to treat a plethora of human diseases. Historically, the dog hookworm has been 
well described on a physiological and biochemical level, with an increasing understanding of 
its role as a human zoonosis. With its similarity to human hookworm, the recent 
publications of hookworm genomes and other omics databases, as well as the ready 
availability of these parasites for ex vivo culture, the dog hookworm presents itself as a 
valuable tool for discovery and translational research. 
 
Introduction 
“His name is not Wild Dog any more, but the First Friend, because he will be our friend for 
always and always and always.” Rudyard Kipling  
2.2 The current hookworm research agenda 
Over one-third of people on the planet harbour a parasitic helminth [49, 83]. Helminth 
infections are responsible for a host of morbidities that trap people in a cycle of poverty. 
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Moreover, parasitic diseases kill millions of people each year, primarily in developing 
countries of the tropics [84, 85]. Over 80 percent of helminth infections are caused by soil 
transmitted helminths (STH) [86]. Elimination of STH in Western society started in the early 
20th century as a result of better sanitation and public sewerage programs [87]. The problem 
of helminth infections in developing nations was recognised, but it was not until the advent 
of anthelmintic drugs and the World Health Organisation initiatives of the 1950s that 
widespread elimination of STH was attempted [88-91]. 
As we approached the 21st century, rather than celebrating the worldwide demise of STH, 
drug failures and incomplete coverage has meant the persistence of this foe. Previously, 
effective drugs like mebendazole and other benzimidazole anthelmintics are now unable to 
completely eliminate STH infections [49, 92-99]. Historical evidence suggests that drugs 
alone will not result in the elimination of STH infections and the development of resistance 
to benzimidazoles in gastrointestinal nematodes of livestock [100-102] is a major point of 
concern for human STH infections, due to the reliance on albendazole for human hookworm 
treatment. Indications are that other means of control should be at the fore of research and 
development agendas [84, 103-105]. Two such avenues are the identification of new 
anthelmintic compounds [106, 107] and the development of vaccines that are effective 
against STH [84, 108]. Key to this research is a fundamental understanding of the 
interactions between helminths and their environments as well as the key signals that 
helminths require from their hosts to facilitate their extraordinary parasitic existence [91]. 
Characterising parasitic helminths at a deep molecular level will reveal vulnerable pathways 
that can be exploited by novel drugs [91, 109], and molecules of immutable vaccine antigen 
potential [110, 111]. 
Developing nations are not the only benefactors of hookworm research. Indeed, in 
developed countries there is an increase in the incidence of autoimmune and allergic 
diseases that has been linked to lack of exposure to pathogens such as STH [33]. It is 
apparent from epidemiological studies [43, 44, 112-114] and clinical trials [115, 116] that 
the immunomodulatory inputs provided by exposure to STH and other pathogens assist in 
the development and maintenance of a healthy immune system in humans. Characterising 
helminth-driven immunoregulation at a molecular level will shed light on the aetiology of 
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inflammatory diseases, and may uncover important disease/pathology pathways that can be 
targeted by helminth-derived therapeutics [39, 117]. 
The identification of a suitable model for the study of such a broad research agenda 
examining both the benefits of iatrogenic helminth infections and the pathogenesis of STH 
infections needs to be carefully considered. The benefit is the generation of a large amount 
of translatable research data coupled with an economy of scientific effort and resources. 
Fruitful models ideally need to be naturally occurring (i.e. not a human parasite manipulated 
to survive in experimental animals) and closely resemble the relationship between a STH 
and its human host. The human-hookworm-dog axis reflects an intimate evolutionary 
relationship between three organisms, a triad that presents a naturally selected model for 
integrated research. The dog hookworm, primarily Ancylostoma caninum, is discussed in this 
context in this review. 
2.3 Of humans, hookworms and hounds – the relationship between 
humans, hookworms, and dogs is enduring and nuanced. 
For thousands of years (estimated to be anywhere between 14,000 and ~35,000 years 
[118]) humans and canines have shared the same evolutionary drivers. The process of 
domestication has resulted in positive selective pressure on dogs to be more like humans 
for thousands of generations [119-121]. Genetic evidence suggests that dogs were 
domesticated from wolves [120, 122], with successive domestication events occurring over 
at least 33,000 years [118]. Importantly, dogs accompanied humans over the threshold from 
hunter gatherers to agricultural based societies, and this close association with humans has 
meant that dogs have evolved to tolerate diets rich in starch [123]. Co-habitation between 
humans and dogs has resulted in shared nutritional, bacterial and pathogenic environments 
[119, 121, 124], making dogs a natural animal model for human disease [125]. Figure 2.1 
illustrates the triad relationship of hookworms, humans, and canines. Sharing environments 
with each other increases the risk of cross-infection with each other’s parasites. We know 
that Strongyloides, Toxocara, tapeworms, and hookworms can be passed from dogs to 
humans and bidirectional transfer occurs in some cases, acting as pools for reinfection. 
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Figure 2.1. The human-hookworm-dog relationship is defined by a long association. 
Positive evolutionary pressure on canines has caused them to adapt to human environments. 
Hookworms have likely had conflicting immunogenic environments during cross-infection 
events between humans and dogs. In the ~14,000 years of association (conservative estimate) 
it is theoretically possible to have nearly 73,000 generations of hookworms in this timeframe. 
2.4 Dogs as functional models for human disease 
The parallel evolution between dog and human may have driven the predisposition to 
autoimmune diseases through antagonistic pleiotropy [41]. Diseases that have underlying 
similarities to human disease can be utilised for the study of aetiology and treatment. 
Genetic bottlenecks that have occurred in dog breed conformation have meant that many 
dog breeds are good models for both monogenic and complex genetic human diseases [48]. 
For example: 
• Nova Scotia duck tolling retrievers develop canine systemic lupus erythematosus 
(SLE) which is homologous to human SLE [48] 
• Osteogenesis imperfecta (brittle bone disease) in beagles and golden retrievers 
(polygenic disease) [49, 50] 
• Several dog breeds (Pembroke Welsh corgi, Boxer, Rhodesian ridgeback, German 
Shepherd dog, and Chesapeake Bay retriever) develop canine degenerative myelopathy, an 
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amyotrophic lateral sclerosis-like disease that has similar underlying genetic basis in humans 
(sod1 gene) [51] 
• Diseases such as narcolepsy [52], cancers [53, 54] and obsessive-compulsive disorder 
[55] that occur in humans have the same underlying genetic basis in dogs 
Diseases like diabetes that occur in both humans and dogs are polygenic with similar 
underlying single nucleotide polymorphisms (SNPs) in T helper 2 type cytokines, reflecting 
the complex environmental and genetic sequelae in the development of this disease [56]. 
Similarly, Dilated Cardiomyopathy (DCM) is associated with a large number of homologous 
genes in both humans and canine breeds [57], making these dogs excellent models for the 
study of DCM in humans. These parallels between human and dog diseases mean that 
canine models provide identification, diagnostic and therapeutic research opportunities in a 
naturally occurring animal model.  
The case of dogs and inflammatory bowel disease (IBD) is a little more confounding. Dogs 
with spontaneous IBD have similar symptoms and clinical presentation to humans with the 
disease [58, 59], yet the underlying basis of these diseases has not been identified. In the 
case of risk for gluten sensitivity in dogs there has been no link to the Major 
Histocompatibility Complex (MCH) genes [60], as has been found in humans with Coeliac 
Disease [61, 62].  
Despite the established value of dog-human disease models, canine models are yet to be 
fully exploited as functional models for human hookworm disease. One exception is the 
Human Hookworm Vaccine Initiative, which used the A. caninum-dog model [63] for 
identifying molecules that could be candidates for human hookworm vaccines [3]. 
2.5 Hookworms are a large group of closely related organisms 
In humans, the term “hookworm” is often used to refer to Necator and Ancylostoma 
interchangeably even though there are several distinctions as highlighted in their lifecycles, 
as described in Figure 2.2. These organisms are grouped together based on clinical 
presentation, the similarity of the organisms (in both appearance and lifecycle) and their 
success as parasites (Table 1.1.). Physically, hookworms can appear similar, with Necator 
americanus and Ancylostoma duodenale ova being difficult to distinguish visually. 
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Phenotypic similarities can mean that species that have large genetic separation can appear 
physically alike, for example Ancylostoma braziliense and Ancylostoma ceylanicum have 
identical mouthparts in the adult stage, making it impossible to accurately identify species 
without genetic tools [126, 127]. This means previous attributions of pathogenesis and 
distribution limits may be more complex than assumed, and in some cases flawed [127]. 
 
Figure 2.2 Hookworm lifecycles 
Lifecycle A – Ova contained in infected faeces hatch in soil and larvae live freely for up to 
two moults. Third-stage larvae (L3) come in contact with skin and penetrate the epidermis. 
Migrating through the lymphatic and circulatory system, L3 reach the vasculature of the lung, 
whereupon the break through the alveolar spaces and creep up the trachea. Larvae mature en 
route to the upper gastrointestinal tract via the pharynx and become fifth-stage larvae in the 
duodenum. Once attached to the small intestine the sexually dioecious parasites feed, mature 
to reproductive capacity and mate. Eggs produced by the female worm are then shed in 
faeces. 
Alternatively, the free-living larvae are capable of infection through the oral route. 
These organisms are capable in some cases of latent stage/hypobiosis and trans-mammary or 
placental transmission.  
Lifecycle B - does not include oral transmission. Latent stage/hypobiosis and alternative 
transfection routes are not reported in these organisms. 
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Species Definitive 
Host 
Human 
zoonosis 
Parateni
c host 
Global 
incidence 
Notes Ref 
Ancylostoma 
duodenale 
Human - 
Cat, Dog 
 
Europe, 
Africa, 
India, 
China, Asia, 
Americas 
Lifecycle 
A* as 
described 
in [60] 
Hypobiosi
s 
Wakana 
disease in 
humans 
[128-130] 
Ancylostoma 
caninum 
Dog 
Cutaneous 
infection, 
usually 
asymptomati
c and arrests 
in tissues; 
adult worm in 
gut can cause 
eosinophilic 
enteritis 
- 
Tropical 
and 
subtropical 
regions 
Lifecycle A 
Hypobiosi
s 
[131-133] 
Ancylostoma 
ceylanicum 
Dog, Cat, 
Human 
- Rodent 
Asia, India, 
Sri Lanka, 
Philippines, 
Australia 
Lifecycle A 
[134-136] 
Ancylostoma 
braziliense 
Dog, cat 
 
Cutaneous 
larva migrans 
Rodent 
Brazil, 
Africa, 
India, Sri 
Lanka, 
Indonesia, 
Philippines 
Lifecycle A 
[137, 138] 
Ancylostoma 
pluridentatu
m 
Wild cats, 
Jaguar, 
leopard 
None noted - 
South and 
Central 
Americas; 
thought to 
be 
introduced 
to Florida 
bobcat 
population
s mid-
1950s 
Lifecycle A 
[139, 
140]Dunbar, 
1994 
#3110;Forrester
, 1998 #5444 
Ancylostoma 
tubaeforme 
Cat, 
Lynx 
Cutaneous 
larva migrans 
Rodent Worldwide Lifecycle A 
[141, 142] 
Ancylostoma 
kusimaense 
Badger None noted Dog Japan Lifecycle A 
[143] 
Ancylostoma 
protelesis 
 
Aardwolf Unknown - Africa nd 
[144] 
Ancylostoma 
somaliense 
 
Jackal Unknown - Africa nd 
[144] 
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Table 2.1. The members of the Ancylostomatidae family and their hosts have 
overlapping distributions. Zoonotic disease potential, distribution and pathogenic 
significance are described. Lifecycles A and B are described above. nd – lifecycle is not 
described in the literature. 
The success of hookworms as parasites hinges on their ability to be well tolerated and 
adaptive to their hosts. Hookworms as gut-dwelling parasites gain their nutrition from their 
hosts in the form of blood [62, 63]. To do this they attach to and slice through the gut wall 
where they feed. Ancylostoma is a voracious feeder, estimated to consume between 0.15-
0.23 mL blood/worm/day, whereas Necator consumes ~0.03 mL blood/worm/day [64]. The 
host reacting to injury and the presence of the parasite attempts to expel the parasite 
through innate immune responses such as mucous production, increased peristalsis and 
eosinophilia [65-67]. Despite this, hookworms are usually well tolerated in a healthy host 
[68, 69] because they actively create an area of immune privilege around the site of their 
attachment by secreting a suite of immunomodulatory molecules [39, 70-72]. 
The hookworm genera Ancylostoma and Necator are intimately associated with the history 
of humanity, and it seems these heirloom parasites have evolved with humans from our 
primate ancestors [32, 150]. Such is the close relationship that hookworm ova have been 
used in archaeology to help identify migration routes of humans [32, 150, 151] and supports 
the intertwined immunomodulatory interactions proposed by Rook’s “Old Friends Theory” 
[33]. In a literature survey of Ancylostoma and related species (Table 2.1), a number of 
taxonomically related hookworms were identified. These hookworms occur across a wide 
range of hosts with some species capable of establishing patent infection in dogs, cats, 
golden hamsters and humans (as is the case for A. ceylanicum). The common dog hookworm 
Ancylostoma 
genettae 
 
Genet 
(small 
African 
carnivore
) 
Unknown - Africa nd 
[144] 
Necator 
americanus 
Human, 
Gorilla 
Ground itch - 
Africa, 
India, Asia, 
China, 
central 
America 
Lifecycle B 
[145-147] 
Necator 
gorillae 
Gorilla Unknown - Africa nd 
[147] 
Uncinaria 
stenocephala 
Foxes, 
Wolves, 
Coyotes 
Cutaneous 
larva migrans 
Dog, Cat, 
Rodent 
Temperate 
climates 
Lifecycle B 
[148, 149] 
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(A. caninum) is closely related to the human hookworm species N. americanus and A. 
duodenale. Phylogenetic studies highlight the close relationship between A. caninum, N. 
americanus and A. duodenale [56-59, 152]. In addition, the lifecycles of A. caninum and A. 
duodenale are very similar [60] - both have a latent stage, faecal-oral transmission, larval 
hypobiosis and mammary-oral infection. The presence of a latent stage is important as 
these organisms have a predisposition to chemotherapeutic resistance [153] and are useful 
for the screening of anthelmintic drugs [154].  
*A section of this review has been moved to Chapter 6 for brevity and to provide relevant 
background to Chapter 6 – this section has been framed by (….) *  
Studies of hookworm transition through developmental stages have failed to 
comprehensively identify the triggers that control the penetration, migration and 
maturation in host tissues. Like the human hookworm A. duodenale [155], A. caninum in 
dog somatic tissues can enter hypobiosis, a hibernation-like state often compared to dauer 
formation in the free-living nematode Caenorhabditis elegans [156, 157]. Experimental 
infection of dogs with hookworms has increased our understanding of these processes. For 
example, experimental infection of dogs with A. caninum results in a greater proportion of 
parasites proceeding to hypobiosis in dogs which are immunosuppressed by corticosteroid 
treatment, and cessation of treatment results in resumption of parasite development, albeit 
in a relatively unpredictable manner [154]. The cause of this resumption is unknown, but it 
implies complex molecular/physiological interactions between host and parasite through all 
stages of development. 
The propensity to hypobiosis is a valuable characteristic of a model because hypobiotic 
larvae are less susceptible to anthelmintic drugs [153], presumably due to their ability to 
slow their metabolic processes. In vitro studies of A. caninum show recovery from 
hypobiosis can be induced by exposure to muscarinic acetylcholine receptor agonists and 
cyclic GMP. This activation process results in a rapid release of infection-associated proteins 
[156, 158, 159], which in part mimics the host-specific signalling events seen in L3 upon 
exposure to host serum [159]. Very little is known about the L3 lung stage of A. caninum or 
the triggers that prompt migration and maturation of the L4 as it arrives in the 
gastrointestinal tract and reaches sexual maturity in the small intestine. Recent reports 
23 
 
show that A. caninum in older dogs induces a tolerogenic area around the site of 
attachment in the gut [160]. In addition, we know from untargeted proteomic and more 
targeted studies that A. caninum produces a number of proteins that putatively interact 
with immune cells and can induce anti-inflammatory responses [5, 161-164], which in turn 
promotes tolerance in the host.  
Our understanding of A. caninum as a human zoonosis has also changed over time. Initially 
the zoonosis was defined by larva migrans, where the parasite was known to penetrate the 
epidermis but failed to successfully migrate and became trapped in the skin and underlying 
musculature, leading to localised irritation and pruritus [137, 165, 166]. It has since been 
shown that A. caninum is able to further its migration in humans, with occasional worms 
reaching the small intestine, although a patent human infection with A. caninum has yet to 
be reported. Studies in mice, a monkey and a cat have shown migration of the parasite into 
muscle tissues with little inflammatory response [167]. This phenomenon has also been 
reported in humans with migration of hookworms to muscle tissues in an individual with a 
large cutaneous exposure [168]. In 1994, Croese [132] described numerous cases where 
solitary A. caninum were identified in the human gut by endoscopy, discovered during 
clinical investigation for eosinophilic gastroenteritis [169]. These observations indicate that 
A. caninum could be a suitable proxy for human-hookworm interactions, and much can be 
learned about human hookworm infection by studying A. caninum in its natural dog host.  
2.6 Omics can provide useful information but must be augmented with 
studies in animal models. 
Omics is the collective term for the characterisation of an organism at the genome, 
transcriptome, proteome and metabolome levels. Increasingly, omics have been used to 
guide research in host-parasite biology and therapeutics discovery. This approach has been 
used in the case of parasitic trematodes to identify the mechanisms of drug resistance and 
to identify novel drug targets [170]. Metagenomics and metabolomics are the newest and 
most rapidly advancing ‘omics’ technologies, and offer under-utilised promise for 
understanding the molecular basis of host-helminth interactions, particularly metabolism, 
pharmacotherapeutic action [171] and the presence and function of commensal microbes. 
The limitation of comparative omics is that often there are no homologs or orthologs of 
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helminth molecules (particularly proteins) in other organisms to assign putative function, 
and many of the metabolites are of unknown origin and function. For example, there are 
over 700 transcripts in the A. caninum transcriptome encoding for proteins with secretory 
signal peptides with no putative function assigned [172]. Unannotated genes in parasites 
are of interest due to their likely role in governing a parasitic existence [173]. To augment 
omics databases to allow for meaningful bioinformatics analyses, animal models provide 
invaluable information. These models provide important bioactivity data that cannot be 
inferred by bioinformatics alone [39]. 
The currently available omics information for the family Ancylostomatidae has been 
assembled in Table 2 and includes for comparison the free-living model nematode C. 
elegans and the filarial nematode Brugia malayi. By using comparative tools it was possible 
using these databases to identify genes putatively associated with parasitism by comparing 
the different transcriptome patterns of the three helminth species [172]. Mining of 
assembled proteomic databases can help to identify proteins, but often the target protein is 
of unknown function. For example, using a shotgun proteomics approach, Mulvenna et al. 
[161] identified 105 A. caninum ES proteins (increased recently to 315 putative proteins in 
our laboratory [174]). Based on gene ontology alone, many of these proteins are of 
unknown function [161, 174]. 
Current databases for helminth omics, particularly hookworm, are incomplete. Only N. 
americanus has a published genome [175], and only A. caninum has a comprehensive 
secreted proteome from the adult worm [161], although the somatic adult worm proteome 
has been reported from N. americanus [175]. The plasticity and adaptability of hookworms 
further accentuates the deficit in bioinformatics data. Significant subpopulation variation of 
A. caninum has been observed [176], and it has been speculated that this variation may 
indicate speciation events. In addition, these subpopulations could reflect differences in 
infectivity for A. caninum [177]. The analysis of restriction fragment length polymorphisms 
(RFLP) of helminths from India and Vietnam supports the observed phylogenetic 
relationships but also identifies unclassified Ancylostoma species [149, 178]. This pattern is 
also observed with N. americanus [179, 180]. The source of hookworm material used to 
generate different omics databases is usually restricted to small populations, often passaged 
through unnatural hosts, and different populations are frequently used to compile different 
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datasets (see Table 2.2). In conjunction with the known plasticity of hookworm species, 
these factors may diminish valid comparisons across databases. By using in silico techniques 
it is possible to use comparative bioinformatics to combine proteomic and transcriptomic 
databases to determine metabolic pathways [181]. 
Organism Genome Transcriptome Proteome/Secretome Metabolome Ref 
C. elegans X X X X [182-191] 
N. americanus X X X − 
[175, 192-
198] 
A. duodenale − − − − − 
A. caninum X† X X − 
[161, 172, 
174, 193, 
199-201] 
A. ceylanicum X X − − [199, 202] 
A. braziliense − X − - [203] 
Brugia malayi X X X − 
[90, 172, 
204-209] 
Table 2.2 The current omics status for the Ancylostomatidae, the free-living model 
nematode Caenorhabditis elegans, and the filarial nematode Brugia malayi. Genome and 
transcriptome progress for Ancylostomatidae can be monitored on the Gold-genome online 
database 
(https://gold.jgi.doe.gov/distributiondata?domain=EUKARYAL&rank=family&group=Ancyl
ostomatidae.) 
Transcriptome, proteome and metabolome database updates can also be monitored at 
http://www.genome.jp/kegg/kegg1.html and www.wormbase.org. 
†Data collection still in process. 
X Omics data available 
− Omics data not available 
Combining omics data with functional data from animal models is a very powerful tool to 
identify critical physiologic and metabolic pathways. Helminth genomes are often poorly 
annotated, which can result in missed identifications of novel pathways in parasites. For 
example, it is only from metabolic labelling of intermediates of the Leishmania parasite 
promastigotes that it was possible to show that the parasite pooled reservoirs of essential 
molecules for the TCA cycle through the fermentation of succinate [109]. This is a novel 
pathway that could potentially be used as a target for anti-parasitic drugs and provides an 
understanding of how parasites cope with changes in their environment. The metabolome 
of Entamoeba during encystation shows the presence of polyamines [210], an unexpected 
finding given that the enzymes responsible for polyamine biosynthesis are not annotated in 
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the genome [211]. Eicosanoids in helminths are likely produced by novel pathways, as 
bioinformatics searches for the genes encoding homologues of the mammalian enzymes in 
this biosynthesis pathway have not been identified [212]. Given these examples, and the 
adaptability of the hookworm and its phenotypic plasticity, metabolomics profiling is likely 
necessary to uncover novel pathways and molecules used by these parasites [213].  
2.7 Animal models of hookworm interaction 
One of the major issues with the study of hookworms is the inability to culture these 
parasites through all developmental stages of their lifecycle in vitro. To this end, animal 
models are employed. The ideal model for human hookworm infection should reflect the 
pathophysiology of the helminth-host interaction and be experimentally accessible. Current 
models all have limitations and many animal experiments are considered "under-powered" 
[214] due to the ethical restrictions on animal experimentation numbers. A further 
restriction on models is the availability of immunological reagents for a given species. 
Reagents are readily available for humans, mice/rats, and to a lesser extent dogs and 
hamsters, but are more restricted for cats, which only have a limited palette of immune 
reagents. Moreover, human hookworms do not generally reach maturity in mice or rats [50, 
215], precluding functional studies using genetically modified hosts.  
There are three main experimental animal models commonly used as a proxy for 
gastrointestinal (GI) nematode infections of humans; mice/rat, hamsters and dogs as 
summarised in Table 3. There have been attempts to establish hookworm-primate models 
using marmots [216] however these models have been constricted by experimental cost 
[217]. The two benchmark murine models used for STH infection discussed in this review are 
Heligmosomoides polygyrus bakeri and Nippostrongylus brasiliensis. Trichuris muris is 
homologous to the human whipworm Trichuris trichiura, and while it is a STH it is not within 
the scope of this review. The rat is the natural host of N. brasiliensis and is considered a 
good model for human hookworm infection, particularly due to the similarities between the 
N. brasiliensis and N. americanus secretomes [218]. However, there are some features of 
the N. brasiliensis life cycle in rodents that are dissimilar to human hookworm infections, 
particularly the rapid transit time from percutaneous infection to reaching the gut, as noted 
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below. N. brasiliensis is not a natural parasite of mice, although it can complete its life cycle 
in them. 
Animal model Naturally 
occurring 
Host-
Parasite  
Similar 
Lifecycle cf. 
Necator/ 
Ancylostoma 
spp. in 
humans 
Infection model Model used to 
study 
Regulatory 
Restrictions 
Ref 
(Mus musculus) 
Heligmosomoides 
polygyrus bakeri 
YES 
NO (no lung 
stage) 
Chronic 
helminthiasis 
Pathophysiology 
of infection, 
immunological 
studies, 
vaccinomics 
- 
[219-225] 
Nippostrongylus 
brasiliensis 
NO YES Rapid expulsion 
Immunology of 
helminth 
infection, 
Pathophysiology 
of infection 
- 
[218, 
224, 226-
229] 
GOLDEN SYRIAN HAMSTER (Mesocricetus auratus) 
Ancylostoma 
ceylanicum 
NO 
NO (infection 
by oral 
gavage) 
Rapid expulsion 
Vaccinomics, 
Anti-helminthics 
Hamsters 
not 
permitted 
in some 
countries 
(e.g. 
Australia) 
[230-232] 
Necator 
americanus 
NO YES 
Chronic 
helminthiasis 
Pathophysiology 
of infection, 
immunological 
studies, 
vaccinomics 
Hamsters 
not 
permitted 
in some 
countries. 
Ova 
transport 
restricted in 
US 
[233-235] 
BEAGLE† (Canis lupus familiaris) 
Ancylostoma 
caninum 
YES 
YES, 
including 
hypobiosis 
Acute and 
chronic 
helminthiasis 
Pathophysiology 
of infection, 
immunological 
studies, 
vaccinomics 
Ethical 
considerati
ons 
[236] 
Table 2.3. The major animal models used to study human hookworm infection.  
†Alternative sources of A. caninum can be from naturally infected dogs in endemic areas.  
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While N. brasiliensis is less closely related phylogenetically to human hookworms than are 
other Ancylostoma spp., it is often used to study the pathophysiology and immunology of 
STH infection. One of the major differences between human hookworm infection and N. 
brasiliensis infection in mice is the self-cure phenomenon that occurs. Within two weeks of 
infection, mice expel N. brasiliensis and develop protective immunity that is dependent on 
CD4+ Th2 cells. Indeed, this model has been used to study the development of host 
protective immunity and the in vivo regulation of Th2 responses in general [237-239]. One 
of the advantages of this model is the minimal inter-animal variation, however, its lifecycle 
is abbreviated and is not characterised by the chronicity of human hookworm infection. 
As a natural parasite of mice, H. polygyrus is often chosen to study the pathophysiology and 
the immunology of intestinal nematode infections [220, 223, 237]. While taxonomically 
related to human hookworms, H. polygyrus differs from the hookworms in that it has a 
much simpler lifecycle. H. polygyrus does not have a lung stage and exhibits an enteric 
lifecycle with a faecal-oral infection route. However, like human hookworm infection, H. 
polygyrus establishes a chronic infection in its definitive host. As such, this model has been 
used to extensively characterise the Th2-skewing and immunoregulatory properties of GI 
nematodes [240], and ultimately resulted in the introduction of the term “modified Th2 
response” [241]. 
The mouse models of N. brasiliensis and H. polygyrus have been used to decipher the innate 
and adaptive immune responses responsible for worm expulsion and the development of 
chronicity [242]. Both parasites drive a modified Th2 response typified by IL-4, IL-5, IL-9, IL-
13 and IL-10 which mediates eosinophilia, mucosal changes such as mast cell hyperplasia, 
mucus production and IgG1 and IgE production [53].  
One of the most important breakthroughs in the development of animal models for human 
hookworm infection was the establishment of patent infections in golden Syrian hamsters 
(Mesocricetus auratus) with N. americanus and A. ceylanicum. Both models however are 
“labours of love” and require considerable time to establish because they generally rely on 
immunosuppression with steroids, at least in the early phases of model establishment [233, 
243, 244]. Immunosuppression with steroids of the golden Syrian hamster allows A. 
ceylanicum and N. americanus infections to reach patency [231, 233], thereby providing 
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material for laboratory analyses including genomic, transcriptomic and metabolomics 
studies. The A. ceylanicum-hamster model [245] has been utilized for testing vaccine 
efficacy, understanding mechanisms of adaptive immunity, and testing of anthelminthic 
drugs, often as a model for human infection with N. americanus [215, 246]. These 
interpretations have been supported by observations in small scale studies in humans [247-
249]. 
The N. americanus-hamster model was first established by Sen and Seth in 1970 [250], and 
tailored as a model for testing drugs and vaccines by Jian and others in 2003 [233]. 
Importantly, the in vivo generation of adult-stage N. americanus enabled the sequencing of 
the adult worm transcriptome [192], and ultimately contributed material to the sequencing 
of the genome in 2014 [175]. It should be noted that N. americanus was adapted to 
hamsters through 100 generations of selective pressure. The ability of a complex 
multicellular pathogen to adapt to a new host within 100 generations reflects a high 
evolutionary rate, also observed in A. caninum and reflected by high DNA polymorphism 
[172]. We currently do not understand the molecular basis of the adaptation of N. 
americanus to the golden hamster. A comparative analysis of mitochondrial cytochrome 
oxidase genes from N. americanus obtained from hamsters and natural human infections 
suggests a severe genetic bottleneck in hamster-adapted N. americanus, which may limit 
the utility of this model [251]. To date there has been no investigation of the differences in 
genomes between N. americanus sourced from hamsters and those from the native human 
host. The ‘omics’ information garnered from such a comparison would be useful to highlight 
those genes related to host adaption and could also enhance our understanding of the 
metabolites produced by a system in response to changes in the host and an environmental 
stimulus. 
There are a number of caveats to consider in the hamster model of human hookworm 
infection. Interpretation of data generated in the N. americanus-adapted hamster model 
may be misleading when applied to human hookworm host-parasite biology due to the 
undefined changes discussed above. In addition, the model using immunosuppressed 
hamsters and N. americanus is still employed [198, 252], so care should be taken when 
interpreting results and drawing parallels between the two models. Another problem with 
the hamster model of N. americanus infection is its restricted geographic use; for example, 
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hamsters are a prohibited laboratory species in Australia due to strict quarantine 
restrictions [55]. This limits its ability to be used in comparative and translatable studies 
universally. Logistically, the hamster is a small animal so the parasite load that the animal 
can tolerate is low when compared to a human or larger animal such as a dog. Moreover, 
adult N. americanus do not reach full size in hamsters [233], even though they do become 
fecund and infections are patent. A further weakness of this model is that the small 
numbers of adult parasites that can be supported in hamsters are rapidly expelled 
compared to the chronicity that develops in human necatoriasis [244]. 
2.8 The canine-hookworm model 
The gut-dwelling, blood-feeding stage of A. caninum is well described at biochemical, 
transcriptomic and immunological levels as discussed here. The Excretory/Secretory (ES) 
component of A. caninum (AcES) at the host-parasite interface has been described, with 
over 200 proteins identified in 2009 [161, 174], many of which were ascribed to either 
feeding [253-255] or putatively evading the host and inducing tolerance [160, 162]. The 
immunomodulatory nature of AcES has been demonstrated [5, 256] with an increasing 
interest in translational applications for selected recombinant versions of AcES proteins 
[164, 253, 257-259]. In addition, possible mechanisms of drug resistance [96] and hypobiosis 
[167] have been studied in this model. The availability of such an accessible and defined 
model is attractive for a gamut of research agendas. 
A major advantage of the A. caninum-dog relationship as a model for human hookworm 
infection is that it is naturally occurring, and moreover, A. caninum and A. duodenale are 
very similar morphologically and genetically. Due to the larger size of the animal, dogs are 
more suitable for recovering larger quantities of adult hookworms for laboratory studies 
than are rodents. From an individual dog it may be possible to recover thousands of adult 
worms, allowing for comprehensive studies to occur from a single collection. One of the 
major objections to the use of dogs as animal models however is the ethical concern around 
their experimental use; this, combined with the expense of keeping such a large animal for 
research purposes, often limits the use of the A. caninum-canine model. Attempts have 
been made to create an A. duodenale-dog model for research purposes. Using 
immunosuppression with prednisolone it was possible to achieve patency within 6 
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generations of beagle [260]. In later experiments A. duodenale was maintained in 
laboratory-raised beagles for 30 generations using decreasing amounts of prednisolone, and 
adaption to the dog was presumed due to observed decreases in the pre-patent period for 
the parasite, however a fully permissive model was not achieved due to the prohibitive 
resource demands of the project [236]. This is a common theme with large animal models. 
Puppies usually harbour the heaviest burdens of A. caninum, and worm numbers (or at least 
eggs in the faeces) tend to diminish over time. An efficacious hookworm vaccine based on 
irradiated parasites was developed for dogs but was discontinued soon after reaching the 
market due to its poor shelf life and low uptake by pet owners [261, 262]. The dog 
hookworm vaccine was based on radiation-attenuated L3 [262], and although the protective 
antigenic components were not identified, two immunodominant L3 secreted antigens were 
described from dogs that received the vaccine [263]. Understanding the mechanisms by 
which vaccine-induced immunity to the dog hookworm develops could inform efforts to 
develop a subunit human hookworm vaccine. Such studies have guided antigen discovery 
for human hookworm vaccines [264], and even underpin proposed human trials with 
irradiated N. americanus L3 (AL, unpublished). 
It is our experience that the dog-hookworm model can be very fruitful when A. caninum is 
sourced from areas where dogs are naturally infected, have not received recent 
anthelmintic therapy, and dogs are excess to requirements. These unwanted animals can 
result from wild dog eradication programmes, the culling of rural/remote camp or village 
dogs, or the sourcing of stray or unwanted dogs from residential communities in tropical 
and sub-tropical environments. The benefit of this approach is three-fold: 1) ethically, these 
animals are not experimentally infected or euthanized for research purposes, so ethical 
concerns on their use are minimised; 2) international partnerships between developed and 
developing countries to source these hookworms means that educational/research facilities 
can be meaningfully engaged in STH research; 3) harvesting of animals from diverse 
geographical areas gives power to observations as it reflects natural host-parasite 
interactions and natural spatio-temporal variation.  
The opportunity for international partnering is emphasised in the modern research agenda 
as it aids capacity building in developing countries [265] that are most affected by STH. It 
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enables the development of collaborative long-term partnerships and stewardship over 
research agendas. This is particularly important in the case of human hookworm research as 
there are direct benefits to both developed and developing nations in terms of vaccine and 
drug development [266], as well as development of novel helminth-derived anti-
inflammatory therapeutics [164]. Additionally, collaborating provides the ability to extend 
research capabilities in a time of increasing economic rationalisation and competitive grant 
processes. The inclusion of a broad base of expertise from immunology, parasitology, 
veterinary and agricultural sciences, public health and medicine is possible in these 
partnerships and is often aligned with current integrated approaches to research programs. 
*A section of the submitted review has been removed here for brevity – the section is titled 
A. ceylanicum as a model for human hookworms in the submitted article. * 
2.9 Conclusions 
In the context of human hookworm research, the human-hookworm-dog axis provides one 
of the unique experimental opportunities for the identification of bioactive molecules for 
development of novel immunotherapeutics, subunit vaccines, and selection of drug targets. 
Domestication has meant that the unique evolutionary relationships between dogs and 
humans can be exploited as natural models for human diseases, notably from our 
perspective, the parasitic helminth infections of humans. Positive selection pressure and 
breed conformation has led to genetic restriction in canines and has meant that many 
diseases have the same underlying genetic basis in dogs and humans. It is likely that humans 
and dogs have shared parasites for millennia, making them an ideal model for the study of 
host-parasite biology. 
Laboratory evidence shows that with the administration of immunosuppressive therapy it is 
possible to achieve patency of hookworm infections in a variety of unnatural definitive 
hosts. There are a number of available models for human hookworm infection; however, all 
of these models have limitations. Mouse models are universally available yet suffer from a 
range of dissimilarities to the natural human hookworm infections. Hamster models have an 
advantage over mouse models in that they are permissive for the human hookworms N. 
americanus and A. ceylanicum, but resistance to infection develops rapidly, unlike human 
hookworm infections. 
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A. caninum in the dog is a robust, naturally occurring relationship, and parasites isolated 
from animals in endemic areas have the potential to provide powerful molecular 
information that is unavailable from other sources and reflects naturally occurring 
interactions. The use of experimentally infected large animal models for such studies is 
fraught with ethical considerations and high economic costs. The study of natural 
interactions has the potential to provide more powerful observations than those of current 
laboratory models. Sourcing naturally infected animals provides an opportunity for 
international partnering and an opportunity for a diverse portfolio of translatable research 
outcomes. It negates many of the ethical and cost concerns rightly expressed over the 
housing of large mammals. By using a strong model for sourcing parasite material, it is 
possible to make reliable and translatable observations about hookworm host-parasite 
biology as well as facilitating programs focused on development of new control strategies 
aimed at eliminating, or at least mitigating, hookworm infection.  
 
The next section focusses on the molecules that helminths produce that influence the host 
immune system and their possible roles as therapeutics. 
 
 
The writing that follows is from: Identifying the immunomodulatory components of 
helminths. Shepherd C, Navarro S, Wangchuk P, Wilson D, Daly NL, Loukas A: Parasite 
immunology 2015, 37(6):293-303. PUBLISHED WORK, Permission to publish here has been 
obtained. 
2.10 Preamble 
Immunomodulatory components of helminths (ICH) offer great promise as an entirely new 
class of biologics for the treatment of inflammatory diseases. Here we discuss the emerging 
themes in helminth-driven immunomodulation in the context of therapeutic drug discovery. 
We broadly define the approaches that are currently applied by researchers to identify 
these helminth molecules, highlighting key areas of potential exploitation that have been 
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mostly neglected thus far, notably small molecules. Finally, we propose that the 
investigation of immunomodulatory compounds will enable the translation of current and 
future research efforts into potential treatments for autoimmune and allergic diseases, 
while at the same time yielding new insights into the molecular interface of host-parasite 
biology.  
2.11 Introduction 
The immunomodulatory properties of helminths are to a large extent attributed to the 
excretory/secretory (ES) molecules that they release when migrating and feeding inside 
their hosts [52, 117, 267]. We herein refer to the immunomodulatory components of ES 
products as ICH, or Immunomodulatory Components of Helminths. The secretomes of 
parasitic helminths are largely the subject of three main avenues of investigation - 
molecular biology of the host-parasite relationship, anti-helminth drug and vaccine 
discovery, and the discovery of novel therapeutics for treating diseases (primarily, but not 
restricted to inflammation) of humans, animals and plants. Given this broad scope we will 
not endeavour to discuss helminth vaccinomics, a topic that has been reviewed elsewhere 
[268, 269]. Considering the enormous disease burden of human and animal helminth 
infections, the identification of ICH could serve to identify targets for novel vaccines that 
aim to interrupt immunoregulatory processes of helminths. It has however become evident 
that targeting ICH for vaccines can result in atopic reactions [163, 270, 271] and more 
selective and strategic approaches to vaccinomics are currently being adopted [272]. In this 
article we will instead focus on the anti-inflammatory properties of helminths and explore 
the notion that therapeutic application of ICH for treating inflammatory diseases is a valid 
and timely approach to drug discovery guided by robust and cutting-edge science and 
clinical medicine. We believe that by identifying the major bioactive ICH we will not only 
identify novel drug leads for the treatment of autoimmune and allergic diseases but will 
augment research into the immunobiology and co-evolution of the host-parasite 
relationship. 
There are five evident themes concerning ICH that emerge from the literature: 
1. ICH is a complex mixture of proteins, peptides, glycans, lipids and small organic 
molecules. 
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2. Successful helminths induce a ‘modified Th2’ response in the host via secretion of 
ICH. 
3. Many individual ICH components are pleiotropic. 
4. ICH bioactivity cannot, for the most part, be predicted by current bioinformatics-
based modelling. 
5. The low molecular weight component of ES has received little attention to date, in 
terms of both characterisation and function. Nonetheless, there are a few 
descriptions of small molecules derived from helminths that display 
immunomodulatory properties and possess desirable pharmacological properties.  
The targeting of potential therapeutic agents from ICH will define motifs that orchestrate 
fundamental processes in host-parasite biology, enable the identification of suitable host 
targets with high druggability, and further our understanding of how these molecules 
modulate the immune system in a safe manner. Indeed, the discovery of targeted, novel 
and effective ICH-derived treatments for the autoimmune and allergic diseases that plague 
industrialized nations may ultimately reveal how these inflammatory diseases develop. The 
field of host-parasite immunoregulation is benefiting from an accelerated momentum and 
unprecedented opportunities to rapidly progress findings out of the academic sphere and 
towards clinical development.  
2.12 Background 
The observed explosion in autoimmune and allergic inflammatory diseases in industrialised 
societies has accompanied the rapid improvement in sanitation and infectious disease 
control [41]. Evidence from epidemiological studies shows the importance of helminths in 
this process. Removal of helminths from populations in economic (and sanitary) transition 
results in an increase in the incidence of inflammatory diseases such as asthma, allergic 
rhinitis, ulcerative colitis, Crohn’s disease, rheumatoid arthritis, food allergy, type-1 diabetes 
and multiple sclerosis [44, 273-275]. Additionally, studies on the migration of populations 
from areas of poor to high sanitation have revealed an increased risk of diseases such as 
inflammatory bowel disease (IBD) [43]. Indeed, the children of migrants can acquire the 
inflammatory disease rates of the population they are born into [276-278].  
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Two of the theories used to explain these observations are the Hygiene Hypothesis and the 
Old Friends theory. The Hygiene Hypothesis proposes that exposure to pathogens during 
childhood (via sibling contact) is necessary for the immune system to develop and self-
regulate [33, 35, 37, 279]. This lack of exposure to pathogens along with an underlying 
genetic pre-disposition can result in the development of autoimmune or inflammatory 
diseases [280]. The significance of exposure to helminth parasites in this process cannot be 
underestimated [33, 41, 113]. The blood-feeding helminths are long-standing parasites of 
humans [151] that are thought to have co-evolved with mammals [280, 281]. The Old 
Friends theory [38] is an extension of the Hygiene Hypothesis and supposes that the long 
association between host and parasite has resulted in a co-evolutionary dependence [282], 
where parasitic helminths rely on their hosts for nutrients and niche, and the host’s immune 
system is primed to expect signals from helminths, including ICH [279]. Without exposure to 
helminths, inflammatory diseases are more likely to develop, however high parasitic 
burdens can result in loss of fitness [50, 279, 283] (Figure 2.3). For the development of a 
healthy immune system, there appears to be a requirement for exposure to helminths, 
while minimising the burden of excessive parasitic load.  
 
Figure 2.3. The relationship between helminth exposure and immune response. In areas 
with high helminth infection rates there is a link to increased infection risk; conversely low 
helminth exposure can result in a pro-inflammatory profile. The proposal that a moderated 
exposure to parasites results in a balanced immune phenotype underpins the key observations 
of the Hygiene Hypothesis and Old Friends theory and is governed by the molecules 
produced by parasites.  Adapted from Wiria et al. [283] 
Mining of ICH for therapeutic compounds has clear advantage over some of the more 
traditional drug development strategies, like the use of combinatorial chemistry [26] and in 
silico screening [284, 285], primarily due to a 24% success rate of taking a drug from clinical 
trials to market compared with 11% for new chemical entities [286]. Despite promising 
outcomes from clinical trials using experimental human helminth infections to treat IBD 
[287, 288], multiple sclerosis [115] and coeliac disease [289], there has been little interest 
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from big pharma in translating live helminth therapy into an industrial scale therapeutic 
modality. Smaller biotech companies have, however, invested in such projects, exemplified 
by ongoing and recently completed phase II clinical trials with Trichuris suis ova (TSO) for the 
treatment of numerous indications including IBD, multiple sclerosis and autism 
(http://www.coronadobiosciences.com/research-development/TSO.cfm). Despite 
significant progress in the clinical development of TSO and its good tolerability in human 
subjects [290], recent clinical trials assessing TSO for the treatment of Crohn’s disease 
(TRUST Phase I and II) failed to meet their clinical endpoints 
(http://ir.coronadobiosciences.com/Cache/1500053915.PDF?Y=&O=PDF&D=&FID=1500053
915&T=&IID=4308955). The notion of treating people with live helminths still poses 
significant hurdles in terms of public acceptability, regulatory approval and standardisation 
procedures. Moreover, helminths are a source of significant morbidity and mortality 
worldwide [55, 60]. Although low-dose experimental infections with human helminths in 
well-nourished individuals appears to be safe and well tolerated [291-294], the use of 
pathogenic human helminths is restricted in some countries, including the U.S. [235] where 
human studies have been limited to zoonotic helminths [287, 295]. The use of zoonotic 
parasites is not without its own risks, as migration paths of these organisms can be 
unpredictable and can result in iatrogenic disease [117, 132, 296, 297]. Additionally, unlike 
maggots and leeches, which are considered “medical devices”, the US Food and Drug 
Administration (FDA) considers helminths to be a “drug”, meaning that studies involving 
experimental infections are required to undergo the same rigorous validation as a chemical 
agent, including a thorough pharmacokinetic study. Table 2.4 provides a summary of live 
helminth treatment of inflammatory bowel disease with a notation on the status of each 
clinical trial.  
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Parasite  Natural 
 Host 
Disease 
Treated 
Treatment 
Regime  
(time period) 
Outcome Clinical 
Trial Phase 
Ref 
Necator 
americanus 
 
CD  25-100 L3 (45 
weeks) 
88.9 % of patients 
showed 
improvement in 
Clinical score index 
 POC [288] 
Necator 
americanus 
 
Celiac 
Disease 
5-10 L3 (21 
weeks) 
 
No significant 
improvement in 
disease 
 
I [291] 
20 L3 (52 
weeks) 
Induction of 
tolerance when 
combined with 
gluten escalation 
I [289] 
Trichuris suis 
 
UC/CD 2500 ova x 1 
(12 weeks) 
Temporary 
remission in 86% of 
patients 
I [295] 
Trichuris suis 
 
CD 2500 ova x 8 
(24 weeks) 
Reduction in 
symptoms (79.3%) 
Remission in 72.4% 
of patients 
I [287] 
7500 ova x 6 
(10 weeks) 
No significant 
improvement in 
disease 
II [298] 
Trichuris 
trichiura 
 
UC 500 + 1000 ova 
(3 years) 
Self-reported 
amelioration of  
disease – single 
subject 
 
POC [292] 
Table 2.4. A summary of experimental human helminth infections for the treatment of 
inflammatory bowel diseases.  
CD = Crohn’s Disease; UC = Ulcerative Colitis; POC = Proof of Concept; I = phase I clinical 
trial; II = phase II clinical trial; L3 = third stage infective larvae. 
 
Despite the drawbacks of live helminth therapy, molecular products derived from helminths 
have been convincingly shown to possess potent immunomodulatory properties in a range 
of animal models of inflammation [299]. Identification and subsequent production of 
recombinant/synthetic versions of specific ICHs will likely overcome many of the problems 
encountered using live helminths or crude ES products as therapeutic modalities for 
inflammatory diseases [9, 44, 117, 300-304]. 
While there is a substantial body of literature showing the immunoregulatory properties of 
helminth ES products, there is however a great deal of variability in the preparation and 
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screening of ES products for activity [305]. This makes it difficult to meaningfully compare 
the immunoregulatory properties of ES products from different helminths. There is little 
consistency in methodologies for the production of ES products and methods employed 
when screening for ICH (Table 2.5). Moreover, many researchers exclude the low molecular 
weight components of ES products (peptides and small molecules) during a 
concentration/diafiltration step; we discuss the potential of small molecule ICH later in the 
review. 
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Species ES Product 
Size 
Model Immunomodulatory Outcome Refs 
Schistosoma 
mansoni 
0.2 μm filtered Mouse chemical colitis 
model 
Induction of modified Th2 
response 
[5, 306] 
Heligmosomoides 
polygyrus  
 
>10 kDa In vitro co-stimulation 
of murine BMDC 
Induction of modified Th2 
response 
[307] 
Trichuris suis 
 
>10 kDa In vitro culture with 
IPEC-1 cells 
 IL-6 
 IL-10 
Th2 type response 
[308] 
Nippostrongylus 
brasiliensis 
>5 kDa 
 
 
0.2 μm filtered 
In vitro co-stimulation 
of murine BMDC 
Murine asthma model 
In vitro suppression  of 
murine D10.G4  
Induction of modified Th2 
response 
 
Suppression of Th2 cells 
 IL-4 
[238, 
309, 
310] 
 
 
[311] 
Fasciola hepatica >10 kDa In vitro co-stimulation 
of murine BMDC 
Induction of modified Th2 
response 
[312] 
Opisthorchis 
viverrini 
0.2 μm filtered In vitro culture with 
H69 cells 
 IL-6 
 IL-8 
Pro-inflammatory 
[313] 
Ancylostoma 
caninum 
>10 kDa 
0.2 μm filtered 
Mouse chemical colitis 
models 
Induction of modified Th2 
response 
[256] 
[5] 
Trichinella spiralis 0.45 μm 
filtered 
Mouse chemical colitis 
model 
Induction of modified Th2 
response 
[314] 
Brugia malayi 0.45 μm 
filtered 
 
 
0.2 μm filtered 
 
In vitro stimulation of 
human PBMC 
 
In vitro suppression  of 
murine D10.G4 
 IL-6 
 IL-8 
 VEGF-A 
Suppression of Th2 cells 
 IL-4 
[315] 
 
 
[311] 
 
Toxocara canis 0.2 μm filtered In vitro suppression  of 
murine D10.G4 
Suppression of Th2 cells 
 IL-4 
[311] 
Taenia sp. >50 kDa In vitro stimulation of 
human PBMC 
Tolerogenic phenotype 
Reduction of pro-inflammatory 
cytokines 
Modulation of CLR 
[316] 
Table 2.5. Variability in preparation techniques and ICH screening approaches for 
different helminth excretory/secretory (ES) products with immunomodulatory 
properties.  
ES = Excretory/Secretory; BMDC = Bone marrow derived cells; IPEC-1 = piglet intestinal cell line; 
PBMC = peripheral blood mononuclear cell; CLR = C-Type Lectin Receptor 
2.13 Successful helminths induce a ‘modified Th2’ response in the host 
through ICH. 
It is recognised that parasitic helminths are often expelled from the host via a T helper type 
2 (Th2) response, typified by elevated secretion of IL-3, IL-4, IL-5, and IL-13, Immunoglobulin 
E (IgE), eosinophilia, alternatively activated macrophages and mastocytosis [317, 318]. IL-4 
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and IL-5 produced by Th2 cells are implicated in cross talk with B cells and eosinophils and, 
ultimately, degranulation of mast cells, basophils and eosinophils. It is this cascade that is 
thought to be responsible for parasite expulsion [319].  This can be seen in the whipworm, 
Trichuris trichiura where the immune response to infection results in chronic diarrhoea and 
protein losing enteropathy in the form of Trichuris Dysentery Syndrome. This is recognised 
as an inflammatory response with the involvement of the innate immune system [320] and 
is well defined in mice infected with the related Trichuris muris, where the bias towards a 
Th2 response results in expulsion of the parasite [321-324]. 
The clear majority of human helminth infections are characterised by a partial activation of 
both the adaptive and innate arms of the immune system termed a ‘modified Th2” 
response. While helminth parasites clearly cause numerous neglected tropical diseases, with 
soil transmitted helminths (STH) estimated to affect over 2.2 billion people [48, 49], their 
effect is considered more in terms of morbidity than mortality [48]. In this context, host and 
parasite appear to have struck a balance between persistent infections over the lifespan of 
the host, but most infected individuals harbour low to moderate worm burdens, thereby 
preventing uncontrollable inflammatory responses and death of the host. 
A successful parasite is benchmarked by its ability to actively skew its host’s immune system 
to prevent elimination and development of immunity [50]. This immune skewing results in 
the induction of a ‘modified Th2’ response [51] characterised by expansion of Th2 cells, 
alternatively activated macrophages, inducible regulatory T cells (Treg) expressing Foxp3, 
increased levels of IL-10, and production of polyclonal IgE by B cells [55], and consequent  
suppression of the Th1/Th17 axis. Classical Th1/17 inflammatory responses can damage 
worms, but at a substantial cost in collateral damage to host tissues [325]. Thus, in 
evolutionary terms, Th2 immunity is thought to have arisen from tissue repair mechanisms 
in  response to tissue damage, with these responses isolating and encapsulating helminths 
through fibrotic processes while simultaneously resolving localised damage [325-327]. 
Indeed, parasitic helminths are one of the most adept infectious agents at driving regulatory 
responses that prevent the development of sterilising protective immunity. Most relevant 
from the perspective of this article is the added benefit of helminth-driven 
immunoregulation in suppression of inappropriate immune responses to self and otherwise 
innocuous antigens [55]. With the exception of the liver fluke Opisthorchis viverrini, which is 
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associated with inflammatory changes in the liver [313, 328], ES products from the majority 
of helminths investigated induce a tolerogenic immune phenotype characterised by reduced 
production of pro-inflammatory cytokines. The ability of a helminth (or its ES products) to 
induce a regulatory response rather than an overt inflammatory response is clearly critical 
when searching for ICH. 
2.14 The complex nature of ICH  
ES products consist of a complex mixture of compounds of diverse molecular nature and 
function. Hewitson and colleagues mined various helminth ES proteomes from which they 
identified nine major ICH motifs on the basis of both experimental evidence from functional 
studies and genomic analyses to identify homologues of known immunomodulators [329]. 
The complexity of ES proteins and limitations in available quantities for separation studies 
has meant that current ICH discovery efforts have often focused on the most predominant 
ES components. For example, ES products of the canine hookworm Ancylostoma caninum 
protect mice against chemical colitis [5, 256]. A proteomic analysis of A. caninum ES 
products identified 105 proteins [161], many of which have predicted immunomodulatory 
properties based on sequence similarity to mammalian homologues including C-type lectins, 
galectins and cytokines. Crude A. caninum ES products when injected into mice induce a 
polarised Th2 response [256]. In contrast however, the most abundant protein in A. 
caninum ES products shares sequence identity with the human Tissue Inhibitor of 
Metalloprotease (TIMP) family, and has been shown to suppresses dendritic cell activation 
and drive production of regulatory T cells and regulatory cytokines [246] rather than 
polarised Th2 responses. On the other hand, ES products of the filarial nematode 
Acanthocheilonema viteae are dominated by the phosphorylcholine (PC)-containing 
immunoregulatory glycoprotein ES-62 [330]. ES products from other parasitic nematodes 
display similar molecular complexities and Th2-inducing capacities, but little information has 
been obtained on the individual ICH and how these contribute to defined immunoregulatory 
pathways. For example, Heligmosomoides polygyrus ES products contain eight protein 
families with predicted ICH activity [52] and Brugia malayi secretes at least 228 proteins 
including the immunomodulatory galectins and proteins modified with PC [206, 207]. Some 
parasitic trematodes also display similarly complex ES products - Schistosoma mansoni 
secretes approximately 188 detectable proteins during its life cycle, including at least four 
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that are known to be associated with immunomodulation [331]. While proteomics has 
served to highlight potential ICH within ES products, in vitro and in vivo studies are required 
to unequivocally attribute this function to crude mixtures and defined purified proteins 
(Table 2). Such studies provide the requisite information on the therapeutic potential of an 
ICH for clinical development and pique the interest of commercial partners [332] as they 
display specific pharmacology relevant to therapeutic discovery.  
2.15 ICH components are pleiotropic  
ICH of helminths are increasingly found to have multiple host targets and can modulate the 
mammalian immune system in many distinct ways [329]. Identification and characterisation 
of individual ICH is facilitating the recognition of motifs that have been adopted by a 
number of helminths to modulate the immune system, including defined post-translational 
modifications such as PC [333, 334]. These molecules are generally large and antigenic, but 
the bioactive component is often substantially smaller and therefore of greater interest in 
terms of drug development [332]. One of the best-studied ICH is the 62 kDa ES protein from 
A. viteae, ES-62. The addition of PC via an N-type glycan bond results in both the induction 
of an anti-inflammatory phenotype in mice [335] which is entirely dependent on the 
presence of PC. Indeed, the same anti-inflammatory effect was obtained when PC was fused 
to bovine serum albumin as a carrier protein [336]. The cellular targets of ES-62 are very 
broad, and include T cells, B cells, macrophages, mast cells and dendritic cells [329]. ES-62 
(via its PC epitope) has shown therapeutic potential for the treatment of inflammatory 
diseases [333] and protects against inflammation in mouse models of asthma [337] and 
arthritis [338]. Due to the antigenicity of the ES-62 protein its development as a therapeutic 
drug is not possible, but small molecule derivatives obtained from the PC moiety of ES-62 
have been synthesised and show promise in the treatment of collagen induced arthritis 
[339]. The PC motif is not well represented in helminth ES products – it has been identified 
in Ascaris suum, where glycosphingolipids have both PC- and non PC-dependent 
immunomodulatory activity [340], but given its potency, the scarcity of PC in other helminth 
ES products is unexpected, and reflects the many distinct ICH and their often divergent 
mechanisms used to manipulate the immune system. 
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In addition to protein and phospholipid ICH, helminths produce unique glycans with 
pleiotropic immunomodulatory properties [206, 334]. Glycans from helminths have been 
demonstrated to induce both C-type lectin receptor (CLR) signalling and cross talk with Toll-
like receptors (TLR) [334, 341]. Glycan moieties of ICH have been described with both 
protective and non-protective properties in inflammatory disease models, and the ability to 
recognise relevant anti-inflammatory motifs is key to unravelling their therapeutic value 
[334, 342, 343]. This is perhaps best reflected in the study of the glycans of the 
schistosomes. Much of the antibody response to schistosomes during infection of primates 
is targeted towards glycans [344]. These glycans have been implicated in “gimmickry” to 
evade expulsion [334] and increase ova survival [344]. Schistosome glycans containing the 
motifs LacdiNAc- and LacNAc have been shown to promote the formation of pro-
inflammatory granulomas [345], while the glycan motifs IPSE/α1 and Kappa-5 induce Th2 
biasing in dendritic cells (DCs) [346]. The ability of helminth derived glycans bearing a Lacto-
N-fucopentaose III structure to improve glucose tolerance and reduce hepatosteatosis (fatty 
liver) in mice fed on a high fat, high carbohydrate diet has led to the suggestion that this 
glycan may provide a novel approach to treat metabolic disease [347].  
2.16 ICH bioactivity cannot always be predicted by current bioinformatics 
modelling 
The limitations of bioinformatics become apparent when considered in terms of predicting 
ICH. Nucleic acid and protein sequence databases can be used to predict the secretome of 
an organism [348, 349], yet despite recent progress in the sequencing of numerous parasitic 
helminth genomes and transcriptomes, the ability to predict ICH bioactivity has been 
limited. In the case of ES-62, filarial cystatins (see below) and hookworm TIMPS, ICH activity 
has been identified from ES products through bioactivity screening rather than 
bioinformatics modelling. 
When ES-62 was first identified from A. vitae it was initially speculated from the 
bioinformatics data available that the protein had homology to aminopeptidases [350]; 
however the protein displayed only weak aminopeptidase activity [350], and instead its 
immunomodulatory properties were assigned to the PC moiety [351]. Where PC is 
represented in helminths [352, 353] there are indications that they are highly conserved 
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structures [354].  Current bioinformatics tools focusing on protein and nucleic acid sequence 
identities and predicted folds would have not revealed the immunomodulatory properties 
of ES-62, a and molecule that is currently being targeted for the development of numerous 
inflammatory indications [337, 338]. 
The extensive body of work on helminth cystatins shows that homology as revealed by 
bioinformatics may not reflect the ICH properties of these molecules. The cystatins are 
reversible cysteine protease inhibitors with ubiquitous distribution [355, 356]. While 
proteomic analyses of ES products reveals an abundance of cystatins and cystatin-like 
proteins [207, 355] the widespread occurrence of the cysteine proteases and their cystatin 
and other inhibitors [356] would have made it easy to dismiss their roles in helminth-driven 
immunoregulation. Indeed early publications revealed a role for protozoan parasite 
cystatins in driving inflammatory responses by promoting nitric oxide (NO) production in 
macrophages in a protease inhibitor-independent manner [357]. Shortly afterwards 
however, the same researchers described cystatins from filarial nematodes that down 
regulated T cell proliferation and increased the production of IL-10 [358, 359]. 
Subsequently, modified filarial cystatin has been used in mouse models of allergy with 
promising results [304, 360].  
The genome of the human hookworm N. americanus [60, 175] was recently published, and 
revealed a number of genes encoding for proteins with sequence similarity to TIMPs. 
However it was only through in vitro studies and detailed modelling that the apparent lack 
of TIMP-like activity of Ac-TMP-1 became apparent [58], suggesting that this protein family 
had developed an alternative mechanism of suppressing inflammation [246] that was 
independent of metalloprotease inhibition. This combined with lack of functional data and 
the diversity of helminth ICH can limit the interpretation of analysis and this limits the ability 
to detect and predict ICH motifs.  
The ability of bioinformatics to identify potential ICH is highlighted by the discovery of 
Stichodactyla helianthus toxin (ShK)-related peptides from parasitic nematodes. This peptide 
was first identified in sea anemones as an inhibitor of voltage gated Kv1.3 K+ channels of 
effector T cells and a therapeutic target for the treatment of autoimmune disease [361]; a 
structural analogue of ShK-186 [362] is currently in phase 1 clinical trials for the treatment 
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of a number of autoimmune diseases (http://www.kinetabio.com/newsArchive.html). Using 
bioinformatics-based approaches, homologues that suppressed T cell proliferation and IFN- 
production in vitro were identified in tissue-dwelling (Brugia malayi) and gastrointestinal 
(Ancylostoma sp.) nematodes [257]. The ShK domain has been described in ES products of 
other helminths including H. polygyrus [363] and T. canis [364], however their role in host-
parasite interactions has received little attention. 
Increasingly, post-translational modifications such as PC and various glycans are being 
recognised as the active components of many ICH [329, 334]. These unique molecules 
cannot be readily predicted by bioinformatics approaches, and it is only through direct 
experimental investigation that these molecules reveal their ICH properties [365]. The 
potential power of bioinformatics must not be discounted; the ability to map motifs 
associated with ICH will be a valuable tool to identify convergent strategies of parasitic 
helminths.  
2.17 Small organic molecule ICH – unexplored pharmacophores? 
Most of the current literature on ICH has focused on proteins. Pursuit of low molecular 
weight ICH is however worthy of attention due to their improved drug development 
properties, such as Lipinski’s rule of five [24, 332]. Additionally, the use of peptides as 
therapeutics provides the means to generate highly targeted, complex molecules that 
negate some of the challenges of protein-based therapeutics, including delivery systems and 
potential antigenicity of large proteins [366].  
Peptide ICH have received little attention other than recent work on helminth defensin-like 
molecules [367, 368], a family of fluke peptides that do not possess anti-microbial 
properties like their mammalian counterparts but instead display a range of 
immunoregulatory roles, primarily through interruption of macrophage antigen processing 
pathways [369]. Genome sequences are available for many of the parasitic helminths but 
traditional open reading frame (ORF) prediction programs often discount short ORFs that 
correspond to small peptides, so tailored approaches are required to mine genomes for 
small peptides.  
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Small organic molecules from helminths have received even less attention as ICH, despite 
their likely presence in ES products [329]. The study of small molecules shifts the 
experimental discovery paradigm from proteomic and genomic strategies to that of 
metabolomics. For instance, the eicosanoids are small oxylipic molecules that are 
recognised ICH with pleiotropic behaviour and are produced by a wide variety of organisms 
[212]. The parasitic helminths are known to produce prostaglandin and leukotriene 
eicosanoids [212, 370, 371]. For example, the cercariae of Schistosoma mansoni utilise the 
linoleic acid present in the host epidermis to produce a prostaglandin, PGE2, implicated in IL-
10 dependent down regulation of host immune responses required for successful migration 
of the parasite [372]. These helminth-derived molecules have not (to our knowledge) been 
screened in animal models of inflammatory diseases to assess their therapeutic potential. 
Indeed there has been surprisingly little research into the low molecular weight ES 
component of parasitic helminths despite promising evidence on their therapeutic 
properties [373]. 
Also worthy of further attention is the ascarosides, a class of small molecules that have been 
well characterised in C. elegans [374] and are present in other helminths [375]. Ascarosides 
are synthesised by peroxisomal β-oxidation of long chain fatty acids and amino acid 
catabolism [376], and as a result the ascaroside distribution pattern provides information 
about the life history and the metabolic status of the worm [374, 375]. Ascarosides are 
chemically stable and display diverse bioactivity at femtomolar concentrations [374] as 
dauer pheromones, male-specific attractants and aggregation signals [377, 378]. They are 
highly species-specific signalling molecules [375] recognised by cyclic guanosine 
monophosphate membrane receptors (cGMPR) on the helminth’s surface and upstream of 
TFG-β signalling pathways [376, 379]. While similar compounds are present in the ES 
products of parasitic nematodes [375] their role in host-parasite biology is yet to be fully 
explored.  
Finally, the immunoregulatory role of short chain fatty acids (SCFAs) from commensal 
microbes has become apparent [380], yet their presence in parasitic helminths has received 
little attention. Even though parasitic nematodes secrete some of the key 
immunoregulatory SCFAs including propionate and butyrate [381-383], their contribution to 
host-parasite immunobiology has not been addressed in depth. 
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While the area of small molecule ICH is worthy of further exploration, we offer a word of 
caution in terms of selection of in vitro culture media used for helminths. Small molecule 
profiles are profoundly affected by the metabolic status of the organism [374, 375]. 
Proteomic analyses typically focus on proteins greater than 10 kDa in mass [161, 307, 308, 
312, 316]. The analysis of smaller molecules in ES products can be confounded by protein 
breakdown products and media components including amino acids that have 
immunomodulatory properties in their own right. For example, the commonly used 
tissue/helminth culture medium RPMI-1640 contains choline [384], glutamine and arginine 
[385], thiamine [82] and tryptophan [386], all of which have been shown to have anti-
inflammatory properties, while glucose has pro-inflammatory properties [387]. Indeed 
glutamine is administered to critically ill patients, where it reduces mortality rates [388] and 
lessens inflammation post-chemotherapy [389] via its non-nutritive roles in modulation of 
the immune system [390]. This complicates the use of ES products from parasitic helminths 
that contain media components, particularly if a concentration/precipitation step has been 
applied. 
2.18 Conclusion 
Many helminths and their ES products are viewed as a valuable source of potential 
therapeutic moieties [117]. Parasitic helminths produce a large repertoire of ES proteins, a 
number of which have been characterised and display immunomodulatory potential. To 
date much of the work on ICH as focussed on proteins with only preliminary investigation 
into the therapeutic potential of low molecular weight peptides and small organic molecules 
[373]. Indications from free-living helminths such as C. elegans suggest a diversity and 
complexity in bioactive molecules that play roles in both helminth-host immunobiology and 
as novel therapeutics for inflammatory and other non-infectious diseases. Despite the 
difficulties of developing proteins as therapeutic agents there is growing interest from 
commercial partners in the development of these compounds into therapeutics [332]. This 
is mainly because proteins are highly specific, targeted and proven through long association 
to be well tolerated. They also address the very real need for curative treatment options for 
a wide range of inflammatory, autoimmune and allergic diseases. Drug discovery guided by 
millennia of host-parasite co-evolution is logical, and immunoparasitologists are now at the 
forefront of this exciting era where the need for out-of-the-box or unconventional 
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approaches to developing drugs to treat the epidemic of inflammatory diseases is urgently 
needed. Parasitic helminths are masters at preventing inflammation, and ICH-derived 
therapeutics offer truly disease-modifying approaches, rather than the focus of current 
biologics, many of which are designed to “mop up” the damage rather than acting upstream 
to reset the effector: regulatory balance. We believe that ICH-derived therapeutics have a 
place in modern medicine and will be available in the clinic in the not too distant future.  
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Chapter 3 
Materials and Methods 
Preamble 
This chapter outlines the experimental procedures and protocols utilised during this 
thesis to achieve the research aims. This chapter also addresses the experimental 
plan, statistical and bioinformatics workflows for the project. Research aims are; 
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Above is a schematic of the experimental workflow; the numbers listed are the 
research aims that are addressed at each stage of the project. 
The following procedures are listed in the approximate order in which they appear in 
the research aims of the project. A more detailed research plan with rationale is 
provided in Chapter 2. 
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3.1 RESEARCH AIM 1: Isolate LES from A. caninum and show protection in a 
Trinitrobenzene Sulphonic Acid (TNBS) colitis model. 
This section covers  
• Isolation of A. caninum and culture. 
• Preparation of ES and LES – the testing of protein concentration (BCA) and 
endotoxin contamination levels (LAL). 
• Sample preparation methods – lyophilisation, preparation for IP injection. 
• Bioactivity assay – Acute chemical colitis induced by TNBS 
• Histology – H&E stain and PAS stain  
3.1.1 Procedure: Preparation of whole Excretory/Secretory component 
from A. caninum. 
Scope: This procedure covers the harvesting of intestines from the dog to the 
preparation of ES material from parasites for transport. It is assumed that the 
investigator can identify ova from and determine the species of adult hookworms. This 
method is adapted from Mulvenna et al. [161] 
Safety/Notes: Dog parasites can cause zoonotic infections in humans. Full PPE 
including gown, gloves and surgical mask is recommended. In addition plastic apron 
and sleeve protectors are advised. Appropriate safety procedures should be adopted 
using when using scalpel blades and appropriate disposal of sharps is required. 
Materials/Instrumentation: 
Equipment Requirements: 
• CO2 (5%) Incubator at 37°C 
• Waterbath (37°C) for warming Substrates 
• Laminar Flow Cabinet 
• Centrifuge – 50 ml tubes/1000 g/10 minutes/4°C 
• Large plastic tray 
• Curved surgical scissors 
• Watchmaker tweezers 
• Pipette boy 
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• Scalpel 
Consumables and reagents: 
• Petri dishes (25 mL capacity) 
• 50 mL Falcon tubes 
• Pipette boy 25 mL tips 
• 5x Substrate – Dulbecco’s Phosphate Buffered Saline (DPBS) (+) Calcium Chloride (+) 
Magnesium Chloride (Gibco, Life Technologies) + 5% antimycotic/antibiotic (Gibco, Life 
Technologies) + 1% Glutamax (Gibco, Life Technologies). i.e. 500 mL DPBS + 25 ml 
anti/anti + 5 ml Glutamax 
• 2x Substrate – Dulbecco’s Phosphate Buffered Saline (DPBS) (+) Calcium Chloride (+) 
Magnesium Chloride (Gibco, Life Technologies) + 2% antimycotic/antibiotic + 1% 
Glutamax. i.e. 500 mL DPBS + 10 ml anti/anti + 5 ml Glutamax 
Substrate is prepared aseptically and can be stored at 4°C prior to use. Warm Substrate 
in a 37°C waterbath before to use (for every 50 hookworms approximately 75 ml of 2x 
Substrate will be required for a 3-day culture). 
Method: 
Collection of Intestines 
Hookworms are obtained from the small intestine of dog cadavers within 180 minutes 
of lethal injection with sodium-pentobarbital. Intestines should be harvested from 
freshly euthanized animals that are suspected of hookworm infestation (this can be 
confirmed by faecal examination for hookworm eggs). Hookworms will detach from 
the gut as the tissue cools that will make it difficult to identify worms. Processing 
intestines quickly is essential to maintain integrity of the parasite. 
Removal of the small intestine from dogs 
1. Using a scalpel make a small transverse cut on the lower abdomen of the animal. 
Cut through the dermis and the abdominal lining carefully to expose a small amount of 
the small intestine. 
2. Using a finger, loop under the small intestine and gently pull the intestine 
through this hole. Locate the junction to either the large intestine or stomach. Cut the 
intestine at this point and gently pull the small intestine out, easing it away from the 
mesenteric membranes until the other end is reached. Tie each end of the intestine to 
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prevent content loss. Place in a container for transport to the laboratory. Dispose of 
the animal as approved. 
Hookworm removal and processing 
1. Process intestines over a large plastic tray. 
2. Using curved surgical scissors cut down the length of the intestine to expose 
the inner surface. 
3. Using clockmaker tweezers gently pick the hookworms from the intestine and 
transfer to 5x substrate (minimum 25mL). Avoid any faecal material and intestinal 
tissue. 
4. Centre the worms by swirling the container for several seconds. While the 
worms are centred use a pipette boy with a 25 ml tip to remove as much of the liquid 
as possible without sucking up the worms. Discard the Substrate. 
5. Quickly replace media with warm 5x Substrate to the container. 
6. Repeat steps 4 to 5 at least 4 times (more if needed) to remove any visible 
intestinal matter. Centre the worms then using a new 25 ml tip aspirate the worms 
ensuring to remove as little liquid as possible.  Place approximately 50 worms per Petri 
dish. 
7. Transfer worms to a petri dish and add 25 mL of 5x Substrate. Incubate for 2 
hours at 37°C in a CO2 incubator. 
ES Production from hookworms (all work to be carried out in laminar flow cabinet) 
1. During the 2-hour incubation period clean all equipment and wipe down the 
laminar flow hood with ethanol. This incubation period is important as it allows the 5x 
anti/anti component to neutralise the bacteria present and the hookworms to purge 
their gut contents. 
2. Remove petri dishes from incubator. Centre the worms by swirling petri dish 
then using a new 25 ml tip suck up all the worms making sure that you aspirate as 
little media as possible. Transfer to a new petri dish containing 2x Substrate. 
3. Retain the 5x Substrate and process as per steps 7-8. Label these tubes 
clearly as 5x ES with the date. Store at -20°C or -80°C until needed. 
4. Wash the hookworms 3 times as previously but with 2x Substrate. 
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5. Incubate worms in approximately 25 ml of 2x Substrate for 16 hours in a 37°C 
CO2 incubator (This is Day 1 ES collection material). 
6. After 16 hours incubation collect Substrate (contains ES proteins) using a 25 
ml tip and transfer to a 50 ml falcon tube (more than one petri dish can be pooled into 
a falcon tube). 
7. Centrifuge at 1000 g for 10 minutes at 4°C to pellet the hookworm eggs. 
These pellets are retained, and an egg shed is estimated. A live to dead ratio can also 
be estimated by staining eggs with Lugol’s iodine.  
8. Transfer the supernatant to a new tube – you can pool but only up to 40 ml 
(to allow for expansion in the freezer). Label tube clearly with day of ES collection and 
date. Store at -20°C or -80°C until needed. 
9. Repeat steps 4 to 7 for Day 2 and Day 3 collections. Remove dead worms 
with tweezers between each incubation (these worms will show signs of 
disintegration or will not be moving in the Substrate – nudge motionless worms with 
the tweezers- they should move if alive).  Store at -20°C or -80°C until needed. This 
material is now ready for transport if required. 
Quality Control: The identity of hookworms needs to be confirmed visually (three 
pairs of teeth in the buccal capsule) using a dissecting microscope to ensure that A. 
caninum is being collected for study.  
3.1.2 Procedure: Preparation of A. caninum Excretory/Secretory 
component (AcES) and low molecular weight AcES (LES) for analysis. 
Scope: This procedure covers the thawing of whole ES material from A. caninum and 
the separation of the low molecular weight component and >10 kDa protein 
component for characterisation and analysis. This method is adapted from Mulvenna 
et al. [161] 
Safety/Notes: Full PPE including gown and gloves is recommended. Appropriate safety 
procedures should be adopted when using scalpel blades and appropriate disposal of 
sharps is required. 
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Materials/Instrumentation: 
Equipment Requirements: 
• Laminar Flow Cabinet 
• Centrifuge – 50 ml tubes/3000 g/20 minutes/4°C 
Consumables and reagents: 
• 50 mL Falcon tubes 
• DPBS 
• 10 kDa spin column 
 
Method: 
 
Figure 3.1 Summary of experimental workflow for A. caninum Excretory/Secretory 
component (AcES) and low molecular weight AcES (LES) preparation. 
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Concentration of AcES and LES  
1. Defrost whole ES material at 4°C and keep tubes on ice throughout the 
procedure. Open tubes and decant liquid in the laminar flow hood to minimise risk of 
contamination. 
2. Decant approximately 15 mL of whole ES into the 10 kDa cut off spin column.  
3. Centrifuge at 3000 g for 20 minutes at 4°C. 
4. Transfer the flowthrough to an appropriately labelled 50 mL falcon tube. Top 
up the 10 kDa column with the whole ES material. Repeat step 2 until all material has 
been loaded through the column. 
5. Once all the AcES material is loaded onto the column start topping up with 
cold DPBS. 
6. Do at least three washes with the DPBS. 
7. Concentrate the AcES to approximately one millilitre in each spin column. 
Rinse the empty spinoff tube with 100μL of cold DPBS. Carefully rinse and remove as 
much ES material as possible. Transfer this material to a 1.5 mL microfuge tube 
(Microfuge) and proceed to the endotoxin clean up procedure. 
8. The flow-through material is considered as the LES and is now suitable for 
characterisation. Material can be stored at -80°C.  
 
3.1.2.1 Procedure: Removal of endotoxin from AcES 
Scope: This procedure covers the removal of endotoxin from AcES for characterisation 
and analysis. This method is adapted from Aida and Past [391]. 
Safety/Notes: Full PPE including gown and gloves is recommended. Appropriate safety 
procedures should be adopted using when using scalpel blades and appropriate 
disposal of sharps is required. 
 
Materials/Instrumentation: 
Equipment Requirements: 
• Laminar Flow Cabinet 
• Microfuge Centrifuge – suitable for 1.5 mL Microfuge tubes 
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• Waterbath 37°C 
• Rotary mixer at 4°C 
Consumables and reagents: 
• Microfuge tubes (1.5 mL) 
• Triton X114 (Sigma)  
 
Method: 
1. In a laminar flow cabinet transfer approximately 500μL of AcES to a Microfuge tube. 
2. To this tube add 1 % Triton X114 to the AcES (μL). Open tubes and decant 
liquid in the laminar flow hood to minimise risk of contamination. 
3. Place tubes on a rotary mixer and mix on medium speed for at least 30 
minutes – overnight. This causes the Triton X114 to bind to the endotoxin. 
4. Heat tubes to 37°C for 10 minutes. This causes the Triton X114 to form 
micelles and trap the endotoxin. 
5. Centrifuge the Microfuge tubes at 17 500 g for 15 minutes at room 
temperature. The liquid will separate into two layers – the bottom layer contains the 
endotoxin. 
6. In a laminar flow hood decant the top layer and add to a fresh tube, then 
repeat step 2. 
7. Warm the supernatant in a waterbath at 37°C for 5 minutes and centrifuge 
again for 15 minutes. 
8. Transfer the top layer (ensuring to not transfer any of the bottom layer) into 
a new tube to ensure the sample is completely free of Triton X114. 
9. Assay AcES material for endotoxin levels using the LAL method and protein 
concentration using the BCA method. 
3.1.2.2 Procedure: endotoxin concentration determination using the 
Limulus Amebocyte Lysate (LAL) assay. 
Scope: This procedure covers the preparation of sample to the assay and calculation 
of bacterial contamination in the form of lipopolysaccharide (LPS) concentration of 
samples. Samples that contain excessive LPS quantities cannot be used in the TNBS 
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mouse colitis model and should be processed through the endotoxin removal method 
until acceptable levels are obtained. 
Note: The LPS molecule is very large and is contained in the ES fraction. LES will not 
contain measurable quantities of LPS 
Safety/Notes: Full PPE including gown and gloves is recommended. 
Materials/Instrumentation: 
Equipment Requirements: 
• Automatic pipettes  
• Incubator 37°C (optional) 
• Automated plate reader – Polarstar Omega (BMG Labtech) 
 
Consumables and reagents: 
• Limulus Amebocyte Lysate (LAL) kit (Lonza-Pharma Biotech) 
• Microfuge tubes (for dilutions) 
• Buffer for dilutions (match to that of the sample) 
• 96 well microplate 
 
Method: 
1. Method is carried out as per the assay kit insert and is briefly summarised 
below. 
2. Prepare standards as indicated in insert using compatible buffer. Samples 
should be serially diluted for the best determination of concentration. 
3. Add 50μL of sample or standard to each well followed by 50μL of sterile DI 
water 
4. Add 50μL of LAL reagent to each well and mix the plate thoroughly. 
5. Cover the plate and incubate at 37°C for 10 minutes. 
6. Add 100μL of Substrate to each well and mix. Incubate plate for a further 6 
minutes at 37°C. 
7. Add 100μL of stop solution to each well and mix. 
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8. Read plate at 405-410 nm and determine the concentration of unknown 
samples using the established standard curve. Use DI water as a sample blank. 
3.1.2.3 Procedure: Protein concentration determination using the Pierce 
BCA protein assay kit. 
Scope: This procedure covers the preparation of sample to the assay and calculation 
of protein concentrations. 
Safety/Notes: Full PPE including gown and gloves is recommended. Appropriate safety 
procedures should be adopted using when using scalpel blades and appropriate 
disposal of sharps is required. 
 
Materials/Instrumentation: 
Equipment Requirements: 
• Automatic pipettes  
• Incubator 37°C (optional) 
• Automated plate reader  
Consumables and reagents: 
• Pierce BCA Protein Assay Kit (Thermo Scientific) 
• Microfuge tubes (for dilutions) 
• Buffer for dilutions (match to that of the sample) 
• 96 well microplate 
 
Method: 
1. Method is carried out as per the assay kit insert and is briefly summarised below. 
2. Albumin standards are prepared in the following concentrations; 2000, 1500, 
1000, 750, 500, 250, 125, 125, 25 and 0μg/mL using kit as guide and matching 
compatible buffer. 
3. Make up working reagent allowing 200μL per sample (50:1, reagent A:B) 
4. Add 25μL of sample or standard (to be run in duplicate) to each well. 
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5. Add 200μL of the working reagent to each well and mix the plate thoroughly 
on a shaker for 30 seconds. 
6. Cover the plate and incubate at 37°C for 30 minutes (room temperature for 2 
hours). 
7. Cool plate to room temperature if incubated at 37°C. 
8. Read plate at 562 nm and determine the concentration of unknown samples 
using the established standard curve. 
 
3.1.3 Sample Processing 
3.1.3.1 Procedure: Sample lyophilisation (freeze drying) or concentration 
Scope: This procedure describes the various methods used to concentrate samples 
through lyophilisation/evaporation. 
Safety/Notes: Full PPE including gown and gloves is recommended. Safety glasses 
must be worn around lyophilisation equipment. The use of dry ice should be carried 
out in a ventilated space and solvents should be disposed of appropriately. 
 
Materials/Instrumentation: 
Equipment Requirements: 
• Fume hood. 
• Freeze dryer – Christ Alpha 1-2 LD Plus (John Morris Scientific) 
• Round bottom flasks compatible with freeze dryer unit. Select flask that is 
approximately four times the volume being dried. 
Consumables and reagents: 
• 50 mL Falcon tubes 
• Microfuge tubes 
• Glass vials 
• Nitrogen gas (BOC gases) 
• Dry ice (commercially available from Collins Ice, Cairns) 
• Ethanol or Acetone (reagent grade) 
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• Parafilm 
 
Method: 
Large volume method – lyophilisation method A 
1. To be done in a fume hood. To a suitable container add approximately one 
cup of dry ice and either ethanol or acetone. This mixture can descend to 
temperatures as low as -80°C – appropriate precautions are to be taken. 
2. Transfer liquid to a round bottom flask, carefully avoiding getting the ground 
glass neck wet. Place an adaptor arm on the flask and parafilm junction securely. 
3. Using a rotating motion move flask in bath ensuring that the solution is 
frozen evenly over the interior surface of the flask. Make sure that the liquid has 
completely frozen before loading onto the freeze dryer. 
4. Once the sample is completely frozen load onto the freeze dryer.  
5. Drying can occur overnight or over the course of a number of days. The 
sample needs to be monitored closely. If the sample thaws during the process it must 
be removed, refrozen and placed back on the dryer. 
6. Once completely dry carefully disengage the vacuum to minimise sample loss 
and remove flask. Dried sample is now available for processing as required. 
 
Large volume method – lyophilisation method B 
7. In some cases, samples will be provided frozen in 50 mL falcon tubes and it 
will be impractical to thaw and transfer these samples. In these cases, a large jar 
suitable for containing several tubes at once can be used. Remove the lid from each 
falcon tube and cover with parafilm. Poke several holes through parafilm. Work 
quickly to ensure that the sample remains frozen. 
8. Once prepared samples can be loaded as per step 4 of the method. 
9. When samples are dry they can be removed and processed as required. 
 
Large volume method – Rotary Evaporator method C 
1. Add ice to the condenser and turn on the water bath to bring up to 
temperature. 
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2. Turn on water to vacuum. 
3. Load sample and start spinning hold until vacuum is reduced to avoid sample 
loss lower into the water. 
4. Set mode to pump down (select using the knob dis-engage the lock and press 
down) at the first bubble – stop the vacuum. 
5. Change mode to auto vacuum then watch to achieve volume required. Raise 
flask out of bath. 
6. Vent while holding flask. 
7. Shutdown by turning off the rotation, heater to water bath. Vent vacuum and 
power down both units. Discard ice; when bath is cool, empty and dry. 
 
Small volume method – lyophilisation method A 
1. When small volumes of sample need to be evaporated they can be processed 
using the Speed vac. Samples in Microfuge tubes - in either liquid or frozen form - 
are loaded into the rotor of the Speed vac (balance rotor if possible). 
2. Press lid down to engage lock and start spinning process. 
3. When lock is engaged the vacuum will start and samples will lyophilize. Check 
regularly  
This method is not suitable for highly volatile or labile compounds and method B 
is more suitable. 
 
Small volume method – lyophilisation method B 
1. When small volumes of samples contain volatile or labile components it may 
be more suitable to dry samples under nitrogen. 
2. Using bottled nitrogen gas and in a fume hood direct a small stream of 
nitrogen into the container that contains the sample. Evaporate to dryness. 
3. Depending on the amount of sample this may take a few minutes, but the 
liquid should evaporate, concentrating the sample – this can be to completely dry the 
sample or just to concentrate it. 
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3.1.3.2 Procedure: Preparation of biological samples for intraperitoneal 
injections. 
Scope: This procedure covers the preparation of biological samples for animal 
injection. This procedure is covered by JCU Ethics A#1848, A#2190 and A#2012. 
Safety/Notes: Full PPE including gown and gloves is recommended. Appropriate safety 
procedures should be adopted when using scalpel blades and syringes and appropriate 
disposal of sharps is required. 
The administration of anaesthetic as described in this procedure requires a current 
DS4-DS8 approval from the Queensland Government. A copy of this approval is held by 
the facility. 
This procedure also requires induction into the Specific Pathogen Free (SPF) facility, 
instruction in the correct handling of small mammals, the record of which will be kept 
by the manager of the facility. 
Adherence to SPF facility safety and requirements is mandatory.  
 
Materials/Instrumentation: 
Equipment Requirements: 
• Laminar Flow Cabinet 
Consumables and reagents: 
• Microfuge tubes 
• 0.22 μm filter cartridges - Millex syringe filter unit 33 mm/4 mm (Merck Millipore 
Ltd) 
• Sterile syringes, 19 G, 21 G and 23G needles (Termo) 
• Insulin syringes (Termo) 
• DPBS 
• Dimethyl sulfoxide (DMSO) 
• Ketamil - Ketamine (as Hydrochloride) 100 mg/mL (Ilium) 
• Xylazil - (2-(2,6 Xylidine)- 5,6 dihydro-4H-1,3-thiazine hydrochloride) 100 mg (10% 
w/v) (Ilium) 
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Method: 
Experimental 
General Notes – The total volume that can be administered at any one time is 200 μL 
to each mouse. All samples must be prepared aseptically in a laminar flow as 
bacterial/LPS contamination will alter assay.  
 
1. Preparation of material for screening – All mouse injections need to be 
prepared aseptically in a laminar flow cabinet. Sample is to be made up to the correct 
concentration in a 200μL volume. Using sterile diluent (usually sterile PBS) take up 
enough to allow for dead volume in the tube (usually done by calculating n+1). 
Material that cannot be heat sterilised is to be filtered through a 0.22 μm filter and 
stored at 4°C until use. In some cases, it is necessary to use DMSO to solubilize 
samples. If DMSO is used, then a control group using diluent sample only is required in 
the bioactivity assay. 
2. Preparation of anaesthetic – To administer these drugs current DS4-DS8 
approval from the Queensland Government is required to have access to and 
administer these drugs. Drugs are to be stored in a secure location and usage is to be 
recorded in drug usage logs. Anaesthetic is to be made on an adhoc basis only. 
Anaesthetic is prepared aseptically to a concentration of 50 mg/kg of Ketamil and 5 
mg/kg of Xylazil is prepared in sterile PBS at a rate of 200μL per mouse (allow for dead 
volume in requirement volume). Prepared material is to be stored at 4°C until use. 
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3.1.4 Biological Screening for anti-inflammatory properties 
3.1.4.1 Procedure: Murine Trinitrobenzene sulfonic acid (TNBS) colitis 
method 
Scope: This procedure covers the preparation of TNBS, administration and monitoring 
of mice during this experiment. JCU Ethics cover this procedure A#2190, A#2012 and 
A#1848. 
The TNBS-induced colitis protocol is defined by Loukas Laboratory Protocol Colitis 
SOP_001 and is adapted from Wirtz et al. and Ruyssers et al. [5, 6] 
Safety/Notes: Full PPE including gown and gloves is recommended. TNBS is an irritant 
and appropriate safety procedures should be adhered to. Appropriate safety 
procedures should be adopted when using scalpel blades and syringes and appropriate 
disposal of sharps is required. 
The administration of anaesthetic as described in this procedure requires a current 
DS4-DS8 approval from the Queensland Government. A copy of this approval is held by 
the facility. 
This procedure also requires induction into the SPF facility, instruction in the correct 
handling of small mammals, the record of which will be kept by the manager of the 
facility. 
Adherence to SPF facility safety and requirements is mandatory.  
 
Materials/Instrumentation: 
Equipment Requirements: 
• Laminar Flow Cabinet 
• Access to an approved SPF facility 
Consumables and reagents: 
• Microfuge tubes 
• 0.22 μm filter cartridges -  Millex syringe filter unit 33 mm/4 mm  
• Sterile syringes, 19G, 21G and 23G needles  
• Insulin syringes  
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• TNBS (2,4,6-Trinitrobenzenesulfonic acid solution), also known as picrylsulfonic acid 
solution (5% w/v H2O) (Sigma)  
• Ethanol  
• DPBS 
• Viscotears® gel (Novartis) 
• KY-Jelly (Johnson & Johnson) 
• Insyte Autoguard Shielded IV catheter 20G x 1" Pink (Becton Dickinson) – discard all 
but the flexible catheter for this procedure. 
• Ketamil  
• Xylazil 
• Trizol – (Invitrogen) 
• Complete media (see ELISA procedure). 
 
Method: 
Sourcing and husbandry conditions: Animals are supplied by ARC (commercial 
breeding facility, Perth, WA). The strains of mice used for these experiments will be 
male C57BL/6 4-6 weeks of age or male BALBC 4-6 weeks of age (strains are not 
mixed in either experiments or replicates). 
Mouse supplied are age and weight matched, assessed for health and placed at 
random in cages of up to 5 animals per cage. Treatment groups can be mixed within 
a cage however, mice in the negative control treatment group (naïve mice) are kept 
separately to prevent cross contamination with TNBS. Mice are rested for 5-7 days 
prior to the start of the experiment. 
Animals are kept in a SPF facility and are provided with mouse chow and water ad 
libitum. They are exposed to a 12-hour day/night cycle and are kept in a 
temperature/humidity-controlled environment. Bedding is changed weekly and 
enrichment is provided to all cages. Animals are visually checked during settling in 
process and monitored daily during the course of the experiment. 
Experimental 
General Notes – The TNBS colitis model is a qualitative model and experimental 
conditions can vary from batch to batch of TNBS. The aim of this experiment is to 
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induce weight loss and symptoms similar to an acute colitis episode. There may be 
variation from lot to lot of TNBS reagent and each lot should be validated by inducing 
colitis in a small number of mice. Please refer to the workflow for the important time 
points of this experiment. 
1. Preparation of TNBS – TNBS is administered at 2-3 mg/mouse dissolved in 40-60% 
ethanol – exact ratios determined with each new lot of TNBS. TNBS is stored 
frozen and is light sensitive and should be prepared immediately prior to 
administration and wrapped in aluminium foil. TNBS is administered rectally at a 
rate of 100μL per mouse. 
2. Preparation of material for screening – All mouse injections need to be prepared 
aseptically in a laminar flow cabinet. Material that cannot be heat sterilised is to 
be filtered through a 0.22 μm filter. 
3. Preparation of anaesthetic – Anaesthetic is prepared aseptically to a 
concentration of 50 mg/kg of Ketamil and 5 mg/kg of Xylazil is prepared in sterile 
PBS at a rate of 200μL per mouse. Prepared material is to be stored at 4°C. 
Experimental procedure 
1. Administration of screening material – Inject animal with a single intraperitoneal 
injection with a 29-gauge insulin needle in the right lower quadrant (total volume = 
200μL (concentration 10-50μg per animal of LPS-depleted material) between 5-6 
hours before TNBS administration. Animals are gently restrained during injection 
using a scruff pad and returned to the appropriate cage to rest prior to procedure. 
2. TNBS Administration - Mice are anesthetized with 50 mg/kg of Ketamil and 5 mg/kg 
of Xylazil prepared in sterile PBS; 200μl is administered by intraperitoneal injection 
with a 29-gauge insulin needle in the right lower quadrant. Animals are gently 
restrained during injection using a scruff pad. Once the mice are unresponsive to 
stimulation, Viscotears® gel is applied to the eyes. Draw up 100μL TNBS (2-3 
mg/mouse) mixed with 40-60 % ethanol with a syringe attached to the catheter for 
delivery to the mouse, lubricating the rectum and catheter with a liberal amount of 
K-Y jelly. Invert the mouse and gently insert the catheter into the colon of the mouse 
and slowly expel the TNBS solution. Invert the mouse for two minutes to prevent 
anal leakage. Return the mouse to the cage and monitor until they wake up 20-30 
minutes later. 
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3. Monitoring and Measurement - Mice will be monitored daily for 3 days post-
injection for weight loss and general appearance according to the following scoring 
criteria: 
• Weight loss, no change or increase = 0; < 5% = 1; 6 – 10% = 2; 11 – 20% = 3; > 
20% = 4. 
• Faecal Output, normal = 0; pasty, semi-formed = 1; past, some blood = 2; 
bloody liquid = 3; unable to defecate after 5 minutes = 4. 
• General appearance (piloerection and mobility), normal = 0; piloerection only 
= 1; lethargy and piloerection = 2; motionless, sickly = 3. Quality of fur and 
grooming behaviour should be observed as well as social interaction and 
curiosity for mobility scores. 
This information is recorded on a worksheet (see below for example). 
Figure 3.2 Example of a clinical/macroscopic score sheet for recording data for TNBS 
colitis experiment. 
 
In the normal course of TNBS administration, exposed animals weight loss ceases by 
day three of the experiment. Any animals that have more than 30% weight loss over 
a 24-hour period or are displaying undue distress are to be sacrificed. Any 
unexpected losses during this experiment must have an “Adverse Event Form” 
lodged with the ethics committee through laboratory channels. 
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4. Sacrifice and collection of material - At the end of the experiment all animals will be 
sacrificed using CO2 asphyxiation and tissues for assessment collected. After the 
harvesting of tissues, the remainder of the mouse will be autoclaved and disposed of 
through JCU approved routes. 
The colon length is measured and assessed for length, oedema, adhesion and 
ulceration. Pictorial evidence is recommended; if possible publication quality photos 
should be taken. 
At sacrifice a number of tissues can be collected for monitoring the effects of the 
treatment, serum, draining lymph nodes, spleen, and gut tissue can be collected. 
Colon 
A portion of the gut tissue (caecum to anus) can be dissected into four pieces: 
1) One piece will be cultured 'ex vivo' and the immune response assessed by 
measurement of cytokines released into culture supernatants. The weight of this 
tissue is recorded in mg. 
2) One piece will be flushed with PBS and then fixed in formaldehyde, blocked in 
paraffin and sectioned and stained. These sections will then be used to determine 
infiltration of inflammatory cells to the intestine. Slides are stained with H&E; 
inflammatory infiltrate is determined using a modified version of the scoring method 
described by Hong et al .[392]. 
3) One piece will be preserved in Trizol for RNA isolation and subsequent conversion 
to cDNA so that real time PCR can be performed using primer pairs for inflammatory 
cytokine mRNA expression. 
4) The final piece of colon tissue will be snap frozen and later homogenized and 
analysed for tissue cytokines. The weight of this tissue is recorded in mg. 
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Experimental Workflow 
 
Figure 3.3 Schema of TNBS induced chemical colitis workflow. 
 
3.1.5 Procedure: Histology procedures 
Scope: This procedure covers the preparation of sample samples, transport, and 
interpretation and scoring of histology slides for this project. Histology is carried out 
by commercial facilities – QIMR Berghofer Histotechnology Services or QML Pathology 
Laboratory. 
Safety/Notes: Full PPE including gown and gloves is recommended. Appropriate safety 
procedures should be adopted when using scalpel blades and appropriate disposal of 
sharps is required. Appropriate disposal of solvents is required. 
 
Materials/Instrumentation: 
Equipment Requirements: 
• Automatic pipettes  
• Aperio image reader (freeware download) (Aperio\ImageScope\ImageScope.exe) 
• Stereomicroscope with x10 and x40 ocular lenses 
• Digital camera for recording images 
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Consumables and reagents: 
• 10% buffered Formalin 
• Microfuge tubes 
• 70% ethanol 
 
Method: 
1. Aliquot 1 mL of 10% buffered formalin into a Microfuge tube. Add tissue and 
fix overnight for 24 hours. Fixing time may be truncated if 
immunohistochemistry staining is desired. 
2. Transfer tissue to 1 mL of 70% ethanol for storage prior to histology 
processing.  
3. Arrange for processing in either of the commercial facilities for staining. 
Generally staining is limited to haematoxylin and eosin (H&E) or Periodic acid–
Schiff (PAS).  
4. Tissue is embedded in paraffin and sectioned longitudinally for histology at 4-
μm thickness. 
5. Slides are de-identified, and scoring is done in a blinded fashion.  
6. High-resolution images of slides are viewed using the Aperio image reader 
(freeware download) (Aperio\ImageScope\ImageScope.exe) or viewed under 
an x40 magnification. Images of representative areas for each group are 
recorded. 
7. Cross-sections of colons are scored as follows: Ulceration (no ulcers = zero; 1 
ulcer = 1; 2 ulcers = 2; 3 ulcers = 3; and >3 ulcers = 4). If ulcers are >200 μm in 
diameter, scoring is based on 200 μm intervals. Infiltration (0 = no infiltrate, 1 = 
infiltrate at crypt bases, 2 = infiltrate reaching to muscularis mucosa, 3 = 
extensive infiltration reaching the muscularis, and 4 = infiltration of the 
submucosa with oedema). The integrity of the epithelium is scored (0 = normal 
morphology, 1 = loss of goblet cells in one area, 2 = loss of goblet cells in more 
than one area, 3 = loss of crypts in one area, and 4 = loss of crypts in more than 
one area). Lymphoid follicles are also scored (none = 0, 1 = 1, 2 = 2, 3 = 3, >3 = 
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4). The aggregate score for each treatment group is determined for a 
maximum score of 16. 
8. PAS staining is assessed by determining the number of goblet cells in 200 μm 
intervals. 
 
3.2 RESEARCH AIM 2: Investigation of Immune cell activation by small molecule 
fractions 
This section covers  
• Sample preparation for ex vivo colon culture and tissue homogenate, 
• Cytokine assays – ex vivo culture and tissue homogenate 
• Signalling pathway assays – tissue homogenate 
• PCR- assays – Trizol preserved tissue 
3.2.1 Procedure: Sample preparation for ex vivo colon culture and tissue 
homogenate 
Scope: This procedure describes the general procedure s preparation of ex vivo tissue 
culture and tissue homogenate for biochemical and immunological assessment.  
Safety/Notes: Full PPE including gown and gloves is recommended. 
 
Materials/Instrumentation: 
Equipment Requirements: 
• Microfuge Centrifuge –suitable for Microfuge tubes 
• gentleMACS™C Tubes 
• gentleMACS tissue DIssociator 
• Tissue grinder 
• balance 
• Access to 4°C cold room 
 
Consumables and reagents: 
• Microfuge tubes 
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• 24 well cell culture plate  
• PhosSTOP™ tablets (Sigma-Aldrich) – reconstituted as per instructions 
• Sterile PBS 
• Complete Media (500 mL total volume)- to 400 mL RPMI (Gibco, Life Technologies), 
50 mL 10% Foetal Bovine Serum (heat inactivated) (Gibco, Life Technologies), 10 mL 
20mM HEPES (Gibco, Life Technologies), 0.5 mL 1X 2-Mercaptoethanol (Gibco, Life 
Technologies), 7.5 mL 1.5 mM Sodium pyruvate (optional) (Gibco, Life Technologies), 5 
mL Gentamicin (50μg/mL) (Gibco, Life Technologies) – make up to 500 mL with RPMI 
and filter through a 0.22 μM Durapore Stericup (Millipore). 
 
Preparation of samples: 
NOTE: All tissues should be weighed prior to processing; this allows for the 
standardisation of all results to unit/mg of tissue. Repeated freeze thaw cycles should 
be avoided on samples. 
Ex vivo tissue cultures –  
1. After collection, each piece of tissue is weighed in mg and transferred to a well 
of a 12(24?) well tissue culture plate with 500 μL of complete media 
2. Tissue is incubated at 37°C for 24 hrs. 
3. The supernatant is then transferred to a labelled Microfuge tube and stored at 
-80°C until required. Samples are thawed on ice prior to assay. 
4. Thawed samples should be centrifuged at XXXX g prior to use for analysis. 
Tissue homogenates –  
1) Tissues are snap frozen in liquid nitrogen and stored at -80°C until required for assay. 
2) Defrost on ice. Determine the weight of the tissue and record in mg. 
3) Prepare PhosSTOP™ as described and homogenize tissue in 200 – 2000 μL of PhosSTOP™ 
by one of two methods outlined below. Keep tissues and buffers ice cold during this 
process. 
a) Use the gentleMACS™C tubes and the gentleMACS Dissociator. Follow Insert 
instructions and use the spleen cycle to disrupt colon tissue. Transfer to Microfuge 
tube. 
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b) Using a glass tissue grinder with 200-500μL of PhosSTOP™ buffer, grind tissue on ice 
completely. Transfer to Microfuge tube. 
4) Centrifuge homogenate and transfer supernatant to a fresh tube for assay. Homogenate 
can be stored on ice or frozen at -80°C  
3.2.2 Procedure: ELISA assay method 
Scope: This procedure describes the general procedure for the determination of 
cytokine levels using eBioscience Ready-Set-Go! assay. 
Safety/Notes: Full PPE including gown and gloves is recommended. 
 
Materials/Instrumentation: 
Equipment Requirements: 
• Microfuge Centrifuge –suitable for Microfuge tubes 
• Microplate Spectrophotometer – Polarstar Omega – BMG Labtech 
• Access to 4°C cold room 
• Multi-channel pipette 
•  
 
Consumables and reagents: 
• ELISA kit (eBioscience Ready-Set-Go) for cytokine containing appropriate antibodies, 
diluents, and buffers. 
• Stop solution – 2N H2SO4 
• Wash solution – 1x PBS and 0.05% Tween-20 (Sigma –Aldrich) 
• Microfuge tubes 
• 96 well Nunc plate suitable for assay 
 
 
Method: 
1. The following cytokines are measured using the following general procedure; 
IL-1β, IL-4, IL-5, IL-6, IL-13, IL-12p70, IL-17, IFN-γ, TNF and TGF-β. Individual 
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variations in procedures are outlined in the package inserts as supplied by 
eBioscience.  
2. A 96 well plate is coated with the appropriate capture antibody (100 μL) and 
incubated at 4°C overnight. 
3. Wash wells three times with wash buffer then tap plate to remove residual 
buffer. 
4. Add 200μL of 1x Assay diluent to block wells. Incubate at room temperature 
for 1 hour. 
5. Wash wells as per step 3. 
6. Add 100 μL of relative standard (see Table 3.1 for concentration) in duplicate, 
carrying out serial dilutions (x8) to below the detection limit of the relative 
cytokine; include blank. Load 100 μL of each sample, including duplicates and 
dilutions as required. Cover plate and incubate at room temperature for two 
hours (or overnight at 4°C). 
7. Wash the wells five times then add 100μL of detection antibody. Cover plate 
and incubate at room temperature for an hour. 
8. Wash the wells five times then add 100 μL of Avidin-HRP to each assay well. 
Cover plate and incubate at room temperature for 30 minutes (in the dark).  
9. Aspirate the wells and wash seven times (each wash should soak for one to 
two minutes) and tap to remove any excess liquid from the well. 
10. To develop the well add 100 μL TMB reagent (supplied in kit) and incubate in 
the dark for 10-15 minutes. Add 50 μL of stop solution – well should turn from 
blue to yellow. 
11. Determine concentrations by reading in a plate reader at 450 nm (corrected by 
the 570 nm reading). Determine the cytokine concentration in pg/mL 
(normalise by tissue weight if available). 
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Table 3.1. Concentrations for the upper standard for each cytokine assayed, as per 
the technical data sheet from eBiosciences. 
3.2.3 Procedure: Tissue p-IκB-α (Ser32) and p-NF-κB p65 (Ser536) assay 
method 
Scope: This procedure describes the general procedure for the determination of the 
levels of phosphorylated inhibitor of κB-α (Ser32) (p-IκB-α (Ser32)) and 
phosphorylated nuclear factor kappa-light-chain-enhancer of activated B cells p65 
(Ser536) (p-NF-κB p65 (Ser536))   
Safety/Notes: Full PPE including gown and gloves is recommended. 
 
Materials/Instrumentation: 
Equipment Requirements: 
• Microfuge Centrifuge –suitable for Microfuge tubes 
• Microplate Spectrophotometer – Polarstar Omega – BMG Labtech 
• Access to 4°C cold room 
• Multi-channel pipette 
 
Cytokine Standard 
concentration 
IL-1β 1000 pg/mL 
IL-4 500 pg/mL 
IL-5 500 pg/mL 
IL-6 500 pg/mL 
IL-13 500 pg/mL 
IL-12p70 4000 pg/mL 
IL-17A 500 pg/mL 
IFN-γ 2000 pg/mL 
TNF α 1000 pg/mL 
TGF-β 1000 pg/mL 
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Consumables and reagents: 
• p-IκB-α (Ser32) and p-NF-κB p65 (Ser536) Pathscan kits (Cell Signalling Technology) 
containing appropriate antibodies, diluents, and buffers. 
• 96 well Nunc plate suitable for assay 
 
Method: 
1. Procedures are outlined in the package inserts as supplied by Cell Signalling 
Technology. 
2. Microwell strips coated with the appropriate capture antibody (100μL) and 
incubated at 4°C overnight. 
3. Load 100μL of each sample, including duplicates and dilutions as required. 
Cover plate and incubate at 37°C for two hours (or overnight at 4°C). 
4. Wash the wells four times then add 100μL of detection antibody. Cover plate 
and incubate at 37°C for an hour. 
5. Wash the wells five times then add 100μL of HRP to each assay well. Cover 
plate and incubate at 37°C for 30 minutes (in the dark).  
6. Aspirate the wells, wash seven times, and tap to remove any excess liquid from 
the well. 
7. To develop the well add 100μL TMB reagent (kit supplied) and incubate at 37°C 
in the dark for 10-15 minutes. Add 100μL of stop solution – well should turn 
from blue to yellow. 
8. Determine concentrations by reading in a plate reader at 450 nm. Determine 
the concentration as relative absorbance (normalise by tissue weight if 
available). 
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3.2.4 Procedure: Reverse Transcription - Polymerase Chain Reaction (RT-
PCR) method (Trizol) 
Scope: This procedure covers the preparation of sample and RT-PCR assay. 
Safety/Notes: Full PPE including gown and gloves are to be used. Appropriate safety 
procedures are to be adopted and appropriate disposal adopted when Trizol™ is used. 
Procedure should be carried out in a fume hood cabinet where possible and all 
solvents should be disposed of appropriately. Procedure should be carried out on the 
RNA bench using suitable precautions to avoid contamination. 
 
Materials/Instrumentation: 
Equipment Requirements: 
• Nanodrop 
• Heating block/waterbath 
• Tissue Dissociator – Qiagen 
• Rotor-Gene 
Consumables and reagents: 
• RNAse free tips and plasticware.  
• Chloroform 
• 75% Ethanol 
• 100% Isopropanol  
• DEPC Water (RNAse free) 
• Qiagen kits for SYBR® Green-based RT-PCR kits 
• Primers for tRNA of interest plus those for housekeeping (HK) genes (Quantitect® 
Primer Assay (Qiagen) 
• RNAseOUT™ 
• Superscript™ III RT 
 
* All equipment and consumables should be RNA (do you mean RNase?) and DNA 
(DNase? free. 
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Step 1: Sample preparation – RNA isolation: Trizol™ method 
Note: Unless otherwise indicated keep samples on ice for this method. 
1. Defrost sample (50-100 mg of tissue) on ice and transfer tissue and 1 ml 
Trizol™ to a flat bottomed 2 mL Microfuge tube. Add a stainless-steel ball to the tube. 
2. Using the Qiagen Tissue disruptor on 25 x 1000 rpm for 2 minutes x 2 
3. Add 0.2 mL of chloroform to each tube. Shake tubes for 15 s and incubate at 
room temperature for 2-3 minutes. 
4. Centrifuge 4°C/12000 x g/15 minutes. 
5. Remove the clear top layer containing the RNA and place in a fresh 1.6 mL 
Microfuge. 
6. Add 0.5 mL of 100% isopropanol to this tube and incubate at room 
temperature for 10 minutes. 
7. Centrifuge 4°C/12000 x g/10 minutes. 
8. The RNA should have precipitated into a pellet. Carefully remove supernatant 
and wash pellet with 1 mL of 75% Ethanol. Quickly vortex tube and centrifuge 
4°C/7500 x g/5 min. 
9. Dry pellet carefully and resuspend pellet in 50μL of RNAse free water. 
10. Incubate tube in a heating block/waterbath 55-60°C/10-15 minutes. Sample 
can be stored at -80°C at this stage 
11. Determine the concentration and purity of the RNA and make up 10 μL of 1 
μg/μL for cDNA synthesis. 
 
Step 2: cDNA synthesis 
1. Assemble a total volume of 13μL of the following; 1μL of oligo (dT) 20 [50 
mM]; 1μL dNTP mix [10 mM]; 10 pg-5μg of total RNA with the remainder RNAse free 
water. 
2. Incubate at 65°C for 5 minutes. Place on ice for 1 minute. 
3. Pellet the tube contents briefly in a microfuge then add; 4 μL 5x First strand 
buffer; 1μL DTT [0.1 mM]; 1μL RNAseOUT™; 1μL Superscript™ III RT [200 U/μL] to 
make a total volume in the tube of 20 μL. Mix gently by aspiration. 
81 
 
4. Incubate 50°C for 30-60 minutes. 
5. Inactivate the reaction by incubating 70°C for 15 minutes. 
6. Determine the concentration and purity using nanodrop. Determine the 
purity of the cDNA and volume required concentration for 100 ng of cDNA for RT-
PCR. 
 
Step 3: RT-PCR using Rotorgene 
Quality control 
Make up super pool of all RT-PCR samples (1μL of each). Make the following dilutions 
1:10, 1:100, and 1:1000 to determine the cycle time (Ct) values. Quality control is done 
on one gene usually a housekeeping gene. Ct values that fall between 18-24 are 
desirable and indicate optimal dilution. 
 
Sample analysis 
1. Sample concentration should not exceed 100 ng of starting material in a total 
reaction volume of 10μL.  
2. In a 100μL Rotor-gene tube add 2 x Rotor-gene SYBR Green PCR Master Mix, 5μL; 
10x QuantiTect Primer Assay, 1μL (0.5μL Forward primer; 0.5μL Reverse primer); 
sample cDNA template (variable volume) (e.g. 1μL of 100 ng cDNA); RNAse free 
water to make up to the final volume of 10μL.  
3. Primers available for the following Assays; Mm_IL10_1_SG(IL10); 
Mm_Tnf_1_SG(TNF); Mm_Actb_1_SG(Actb)(HK gene); Mm_IL2_1_SG(IL2); 
Mm_Ifng_1_SG(IFN-γ); Mm_IL17a_1_SG(IL17a); Mm_IL1b_2_SG(IL1β); 
Mm_IL6_1_SG(IL6); Mm_IL13_2_SG(IL13). 
4. Load and run the Rotorgene on a 3-step melt using the following settings (84 
minutes run). Hold 95°C/10 minutes; Cycling (40 cycles) of 1) 95°C for 10 sec, 2) 60°C 
for 15 sec, 3) 72°C for 20 sec (cycling A); Melt ramp 72°C →95°C at 1°C per step, hold 
5 seconds.  
5. Record the M value from the RT cycler 
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3.3 RESEARCH AIM 3: Separate LES into fractions and determine which of 
these confer protection in TNBS colitis.  
This section covers  
• Polarity extractions for sample separation. 
• TLC separation for characterisation. 
3.3.1 Procedure: Polarity extraction method 
Scope: This procedure covers the preparation of sample for GCMS or bioactivity 
screening via the TNBS colitis method. This procedure can be applied to lyophilised 
samples or liquids. Extractions should be carried out in order of increasing polarity. 
Safety/Notes: Full PPE including gown and gloves is recommended. Appropriate safety 
procedures should be adopted when using scalpel blades and appropriate disposal of 
sharps is required. Procedure should be carried out in a fume hood cabinet and all 
solvents should be disposed of appropriately. 
 
Materials/Instrumentation: 
Equipment Requirements: 
• Separation flasks* 
• Schott bottles* 
• Glass beakers* 
• Rotary evaporator  
* All glassware is to be pyrogen-free and appropriately cleaned (rinsed with acetone). 
 
Consumables and reagents: 
• Ashless filter paper (Whatman)  
• Chloroform (Chem Supply – HPLC grade) 
• Ethyl Acetate (Chem Supply – HPLC grade) 
• Petroleum Spirits 40-60°C (Chem Supply – Analytical reagent) 
• Methanol (Sigma-Aldrich – HPLC grade) 
• Acetone (Vetec – Analytical Reagent) 
83 
 
• Dichloromethane (DCM) 
• Dimethyl ethylene (DME)  
Note: Avoid plastic when carrying out polarity extractions to limit the leaching of 
phthalates and other compounds from plastic into the extraction. 
 
Method A – liquid sample: 
General method 
1. Defrost sample for polarity extraction (approximately ~50 mL) and store at 4°C 
until ready for extraction. 
2. Make up a 2:1 solution of chloroform: methanol – chloroform 4 mL: methanol 2 
mL (CM). Otherwise aliquot 6 mL of the desired solvent. 
3. Using a separating flask combine 50 mL of solution of interest and 6 mL of the 
extraction fluid and mix by inversion 30-50 times (vent periodically) until thoroughly 
mixed. Allow phases to separate and remove the bottom layer, ensuring that there is 
no aqueous layer in the decanted material. 
4. Repeat step 3 two times making a total of approximately 18 mL of extracted 
solutions. 
5. Solutions are reduced in volume on the rotary evaporator. 
6. Small volumes of ~500μL are dried down under nitrogen (small volume method B). 
 
Method B – dried sample: 
General method 
1. Lyophilised material (~300 mL of original volume lyophilised to dryness). 
2. Make up a 2:1 solution of chloroform: methanol – make approximately 15 mL of 
chloroform: methanol solution. Otherwise aliquot 15 mL of the desired solvent. 
3. Extract lyophilised material with 13 mL of the chloroform: methanol (or solvent) 
solution. Use a glass stick and ensure that solid material is mixed with the 
extraction solution. Rest the solution for approximately 15 minutes. Filter through 
Whatman filter paper to remove solids. Rinse with 2 mL of the chloroform: 
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methanol extraction material. Rinse beaker with a small amount of DCM (or 
matched solvent)  
4. Transfer material to sample vial and dry under nitrogen to concentrate.  
5. Repeat step 3 two times making a total of approximately 18 mL of extracted 
solutions. 
6. Solutions are reduced in volume on the rotary evaporator. 
7. Small volumes of ~500 μL are dried down under nitrogen (small volume method 
B). 
3.3.2 Procedure: Thin Layer Chromatography and band extraction 
method 
 
Scope: This procedure covers the optimisation of thin layer chromatography (TLC) and 
extraction of bands for further testing. To simplify this method samples should be polarity 
extracted prior to running on TLC to group in to similar polarity. 
Safety/Notes: Full PPE including gown, gloves is recommended. Appropriate safety 
procedures should be adopted using when using scalpel blades and appropriate disposal of 
sharps is required. Procedure should be carried out in a fume hood cabinet and all solvents 
should be disposed of appropriately. 
 
Materials/Instrumentation: 
 
Equipment Requirements: 
• Separation flasks* 
• TLC tank (with lid) 
• Schott bottles* 
• Glass beakers* 
• UV light for visualisation ( 254nm, 365 nm – Spectroline Model CM-10A) 
* All glassware is to be pyroneg free and appropriately cleaned (rinsed with acetone and 
optimised solvent system). 
 
Consumables and reagents: 
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• Ashless filter paper (Whatman)  
• Silica Plate – Analtech-Unitplate Chromatography TLC plate (Cole-Palmer 34103-05) 
Silica Gel GF preparative layer with UV254 (Lot # 30014 (Cat # 02013) 
• Chloroform (Chem Supply – HPLC grade) 
• Ethyl Acetate (Chem Supply – HPLC grade) 
• Petroleum Spirits 40-60 °C (Chem Supply – Analytical reagent) 
• Acetonitrile (ACN)  
• Ammonia (30%) 
• Methanol (Sigma-Aldrich – HPLC grade) 
• Acetone (Vetec – Analytical Reagent) 
• Dichloromethane (DCM) 
• Dimethyl ethylene (DME) 
• Petroleum Spirit 40-60 °C 
 
TLC Optimisation: 
 
Rationale:  
The separation system for TLC needs to be optimised to ensure the maximal separation of 
components of the sample. A polarity extraction prior to TLC is recommended to ensure 
maximal separation of components in the mobile phase. 
Optimising solvent system for TLC 
1. In small beakers set up approximately 5 mL of mobile phase. Using the polarity 
extraction as a guide make up a variety of solvent combinations of spot a small amount of 
the sample of interest on origin of small portions of silica gel plate (2 cm x 5cm) at the 
origin. 
2. Initial separation is trialled in a single solvent system. Optimisation is judged by 
maximal separation of components as judged by visualisation at 254 and 365 nm. 
3. A mixed solvent system is subsequently trialled 50:50 combinations of 
chloroform:methanol, ethylacetate:methanol, chloroform:ethylacetate again assessing 
separation by visualisation at 254 and 365 nm.  
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4. A final optimisation step is to trial different proportions of solvent mixture. In the 
case of this study a chloroform:methanol solvent system proved the most effective and the 
following ratios are trialled: 
Chloroform %  Methanol % 
95    5 
90  10 
80  80 
70  30 
5. The last step in optimisation is to select two solvent systems and trial them along 
each other and then select the optimal separation for all compounds as visualised at 254 
and 365 nm. 
 
Large plate TLC Separation 
Note: It is important to proceed to extraction from the silica plate quickly after this 
separation to avoid sample binding and loss. Have equipment and supplies prepared prior to 
commencing this separation. 
1. Prepare a large TLC tank by cleaning thoroughly with acetone. All solvent systems 
are to be made up fresh and loaded just before running separation. The final step of solvent 
system preparation is addition of ammonia. This should happen in the tank and gently 
mixed. A wick of filter paper is added to the tank is then covered and the system is left to 
equilibrate prior to loading plate. 
2. The solvent system used in this extraction is choloroform:methanol (70:30) ratio (70 
mL with 60 drops of ammonia) 
3. The sample is loaded onto the bottom of the plate (the origin – Rf0) (approximately 
2 cm from the bottom). This is done sequentially allowing for drying between applications 
with up to 50 μg being loaded on the plate. Ensure that the plate is completely dry before 
loading into the separation system. 
4. Carefully place the silica plate into the tank ensuring that it is not in contact with the 
side of the tank. Replace the lid and run until the solvent front is 7/8- 9/10 up the plate. 
5. Remove the plate and let dry briefly. Visualise the plate and outline bands carefully 
using a soft leaded pencil. Proceed promptly to band extraction. 
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Band extraction from TLC Separation 
1. Carefully cut out each band and subsequently into small pieces and place in separate 
clean glass beakers each containing dicholormethane:methanol (70:30). Bands closer to the 
origin are extracted in dicholormethane:methanol (60:40). 
2. Let sit for 30 minutes in solvent extraction system then filter carefully to remove 
silica particles. Transfer to vials and dry under nitrogen and determine the weight of the 
extract. 
3. This material can be prepared for bioactivity screening and characterisation as 
described in this chapter. 
 
3.4 RESEARCH AIM 4: Characterise LES 
This section covers  
• Sample preparation methods- zip tip for MS, preparation for HPLC, preparation 
for LCMS 
• HPLC – Agilent 1600 system 
• GCMS – Underivatised samples on the Shimadzu  
• GCMS – Derivatised samples on the Agilent 
• NMR Sample preparation and analysis 
• Statistical analysis of data. 
• Bioinformatics workflows 
3.4.1.1  Procedure: method for de-salting samples using the C18 Zip tip™ 
procedure 
Scope: This procedure covers the procedure for de-salting small amounts of sample in 
preparation for characterisation on the mass spectrometer. This procedure is adapted 
from the product insert. 
Safety/Notes: Full PPE including gown, gloves is recommended. Appropriate disposal 
of waste is required. 
 
Materials/Instrumentation: 
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Equipment Requirements: 
Automatic pipettes 
Consumables and reagents: 
• C18 Zip tips™ 
• Wetting solution: 100% ACN  
• Equilibration and Wash solution: 0.1 % Trifluoroacetic acid (TFA) 
• Elution solution: 1:1 solution of 0.1% TFA: 50% ACN or 1:1 of 1% Formic Acid (FA): 
50% ACN 
• Microfuge tubes 
NOTE: All reagents are HPLC grade. 
 
Method: 
1. Using a regular pipette transfer 5μL of elution buffer to labelled Microfuge. 
2. Using a C18 Zip tip pipette 10μL of wetting solution and discard into a tissue. 
Repeat this step. 
3. Repeat this with the equilibration solution two times, discarding into a tissue. 
4. Pipette up 10μL of sample and pipette up and down repeatedly but gently to 
adsorb sample into tip. Repeat this with the rest of the sample until the entire sample 
is processed. 
5. Pipette 10μL of wash solution X3 and discard into tissue. 
6. Change the pipette to 4μL. Pipette elution buffer (from tube in Step 1.). pipette 
gently up and down gently several times. 
7. Dry down sample in the Speedivac (using small sample lyophilisation method A). 
Store at -20 °C or prepare for application onto plate for mass spectrometry. 
 
3.4.1.2 Procedure: method for preparing samples for HPLC and LCMS  
Scope: This procedure covers the procedure for preparation of samples for HPLC and 
LCMS analysis. 
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Safety/Notes: Full PPE including gown and gloves is recommended. Appropriate 
disposal of waste is required. 
 
Materials/Instrumentation: 
Equipment Requirements: 
Automatic pipettes 
Consumables and reagents: 
• 0.1 % TFA 
• 1% FA 
• 0.22μm filter  
• syringes 
• Glass vials and inserts 
• HPLC filtered de-ionised water 
NOTE: All reagents are HPLC grade. 
 
Method: 
1. All samples to be loaded onto either the LCMS or HPLC platforms must be filtered 
prior. Using syringe aspirate the sample and then using a 0.22μm filter remove 
particulate material from the sample. 
2. Samples can be prepared in either TFA of FA if they are being prepared from 
lyophilised material. 
3. Consideration should be given to the type of sample being run. An unknown sample 
may have a high proportion of “sticky” components, so a guard column must be 
used and care should be taken not to overload the column. 
4. Load sample into a glass vial (use an insert if volume is <100μL). A larger volume 
may be loaded directly via the sample tubing. 
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3.4.2 Procedure: HPLC method for the detection and separation of 
components from a mixture 
Scope: This procedure covers the preparation of samples and buffers used for the 
HPLC instrument – Agilent Technologies 1260 Infinity. Samples are to be run as 
described by the instrument manual. 
Safety/Notes: Full PPE including gown, gloves is recommended. Safety glasses must be 
worn when operating the HPLC instrument. Appropriate safety procedures should be 
adopted using when using scalpel blades and appropriate disposal of sharps is 
required. 
 
Materials/Instrumentation: 
Equipment Requirements: 
HPLC Agilent Technologies 1260 Infinity system 
Consumables and reagents: 
• C18 Semi-prep and analytical columns (as outlined in table 3.2.) 
•  Buffer A – 0.05 % TFA 
• Buffer B – 30% ACN 
• HPLC vials and inserts 
• Tubes for fraction collection 
• De-ionised water 0.22 μm filtered 
NOTE: All reagents are HPLC grade and all solutions used on the HPLC must be 0.22 μm 
filtered. 
 
Method: 
12. Sample preparation – samples are loaded into glass vials or inserts and 
loaded into position on the automatic sampler of the instrument. If samples contain 
salt buffers, a de-salting profile is to be set up. Examples of the run methods are set 
outlined in Table 3.3. 
13. Buffer A – 0.05 % TFA and filtered through a Durapore Stericup 0.22 μm 
membrane (Millipore). Buffer can be stored at room temperature 
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14. Buffer B – 30% ACN – 300 mL of ACN is added to 700 mL of dH2O and filtered 
through a Durapore Stericup 0.22 μm membrane (Millipore). Buffer can be stored at 
room temperature. 
 
Analytical column 
Jupiter 4 μ Proteo 90 Å 250 x 10.00 mm (4 micron), PN-00G-4396-NO, S/N: 648429-1, 
maximum flow rate 4mL/min  
Semi-prep column 
Jupiter 4 μ Proteo 90 Å 150 x 200 mm (4 micron), PN-00F-4396-BO, S/N: 639622-3, 
maximum flow rate 0.4mL/min 
Table 3.2. List of columns used for separation and characterisation on the HPLC 
Agilent Technologies 1260 Infinity series instrument. 
 
15. Gradient profiles were run at a 1-2 % gradient with a 5-minute wash at the 
beginning of the run to remove buffers and salts from the column. The appropriate λ 
max was determined for each sample by assessing the absorbance of the sample 
across the spectrum using the Polarstar Omega. Generally, monitoring absorbance 
was 214 nm (for peptide bonds), 280 nm (for phenol groups) or an experimentally 
determined wavelength such as 230 nm (λmax =phenol red) 
 
Analytical column 
Sample volume: 20-40μL 
Collection of peaks: 1-minute slices or selective peak collection 
Gradient profile: 
Time (min) Buffer A [%] Buffer B [%] Flow (mL)/min Max Pressure 
0 95 5 1.0 400 
5 85 15 1.0 400 
50 40 60 1.0 400 
55 10 90 1.0 400 
60 10 90 1.0 400 
62 95 5 1.0 400 
 
Semi-prep column 
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Sample volume: 40-100μL 
Collection of peaks: 1-minute slices or selective peak collection 
Gradient profile: 
Time (min) Buffer A [%] Buffer B [%] Flow (mL)/min Max Pressure 
0 95 5  400 
5 85 15  400 
50 40 60  400 
55 10 90  400 
60 10 90  400 
62 95 5  400 
 
Table 3.3. HPLC methods used for the separation of LES material.  
 
3.4.3 Procedure: The operation of GCMS Shimadzu QP2010 Ultra 
Scope: This procedure describes the operation of the gas chromatography mass 
spectrometer (GCMS) and Flame Ionization Detection (FID) Shimadzu QP2010 Ultra for 
the separation and identification of molecules.  
Safety/Notes: Full PPE including gown and gloves is recommended. Appropriate safety 
procedures should be adopted using when using solvents and dispose as required. 
 
Materials/Instrumentation: 
Equipment Requirements: 
GCMS Shimadzu QP2010 Ultra – System No – 4-00081 with AOC-20i Auto-injector 
Consumables and reagents: 
 
• Column: Phenomenex Zebron ZB-50 – 30 m x 0.25 mm, Liquid Phase: 50% Phenyl-
50% Dimethylpolysiloxane. Temperature Limits: 40-320/340°C isothermal. Part #: 
7HG-G004-11 
• Glass sample vials 
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• Solvent carrier system DCM, Chloroform, Methanol, Ethyl Acetate, Petroleum Spirit 
(all reagents are to be GCMS quality) 
• Wash solution Methanol 
 
Method: 
Method Run  
Load the appropriate method and download parameters. Set up runs in single or batch 
modes. Load samples onto the auto sampler. At the end of each run put a vial in 
position -1 and select the Standby method. 
 
 
 
 
 
 
 
 
Table 3.4 Run conditions for samples on the Shimadzu QP2010 Ultra for both MS and FID 
runs. 
Determining Kovat’s Indices 
This method utilises the method for determining Kovat’s indices as described by Girard 
[393]. 
3.4.4 Procedure: GCMS – derivatized Polar metabolites 
GCMS Derivatization performed on Agilent with a Gerstel autosampler 
This analysis is carried out at the Bio21 institute (Metabolomics Australia), University of 
Melbourne, using methods and workflow standard operating procedures approved by the 
facility, briefly described as follows:  
Column ZB-50 
Oven Temperature Program  
Rate Temperature (°C) Hold Time (min) 
- 40.0 1.00 
45.00 190.0 20.00 
12.00 210.0 10.00 
7.00 320.0 4.00 
7.00 320.0 5.00 
Standby   
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Materials/Instrumentation: 
Equipment Requirements: 
Automatic pipettes 
Refrigerated centrifuge for microfuges 
 
Consumables and reagents: 
• 100% Methanol 
• 100% Chloroform 
• Extraction solution: (4.5 mL + 1.44 mL Milli-q water+ 30μL 1mM 13C-sorbitol + 30μL 
10mM 13C,15N-valine)- enough for 10 samples 
• Methoxamine (30mg/mL) in pyridine (Sigma) 
• N,O-bis-(trimethylsilyl) trifluoroacetamide (BSTFA + 1% TCMS) (Pierce Technologies) 
• Microfuge tubes 
• 200μL pulled point inserts 
• 2mL GC/LC sample vials 
NOTE: All reagents are HPLC grade 
Method - Sample preparation  
1. An equal volume of fluid for extraction and chloroform (50μL) are placed in a 
microfuge tube and vortexed for 10 seconds.  
2. Add 150μL of chilled methanol containing internal standards (130μL methanol + 
10μL of 1mM 13C-sorbitol + 10μL of 10mM 13C, 15N-Valine per sample.  
3. Vortex again and centrifuge samples at 16,100 g at 0°C for 5 mins.  
4. Place the supernatant into a new 1.5mL tube containing 100μL of MilliQ filtered 
water, discard any cell debris.  
5. Vortex for 30 seconds then centrifuge samples at 16,100 g at 0°C for 5 minutes.  
6. Finally transfer aqueous phase (top) into a fresh tube. 
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GCMS derivatization and analysis 
1. A 20μL aliquot of sample is loaded into a GCMS microvial insert then evaporated to 
dryness.  
2. The sample is washed with 50μL of methanol and then dried again to ensure sample 
is completely dry.  
3. Tubes are then crimped to seal and loaded onto the GCMS for analysis.  
4. Derivatization is an automated process and is carried out by the Gerstel MPS2 XL 
autosampler robot (Mülheim) with each sample being treated with methoxyamine, 
in pyridine, (20μL of 30 mg/mL, w/v) and the methoximated metabolites derivatized 
with BSTFA + 1% TMCS (20μL, Pierce Technologies). The Agilent 7890A gas 
chromatograph coupled to an Agilent 5975C mass spectrometer are used to analyse 
derivatized samples.  
5. A 30 m J & W Scientific VF-5ms column (plus 10 m Eziguard pre-column Agilent 
Technologies) (250 μm internal diameter and 0.25 μm film thickness) is used. An 
inlet temperature of 250°C and GCMS interface temperature of 280°C and ion source 
temperature of 250°C is maintained. Helium is supplied at a rate of 1 mL. minute−1. 
The initial oven temperature is started at 35°C (hold for 2 minutes) and ramped by 
25°C.minute−1 to 325°C (hold for 5 minutes). Mass spectra are recorded in t 9.19 
scans/s over an m/z range of 50–600. 
Data processing 
1. Data is processed through Bio21 Institute in-house workflows using Metabolomics 
Australia GCMS alignment and integration software, PyMS python toolkit [394].  
2. The peaks identified are then quantitated by automated integration of the area 
under the peaks using Agilent MassHunter Quantitative analysis software. The peaks 
are manually visualized, validated, and gap-filled.  
3. Any peaks that are not been correctly identified by the software are manually 
integrated. Following this, the data is exported as an integrated area matrix for 
statistical analysis. These data sets are supplied in both raw and processed form for 
this project. 
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3.4.5 Nuclear Magnetic Resonance (NMR) – Sample preparation and 
analysis 
Materials/Instrumentation: 
600 MHz AVANCE III NMR spectrometer (Bruker, Karlsruhe, Germany) 
Equipment Requirements: 
Automatic pipettes 
 
Consumables and reagents: 
• NMR tubes with caps 5 mm diameter x 160 mm 
• A suitable heavy solvent: 
• D2O 
• Methanol-D (Aldrich Lot number: TA2073V) 
• Acetonitrile-D3 (ID NMR DLM-53-IOXO Lot number: 12J-112) 
• Chloroform-D (Cambridge Isotope Laboratories Inc. DLM-7TA 50S Lot number: 14H-
248) 
NOTE: All reagents are HPLC grade 
Method - Sample preparation 
1. Using up to 1 mg of sample dissolve in 450μL of matched solvent. Where possible 
the sample is dissolved in 450μl H2O and 50μl D2O, 
2. In a NMR tube add 50μL heavy solvent and mix thoroughly.  
3. Load sample into NMR spectrometer.  
4. Analyse sample as guided by technician (analysis profiles have to be established 
individually but may be repeated after this stage). 
5. Perform 2D 1H,1H TOCSY, 1H,1H NOESY, 1H,1H DQF-COSY, 1H,15N HSQC, and 13C,1H 
HSQC and acquire spectra at 290 K  
6. Samples can be recovered from tubes post analysis. 
Note: Step 3 onwards must be performed under the supervision and direction of a fully 
trained technician.  
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Sample Analysis 
 
1. To analyse the structures of small molecule components, a 600 MHz AVANCE III NMR 
spectrometer (Bruker, Karlsruhe, Germany) equipped with a cryogenically cooled 
probe is used and the following spectra were D2O. 2D 
1H,1H TOCSY, 1H,1H NOESY, 
1H,1H DQF-COSY, 1H,15N HSQC, and 13C,1H HSQC spectra are acquired at 290 K. 
2. Spectra are recorded with an interscan delay of 1 s. NOESY spectra are acquired using 
mixing times of 200–300ms, and TOCSY spectra is acquired with isotropic mixing 
periods of 80ms. Standard Bruker pulse sequences are used with an excitation 
sculpting scheme for solvent suppression. 
 
3.4.6 Statistical analyses 
 
All statistical analyses are performed using GraphPad Prism (version 6.0 or version 7.0). 
Where comparisons are made between groups it is the sample treatment + TNBS groups and 
the TNBS only group; P values of < 0.05 are considered significant *P < 0.05; **P < 0.01; 
***P < 0.001, ****P < 0.0001. 
When determining the differences, two groups are compared using a Mann-Whitney 
(unpaired, non-parametric) U test. One-way ANOVA with a Bonferroni test applied (95% 
confidence interval) is carried out when comparing three or more groups. Results were 
compared to the TNBS negative control.  All results reported denote mean ± standard error 
of the mean (SEM). All data are representative of at least two experiments. The total n is 
noted in the respective figure legends and Results section.  
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3.4.7 Bioinformatics workflows 
LC-MS, MS/MS data 
 
Data obtained from analysis platforms is processed through Protein Pilot™ and Mascot™ for 
sequencing data. Putative sequences are then processed through NIST protein blast 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) and Swissprot (accessed via 
http://uniprot.org/) both with and without specific species filter to identify peptide 
matches. 
 
GCMS Data 
 
Underivatized GCMS data are processed using Shimadzu 2010 software. All chromatograms 
are processed both automatically and manually. Each peak is validated manually and 
fragment patterns are compared to the NIST spectral library for matches. Fragment patterns 
for each chemical are compared to the database and consideration is given to both the 
relative abundance and the probable identity. Matched peaks from separate runs with the 
same probable identity are assigned an identity. Probable identities of less than 69% are 
classified as unconfirmed and unknown molecules are identified. 
 
NMR Data 
 
Spectra are compared to published data and chemical identity assigned if matched. 
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Chapter 4 
Media selection 
Experimental workflow and rationale 
Preamble 
In this chapter I present; 
The preliminary screening and initial proteomic work up for RPMI-cultured low molecular 
weight AcES from dog hookworm. 
The experimental evidence demonstrates a need for a new method for the culture of dog 
hookworm in vitro for small molecule collection as well as the results of media selection 
experiments.  
Finally, I present the experimental workflow that was the basis of the following chapters on 
the isolation and characterisation of anti-inflammatory small molecules from AcES. 
Outputs from this Chapter: 
A collection and culture procedure for A. caninum – See Appendix A 
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4.1 Preliminary screening and proteomic work 
This project commenced with access to a large amount of LES reserved from proteomic 
studies of A. caninum cultured in RPMI as previously described [161]. This material was 
collected from animals in Thailand, Brisbane and locally in Cairns. There were concerns that 
storage as well the diverse geographic location may result in batches with different 
molecular composition, and therefore we should be wary of pooling samples. To eliminate 
this issue each separate collection was run on an analytical HPLC (C18-1% gradient) and 
overlayed prior to pooling. Typical results can be seen in Figure 4.1. Results show minor 
differences and it was decided because of these results that samples would be pooled for 
subsequent work. 
 
Figure 4.1. An Overlay of absorbance (214 nm) traces of six batches of <10 kDa AcES. 
The traces show minor component differences. Samples were pooled for screening and 
characterisation. This is a representative sample only of the 14 batches of AcES compared in 
this way. 
4.2 Peptide component 
The initial focus of research effort was on the potential peptides present in the <10 kDa ES 
from A. caninum. The bulk of this research was done on ES obtained from RPMI culture. 
Samples were prepared and sent to QMIR Berghofer Medical Research Institute (QIMRB) for 
LC-MS analysis using an ABI 5600 mass spectrometer to identify peptides. These samples 
included pooled low molecular weight AcES as well as HPLC fractions that had been shown 
to infer partial protection against inflammation in murine TNBS colitis [373]. In concert with 
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this, LES was separated by HPLC (Agilent 1600) and peaks were collected for MALDI TOF 
analysis. Data returned was analysed through Mascot software and putative peptide 
sequences were aligned to public databases using blast in the NCBIprot and Swissprot 
databases. Sequences were also aligned specifically to the A. caninum draft genome [200]. 
Putative LES peptide sequences can be found in Appendix B. Most of the peptide sequences 
identified corresponded to fragments of larger A. caninum proteins (100% coverage but low 
maximum scores) and likely represent proteolytic degradation products of AcES proteins. 
I also performed HPLC purification followed by MALDI-TOF MS/MS of LES fractionation 
peaks that had previously been shown to protect against TNBS colitis [373]. One peptide 
was identified in all peaks (n=10) and yielded the putative sequence GGPEGPPFLK (See 
Figure 4.2.). This peptide shared 100% identity (max score 37.5) with the A. caninum 
immunodominant hypodermal antigen Ac16 (Accession ABD98404.1), again corresponding 
to a small fragment of a larger protein. To investigate the contents of this fraction it was 
subjected to 1D 1H NMR, however a weak signal meant that the presence of this peptide 
could not be confirmed. 
 
Figure 4.2. The MS/MS peak series of Mw 1206.56 for the putative peptide 
GGEGPPPFLK. 
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It likely that the peptides detected here are the degradation products of larger proteins 
present in AcES. Due to the collection method employed, small peptides produced by the 
hookworm are likely destroyed by proteases and natural degradation during the culture 
period (24 hours). As we had observed protection against TNBS colitis from these fractions 
and we could not definitively find a likely peptide candidate as a final check we carried out 
1D 1H NMR on LMW AcES and compared it not only to the RPMI culture fluid alone but to 
the NMR spectra previously recorded [373]. Figure 4.3. compares these three spectra. It is 
quite apparent from direct comparison that the peaks in the amide region (7.5-9.5 ppm) are 
present in the RPMI media alone and corresponds with the signature peaks of phenol red 
(RPMI pH indicator phenol sulfophalein) which has two peaks at δ 6.62-7.37 [395]. The lack 
of strong indicators in either Figure 4.3a. or 4.3c. NMR spectra do not support a strong 
peptide component present in LES. 
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Figure 4.3. Comparison of 1D 1H NMR spectra of a. LES collected in RPMI media; b. 
RPMI media alone and c. spectra published in the thesis of Markus Baumann, 2012 [373] of 
peak C, the protective fraction identified in his study. The blue circles highlight the peak 
corresponding to the pH indicator in RPMI media, phenol red. 
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4.3 Multiple components of RPMI complicate small molecule analysis 
The strong spectral absorbance of phenol red overwhelmed other components in LES, as 
highlighted in Figure 4.4. It was difficult to determine a suitable λmax for media components 
due to the abundance of phenol red and its high absorbance across the spectra. In addition 
to this phenol red co-elutes in HPLC with peaks of interest.  
In addition to the technical problems associated with phenol red, RPMI contains over 40 
ingredients, all of which are detectable using the techniques that I employed. Many of these 
compounds had reported anti-inflammatory activity. To eliminate the possibility of RPMI 
components contributing to anti-inflammatory activity in the TNBS colitis screen employed 
in this study, the therapeutic properties of RPMI culture media was assessed in the mouse 
model of TNBS colitis. RPMI alone induced significant protection against weight loss induced 
by TNBS colitis (Figure 5). LES cultured in RPMI afforded no protection in this colitis model, 
findings that are concordant with previously described results [373]. 
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Figure 4.4. Phenol red has an overwhelming spectral presence in RPMI dominating the 
visual spectrum and contributing to absorbance at the <280 nm. The λmax indicated (red 
trace) in a. and c. by the arrows at 560 nm and 430 nm respectively represent those of phenol 
red at different pH values.  a. represents the absorbance for RPMI culture material across the 
visual spectrum c. is the visual spectrum (nm) absorbance for low molecular weight AcES 
cultured in RPMI. These spectra show both a pH change and the contribution of phenol red 
indicator to the overall absorbance. b. represents spectral changes of phenol red across the 
spectrum as the pH changes. The λmax for phenol red changes as the media becomes more 
acidic  
< 10 kDa AcES 
cultured in 
RPMI media 
RPMI media 
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Figure 4.5. Weight loss induced by TNBS chemical colitis in C57BL/6 mice. The 
administering 50ug/mouse of RPMI culture media (prepared in the same manner as LES) 
afforded significant protection (* P=0.048) against TNBS-induced weight loss when 
compared to TNBS-treated controls. In contrast mice that are pre-treated with 50ug/mouse of 
LES from hookworms cultured in RPMI show no appreciable protection when compared with 
the TNBS negative controls  Significance was determined using 1-way ANOVA (n=6) 
 
These results indicate that RPMI is unsuitable as a media for A. caninum culture when the 
focus is on small molecule anti-inflammatory activity. This screen also highlights the 
necessity to validate the media used in further work in the TNBS colitis model to ensure that 
it is not a contributing factor to protection. 
4.4 Identifying a new culture method for ES production for small molecule 
study 
To date, it has not been possible to culture hookworms through all their life stages in vitro. 
This is because we do not fully understand the cues this parasite requires from the host to 
trigger life stage changes during its complicated lifecycle. To facilitate my study, it was 
necessary to harvest adult hookworms directly from the intestine of the host animal and 
culture these organisms ex vivo. 
There has been an evolution of culture methods for the dog hookworm as the nature of 
enquiry has changed. These can grouped into three broad themes: (i) physiological studies; 
(ii) proteomics studies; and (iii) my current interest in small molecule secreteomics and 
metabolomics. This study found itself at the crux of the proteomic/small molecule 
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transition, so a number of depleted media combinations were assessed for their ability to 
support hookworms in culture with a view to subsequent small molecule isolation and in 
vivo testing in a colitis mouse model. The remainder of this chapter will focus on substrate 
selection and the ongoing experimental workflow. 
Physiological studies of A. caninum are aimed at optimising the fecundity versus the 
longevity of the parasite in culture. This is determined by both the time the organism 
survived in vitro and the yield of egg production/shedding by female worms. The use of 
Krebs-ringer solution supplemented with 50% dog serum resulted in hookworm survival in 
vitro for >10 weeks [61]. This culture method has been shown to be suitable for studying 
basic physiology of the organism, as well as the effectiveness of anti-helminthic therapy in 
vitro. The presence of dog serum however precluded analyses of the protein and small 
molecule content of AcES. Worms were instead cultured in PBS, but rapidly became 
immotile and were lethargic by 12 hours and up 60% dead by 22 hours [396]. RMPI and 
Glutamax™ were later tested [5, 161] and supported hookworms for up to three days in 
culture.  
It was decided that three culture conditions would be trialled for their ability to support 
adult hookworms in vitro (Table 4.1). The specific aim of these formulations was to reduce 
possible small molecule confounders while supplying an energy source; D-glucose as a 
carbohydrate source and Glutamax™ as an amino acid source. Glutamax™ is a dimer of 
glutamine and alanine. Concentrations were selected based on those provided in RMPI 
media formulation (Table 4.1.). Culturing worms in PBS (Table 4.1) was also conducted for 
comparative purposes. 
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Culture media 
formulations Key ingredients of culture conditions for A. caninum adults 
1% Glutamax 
Dulbecco’s Phosphate Buffered Saline (DPBS) (+) 
Calcium Chloride (+) Magnesium Chloride (Gibco, 
Life Technologies)  
485 mL 
2% antimycotic/antibiotic  10 ml anti/anti  
1% Glutamax.  5 ml Glutamax 
2g/L Glucose/ 1% 
Glutamax 
Dulbecco’s Phosphate Buffered Saline (DPBS) (+) 
Calcium Chloride (+) Magnesium Chloride (Gibco, 
Life Technologies)  
490 mL 
2% antimycotic/antibiotic  10 ml anti/anti  
1% Glutamax 2g/L glucose 5 ml Glutamax  
1 g D-glucose 
2g/L Glucose 
Dulbecco’s Phosphate Buffered Saline (DPBS) (+) 
Calcium Chloride (+) Magnesium Chloride (Gibco, 
Life Technologies)  
490 mL 
2% antimycotic/antibiotic  10 ml anti/anti  
2g/L glucose 1 g D-glucose 
PBS† 
Dulbecco’s Phosphate Buffered Saline (DPBS) (+) 
Calcium Chloride (+) Magnesium Chloride (Gibco, 
Life Technologies)  
490 mL 
2% antimycotic/antibiotic  10 ml anti/anti  
RPMI† 
RPMI 1640 (Gibco, Life Technologies)  485 mL 
2% antimycotic/ 
antibiotic  
10 ml anti/anti  
1% Glutamax.  5 ml Glutamax 
Table 4.1. Culture conditions employed in this study for the aim of harvesting low 
molecular weight ES from A. caninum. †Both RPMI [5, 161] and PBS [397] formulations 
are included in this table for comparison and were employed in the initial stages of this study. 
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4.5 Results 
Adult A. caninum were collected as described in Chapter 3 and cultured for a total of three 
days and survival recorded. The percent survival of adult hookworms is reported (Figure 
4.7). Based on these results any of the three culture formulations was deemed appropriate 
for culture of A. caninum ES and are comparable to the established RPMI culture method. In 
all three culture conditions, hookworms were noted to shed ova across the course of the 
experiment. The PBS only culture method showed poor survival and hookworms surviving 
past 24hours were lethargic and many only responded when gently palpated. 
 
Time (days) 
Figure 4.7. The percent survival of adult A. caninum in different media formulations. 
Hookworms cultured in PBS showed poor survival over the course of monitoring. Worms 
supplemented with the other formulations showed comparable survival rates to RPMI.  
4.5 Experimental Rationale and Workflow 
The general experimental workflow that formed the basis for this thesis is detailed in Figure 
4.8. Using this workflow, it was possible to concertina the dual aims of molecular 
characterisation of LES and identification of anti-inflammatory bioactivity. 
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Figure 4.8 Workflow of A. caninum LES characterisation, separation, and in vivo 
screening for anti-colitic bioactivity along with the decision rationale for each step.  
4.6 Discussion 
The aim of this body of work is to identify immunomodulatory small molecules produced by 
the dog hookworm at the gut interface. Since LES was harvested from the diffusate using a 
10 kDa size exclusion column a wide range of molecules are possible. This work is builds 
upon on the initial screening of RPMI derived LES was carried out by Markus Baumann and 
detailed in his Master’s thesis [373]. His work demonstrated that while LES showed little 
protection against TNBS induced colitis, some of the HPLC-separated fractions resulted in 
protection against TNBS-induced weight loss and macroscopic pathology when compared to 
control mice that received TNBS. Based on 1-D NMR it was concluded that the protective 
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component of low molecular weight AcES was proteinaceous in nature [373]. Work here has 
failed to support this conclusion.  
It was not possible to establish a pool of peptides for screening here. On reflection, this may 
be due to collection methods. Culture media is only collected every 24 hours. Peptides 
unless they are stabilised in some way (through cyclisation or multiple disulphide bonds) are 
unstable. Most peptides are thought to have a half-life of between 2-30 minutes in vivo in 
part due to proteolysis. Since we know that there is at least six proteases identified in the ES 
of A. caninum [161] prolonged culture is likely to limit the ability to detect peptides due to 
degradation. Due to limited access to source material it was decided to shift focus to the 
small molecules that A. caninum produces and look for molecules that may have anti-
inflammatory potential. 
I was able to show here that mice treated with RPMI alone are protected against the effects 
of TNBS induced weight loss. This may be due to one or many of the components of RPMI 
and has been discussed in more detail in Chapter 2. The contribution of the media indicator 
phenol red was also problematic as it had an overwhelming spectral presence and co-eluted 
with fractions of interest. The technical difficulties of the small molecules present in the 
RPMI meant that other formulations had to be considered. I have screened a number of 
simple formulations here that are able to support hookworms in culture for up to three 
days. These depleted media mean that hookworms may not be cultured in optimal 
conditions to support physiological functions yet all three formulations displayed ova shed 
indicating that fecundity was maintained. 
In the shift from proteomic studies to small molecule studies has shown that established 
culture methods for proteomics are not suitable. The study of helminth small molecules 
means that a complex media adds a technical difficulty that can be overcome by the use of 
minimal media combinations.  
The next chapter: In the next chapter I utilise small molecule techniques to separate small 
molecule components from LES. This is guided by the TNBS chemical colitis screen (a broad 
based bioactivity screen for anti-inflammatory potential). Using these combined techniques 
I highlight fractions from LES that have therapeutic potential. 
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Chapter 5 
Hookworm LES protects against TNBS-
induced acute colitis in mice 
Preamble 
In this chapter I present the results of screening A. caninum LES produced in a variety of 
media combinations using a mouse model of TNBS chemical colitis. 
I demonstrate that protection can be elicited with LES collected from hookworms cultured 
in minimal media supplemented with Glutamax™, but none of the other media 
combinations investigated. I also demonstrate that the media alone has no protective 
properties in the TNBS colitis model, indicating that it is the hookworm derived molecules 
responsible for protection. 
I show that hookworm LES components can be separated by polarity extraction and 
bioactivity is retained in some fractions. 
Finally, a protective fraction is further separated by thin layer chromatography into 11 
fractions. Only four of these fractions elicit protection in the TNBS colitis model, 
demonstrating that protection is caused by distinct moieties within hookworm LES. 
Outputs from this chapter 
The low molecular weight secretome of Ancylostoma caninum protects against colitis in a 
murine model. Shepherd, C., Wangchuk, P., Constantinoiu C., Navarro S., Wilson D., 
Kouremenos, K. A., De Souza, D. P., McConville, M., Daly N., and A. Loukas  
First Author 
IN DRAFT; Target journal: International Journal for Parasitology 
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5.1 The TNBS chemical colitis model as a bioactivity screen 
The murine TNBS chemical colitis model used in this thesis is adapted from the method 
described by Ruyssers et al. [5] and Wirtz et al. [6]. In this model, trinitrobenzene sulfonic 
acid (TNBS) is administered directly to the colon via rectal enema of the animal in an ethanol 
solution. The ethanol acts to disrupt the cells of the gut lining, lyse bacteria, as well as react 
with gut contents. The highly reactive TNBS then haptenises these normally harmless 
components, allowing them to translocate and be presented to the immune system, 
initiating a series of inflammatory responses. Outwardly, the mouse will present as if they 
have an acute bout of UC. They will lose weight over the course of a couple of days, be 
lethargic, lose interest in preening and their natural curiosity will wane. All of these changes 
can be closely measured to gain clinical indices scores. By the third day the TNBS/Ethanol 
treated mice will start to recover, and it is here that our screening ends. 
The TNBS colitis model is mechanistically complex, and triggers Th1, Th17 and Th2 immune 
responses, as well as inducing innate responses, including the inflammasome pathway. It is 
for this precise reason that this model lends itself well to screening for LES molecules with 
unknown targets/mechanisms of action. At the initial screening stage, assessment of 
cytokine responses confirms that the immune response is stimulated as part of this 
protection process. As the separation of LES components progresses, it is possible to 
determine whether this protection is due to individual molecules or groups of molecules 
acting synergistically. By assessing mouse cytokine responses, we may be guided to select 
appropriate and more refined mechanistic models for future testing. It is worthwhile 
emphasising here that the TNBS chemical colitis screen is used in this body of work in its 
capacity as a screening tool, and not as a final mechanistic model. 
Additional advantages of the TNBS colitis model for this study are that it uses relatively 
small amounts of test material (single treatment per mouse) and the experiment has a short 
timeframe. This means valuable material can be used sparingly and that protection is 
gauged quickly by the assessment of weight loss and other clinical and pathologic indices. 
This allows successive screens to occur in a relatively short period.  
The following data is presented in the context of TNBS chemical colitis as a bioactivity 
screen for protection against colitis. I combine this bioactivity screen with small molecule 
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techniques for the separation of LES components, with the ultimate aim of isolating 
hookworm molecules that may have therapeutic potential. The experimental rationale for 
proceeding to the next step is outlined throughout this chapter. 
5.2 Hookworms cultured in Glutamax™ media produce LES components 
that protect against TNBS colitis 
Four media combinations were trialled for the culture of A. caninum and harvesting of small 
molecule ES. These are outlined in Chapter 4 but are briefly; PBS only, PBS with 1% 
Glutamax™, PBS with 1% Glutamax™ combined with 2 g/L D-glucose and finally PBS with 2 
g/L D-glucose. All of these media contained Anti-Anti (Gibco) to suppress fungal and 
bacterial growth during culture. Samples were prepared as outlined in Chapter 3 and 
administered to mice i.p. at a dose of 50 μg/mouse prior to TNBS colitis induction. In Figure 
5.1 weight loss of each treatment group as a percentage of their starting weight is plotted 
over the course of the experiment. Only LES derived from hookworms cultured in 
Glutamax™ protects against weight loss. 
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Figure 5.1. Mice treated with LES harvested from adult A. caninum cultured in 1% 
Glutamax™ are significantly protected against TNBS induced weight loss. Weight loss 
of mice in the treatment groups is compared to the TNBS control by 2-way ANOVA. Mice 
treated with 50 μg of LES material harvested from hookworms cultured in 1% Glutamax™ 
showed significant protection against weight loss when compared to the TNBS control (**** 
= P<0.0001). Hookworms cultured in either PBS (LES (PBS)) alone or a combination of 1% 
Glutamax™/2 g/L D-glucose (LES (Glutamax™/Glucose) showed no significant difference 
in weight change from the TNBS control. Finally, hookworms cultured in a medium of 2 g/L 
of D-glucose had significantly lower weights than the TNBS control group (** = P<0.01). All 
results are the aggregation of at least two independent experiments. Treatment groups 
received 50 μg of LES material per mouse via i.p. injection (n=12). 
Interestingly, the LES (Glucose)-treated mice fared worse than negative control mice that 
received TNBS in this model. The LES (Glucose)-treated mice lost significantly more weight 
than TNBS controls and did not recover in the timeframe of the experiment. It would be 
interesting to explore the drivers of this observation later. 
Colon lengths of treated and control mice were assessed for shortening, one of the key 
indicators of TNBS chemical colitis. Colon lengths were measured at the end of the 
experiment upon euthanasia of the mice. Mice pre-treated with 50μg of LES from 
hookworms cultured in 1% Glutamax™ had significantly longer colons than the TNBS 
controls.  
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Figure 5.2. Mice treated with LES harvested from adult A. caninum cultured in 1% 
Glutamax™ are significantly protected against TNBS-induced colon shortening. Colon 
length of mice in treatment groups is compared to the TNBS control by 2-way ANOVA. 
Mice treated with 50 μg of LES material harvested from hookworms cultured in 1% 
Glutamax™ showed significant protection against colon shortening when compared to the 
TNBS control (** P = 0.018). Colon lengths of mice treated with LES from worms cultured 
in PBS (LES (PBS)) or 2 g/L of D-glucose (LES (Glucose)) showed no significant difference 
from the TNBS control group. Colon lengths of mice treated with LES from hookworms 
cultured in a combination of 1% Glutamax™/2 g/L D-glucose (LES (Glutamax™/Glucose)) 
showed significantly longer colons than the TNBS control group (* P =0.0197). All results 
are the aggregation of at least two independent experiments. Treatment groups received 50 μg 
of LES material per mouse via i.p. injection (n=12). 
These two results clearly indicate that Glutamax™ cultured hookworms produce small 
molecules that are able to protect against TNBS chemical colitis. Due to the complications of 
media selection it was considered prudent to screen Glutamax™ media (PBS, 1% Glutamax™ 
and 2X Anti-anti (Gibco)) in the TNBS model to eliminate the possible role of media 
ingredients in protection against TNBS colitis. Glutamine is one of the components of 
Glutamax™. Glutamine is considered an immune supportive nutrient [390], and 
administration has been shown to be protective in cases of colitis in humans [385, 398]. 
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Administration of glutamine results in reduction of TNF and the main pro-inflammatory 
cytokines released in in active CD [385]. I also addressed the role of Anti/Anti (Gibco) in 
protection. There are no reported anti-inflammatory activities for either streptomycin or 
penicillin and its breakdown products (penilloic acid, penicilloic acid and isopenillic acid), 
however the anti-mycotic amphotericin B has reported immunomodulatory activity in the 
literature [399]. The results for this screen are detailed in Figure 5.3.  
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Figure 5.3. Mice treated with 1% Glutamax™ media alone are not protected against 
TNBS-induced weight loss and colon shortening. Weight loss (left) and colon lengths 
(right) of mice treated with Glutamax™ media alone were comparable to the TNBS control, 
and conferred no protection compared to LES (Glutamax)-treated mice (P<0.0001 weight 
loss; P<0.01 colon length). Weight loss and colon lengths were assessed by 1-way ANOVA. 
Mice were treated with 50 μg material via i.p. injection. All results are the aggregation of at 
least two independent experiments. Treatment groups, n=8. 
Based on the results it was decided that A. caninum would be cultured in 1% Glutamax™ 
media for all further work. These preparations showed convincing protection in the TNBS 
colitis model and the work that follows details the separation of LES (Glutamax™) into 
fractions in an attempt to isolate molecules that exhibit anti-inflammatory activity but also 
have therapeutic potential (or druggability). Characterisation of A. caninum LES can be 
found in Chapter 6. 
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5.3 A. caninum LES (Glutamax™) treatment results in improved clinical 
indices, reduced histopathology and promotes anti-inflammatory cytokine 
production in TNBS colitis 
 
Given the significant protection against TNBS-induced weight loss and colon shortening 
afforded by LES (Glutamax™), the nature of the protection was examined in closer detail. 
Clinical indicators, macroscopic pathology scores, histology, and cytokine analyses were 
carried out. Overall mice that were pre-treated with LES (Glutamax™) were much healthier 
and showed less tissue damage than TNBS alone treated mice. In addition, treatment 
resulted in altered levels of cytokines associated with IBD. Figure 5.4 shows the clinical 
indicators of mouse health (mobility, piloerection, stool quality/output) along with the 
clinical score (an aggregated score including weight loss indices). In all cases LES 
(Glutamax™)-treated mice are significantly healthier than the TNBS control mice during the 
course of the experiment. 
 
119 
 
N
a
i v
e
T
N
B
S
L E
S
 G
l u
t a
m
a
x
0 . 0
0 . 2
0 . 4
P
il
o
e
r
e
c
t
io
n
 s
c
o
r
e
* * *
N
a
i v
e
T
N
B
S
L E
S
 G
l u
t a
m
a
x
0 . 0
0 . 2
0 . 4
0 . 6
M
o
b
il
it
y
 s
c
o
r
e
* * * *
N
a
i v
e
T
N
B
S
L E
S
 G
l u
t a
m
a
x
0 . 0
0 . 5
1 . 0
1 . 5
2 . 0
2 . 5
F
a
e
c
a
l 
c
o
n
s
is
t
e
n
c
y
 s
c
o
r
e
* * * *
0 1 2 3
0
1
2
3
4
5
D a y s
C
li
n
ic
a
l 
s
c
o
r
e
L E S  G l u t a m a x
T N B S
N a i v e
*
*
*
a
dc
b
Figure 5.4. Mice treated with 50 μg of LES (Glutamax™) have significantly lower 
clinical disease scores than the TNBS only treated controls. Piloerection score for mice 
treated with LES (Glutamax™) is significantly lower than the TNBS control group (a; *** P 
= 0.0003). The mobility score was significantly lower for the LES (Glutamax™) treatment 
group when compared to the TNBS control (b; **** P <0.0001). Similarly, stool consistency 
showed a marked improvement in LES (Glutamax™)-treated mice when compared to TNBS 
controls (c; **** P <0.0001). Finally, there was a significant difference in clinical scores of 
LES (Glutamax™)-treated mice compared to TNBS controls (d; *** P=0.0005). All 
differences were assessed by 2-way ANOVA when compared to the TNBS control. All 
results are the aggregation of at least two independent experiments. Treatment groups 
received 50 μg material per mouse via i.p. injection (n=10). 
As part of the TNBS colitis, colon quality at necropsy can be assessed. Markers of colitis such 
as colon edema and thickening, adhesion to tissues and the presence of ulcers are 
macroscopic indicators of the colitic process. In Figure 5.5 I compare the colons of LES 
(Glutamax™)-treated mice with the TNBS control; these mice have significantly lower 
macroscopic indicators of colitis than the negative controls. 
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Figure 5.5. Mice treated with 50 μg of LES (Glutamax™) prior to administration of 
TNBS have significantly lower macroscopic scores than controls. Colon adhesion for 
mice in the LES (Glutamax™)-treated group is significantly lower than the TNBS control 
group (a; * P = 0.0111). Colon thickening was reduced in the LES (Glutamax™)-treated 
group when compared to the TNBS control (b; *** P = 0.0002). Similarly, when assessing 
edema there was an improvement in LES (Glutamax™)-treated mice when compared to 
TNBS controls (c; ** P = 0.0024). Finally, ulceration is significantly lower in LES 
(Glutamax™)-treated mice compared to TNBS controls (d; *** P=0.0001). All differences 
were assessed by 1-way ANOVA when compared to the TNBS control. All results are the 
aggregation of at least two independent experiments. Treatment groups received 50 μg 
material per mouse via i.p. injection (n=10). 
Colon tissue was stained with haematoxylin/eosin (H&E) stain and a blind scoring was 
carried out of on the criteria outlined in Chapter 3 (Material and Methods). Briefly, slides 
were assessed at high resolution for ulceration, infiltration of the muscularis mucosa, overall 
integrity of the epithelium and the presence of lymphoid follicles, and scored to a maximum 
16. Figure 5.6 shows typical representations of histology of naïve, TNBS only, and mice pre-
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treated with LES (Glutamax™) prior to TNBS, as well as the aggregate histological score for 
each treatment group.  
Colons of LES (Glutamax™)-treated mice were also assessed for production of a number of 
cytokines to confirm that treatment protected against changes in cytokine-driven 
pathological outcomes and resulted in an anti–inflammatory profile. These results were also 
used as a guide to frame the isolation of the immunomodulatory agents that may be 
present in LES (Glutamax™). Figure 5.7 presents cytokine results for both colon culture and 
colon homogenates. All cytokine results presented are normalised to tissue weight to allow 
for comparison across experimental groups and will be reported in pg cytokine/mg tissue. 
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Figure 5.6. Pre-treatment with 50 μg of LES (Glutamax™) per mouse results in 
significant protection against TNBS-induced colitis. Panels a-c show longitudinal sections 
(3-4 μm) of mouse colon stained with haematoxylin & eosin; the white bar represents a scale 
of 200 μm. All pictures are in the same orientation. Panel a) shows a typical section from a 
naïve (no treatment mouse) colon. Panel b) shows a section from a TNBS-treated colon – 
note the massive destruction of mucosal layer (M), thickening, and infiltration of the 
muscularis externa (ME) due to ulceration. Panel c) shows colon tissue from mice pre-treated 
with 50 μg of LES (Glutamax™) via i.p. injection and then exposed to TNBS, note the 
maintenance of mucosal layers and relatively little immune infiltration of the tissue. Panel d) 
shows the aggregate of blinded scoring of histopathology slides, where a score of 0 is 
completely normal tissue and 16 completely degraded. TNBS treated mice score highly 
whereas LES (Glutamax™)-treated mice have significant (1 way ANOVA n=8) protection 
against colitis (**** P<0.0001). It should be noted that LES (Glutamax™)-treated mice only 
received a score above zero based on lymphoid follicles. 
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Figure 5.7. Changes in colon cytokine levels induced by treatment with 50 μg LES 
(Glutamax™) prior to induction of TNBS colitis in mice. Of the nine cytokines assayed, 
five are significantly different between the treatment and control groups after TNBS 
administration (1 way ANOVA). Cytokines were measured from colonic tissue cultured for 
24 hours in complete media (a-f). LES (Glutamax)-treated mice had significantly lower levels 
of a) IL-1β (* P = 0.0109); e) IL-13 (* P = 0.0100) and f) TNF (** P = 0.0090) when 
compared to TNBS control groups. There were no significant differences in the levels of IL-4 
(b), IL-5 (c), and IL-6 (d). Measurement of cytokine levels in homogenates of colons from 
LES (Glutamax™)-treated mice showed a significant increase in IFN-γ (g; ** P = 0.0090) 
and IL-17A (i; * P = 0.0154) with respect to the TNBS control. There were no discernible 
changes in TGF-β levels (h). All results are the aggregation of at least two independent 
experiments. Treatment groups received 50 μg material per mouse via i.p. injection (n=8).  
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These results are notable for a number of reasons; cytokines from the colon cultures 
indicate an anti-inflammatory response induced by LES (Glutamax™) but colon 
homogenates have increased levels of pro-inflammatory cytokines like IL-17A and IFN-γ. 
There is also a mismatch of high IL-17A levels and those of the downstream cytokines of TNF 
and IL-6. What is perhaps most interesting is that a spectrum of Th1, Th2 and Th17 cytokines 
are affected by LES (Glutamax™) treatment. It is worth noting that IL-17A does not always 
display pro-inflammatory activity but also plays a role in anti-inflammatory/regulatory 
responses. This is the first time that the small molecule milieu produced by any helminth 
has been shown to induce protection against colitis and induce an anti-inflammatory 
response. 
Encouraged by these results, I progressed with separation of LES (Glutamax™) utilising small 
molecule chemistry techniques. These techniques have been used extensively in the study 
of ethnobotanicals for the isolation and identification of small molecules. It was hoped that 
using these processes it would be possible to identify the anti-inflammatory agents present 
in hookworm LES (Glutamax™) with a view to exploiting their therapeutic potential. 
5.4 Polarity extraction of LES (Glutamax™) into three fractions yields only 
two fractions that retain protection in the murine TNBS colitis model. 
The first separation process was the Folch extraction [400] which primarily separates 
components on the basis of their polarity. Three fractions of LES (Glutamax™) were 
generated using this technique; the first was chloroform: methanol (CM) fraction; the 
second was the non-polar ethyl acetate (EA) fraction; and a final polar salts (PS) fraction was 
generated. There were still concerns regarding the concentration of media components at 
this stage, so a polarity extraction of media alone was also carried out and tested alongside 
the LES (Glutamax™) fractions. The three LES (Glutamax™) fractions were then tested in 
TNBS colitis. 
At the same time as these experiments were carried out, I conducted a dosing study in the 
TNBS colitis model. Initial screens of the three LES (Glutamax™) fractions in TNBS colitis 
were carried out using 50 μg of material per mouse, but this did not significant protection 
against colitis. Given that the extraction processes would have concentrated some 
125 
 
components (including potentially toxic ones); I tested a lower dose (20 μg) of material in 
TNBS colitis.  
When compared to the TNBS control group, mice treated with both the EA and CM LES 
fractions showed significant protection against TNBS-induced weight loss (Figure 8a). The PS 
LES fraction elicited no significant protection in this model. To rule out the anti-
inflammatory potential of Glutamax™ media components, the media alone (in the absence 
of hookworm culture) was extracted in the same manner as the LES (Glutamax™) material, 
and the EA and CM fractions were tested in the TNBS colitis model (Figure 5.8b). In this 
screen I demonstrated that protection was elicited by the EA media fraction but not the CM 
fraction. This fraction contained the most non-polar compounds, and were likely to be less 
soluble and therefore less bioavailable than compounds in the other fractions [24]. 
Moreover, it was decided that due to the confounding issue of media components present 
in the EA fraction that elicit protection against TNBS colitis, that the LES EA Glutamax™ 
fraction was not suitable for further exploration. I therefore decided to pursue the CM LES 
fraction for further experimentation. Screens of the media fractions - EA Glutamax™ and CM 
Glutamax™ - indicated that the EA fraction protected against weight loss (Figure 5.8b). 
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Figure 5.8. Polarity extraction of small molecule ES (LES) harvested from adult A. 
caninum cultured in 1% Glutamax™ yields two protective fractions. a) Mice treated with 
20 μg of either EA LES Glutamax™ (*** P = 0.0001) or CM LES Glutamax™ (**** 
P<0.0001) showed significant protection when compared to the TNBS control (1 way 
ANOVA, n=10). Polar salt extracts elicited no protection in the TNBS colitis model. When 
mice were treated with 20 μg of the media via i.p. injection prior to TNBS administration, 
only EA Glutamax™ and CM Glutamax™ extracts elicited significant protection (** P = 
0.0012) in the TNBS colitis model (1 way ANOVA, n=6). 
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A more thorough assessment of the anti-colitic properties of LES-CM was conducted to 
assess clinical scoring, histology and cytokine analyses.  
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Figure 5.9. Mice treated with 20μg of LES CM (Glutamax™) have significantly lower 
clinical disease scores than the TNBS only treated controls. Piloerection score for mice 
treated with LES (Glutamax™) is not significantly lower than the TNBS control group (a). 
The mobility score was significantly lower for the LES (Glutamax™) treatment group when 
compared to the TNBS control (b; **** P <0.0001). Similarly, stool consistency showed a 
marked improvement in LES (Glutamax™)-treated mice when compared to TNBS controls 
(c; **** P <0.0001). Finally, there was a significant difference in clinical scores of LES 
(Glutamax™)-treated mice compared to TNBS controls (d; *** P= P=0.0042). All 
differences were assessed by 1-way ANOVA when compared to the TNBS control. All 
results are the aggregation of at least two independent experiments. Treatment groups 
received 20 μg material per mouse via i.p. injection (n=10). 
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Figure 5.10. Mice treated with 20 μg of LES CM (Glutamax™) prior to administration of 
TNBS have significantly lower macroscopic scores than controls. Colon adhesion for mice in 
the LES CM (Glutamax™)-treated group is significantly lower than the TNBS control group (a; 
(*** P = 0.0002). Colon thickening was reduced in the LES CM (Glutamax™)-treated group 
when compared to the TNBS control (b; **** P <0.0001). Similarly, when assessing edema 
there was an improvement in LES CM (Glutamax™)-treated mice when compared to TNBS 
controls (c; (**** P <0.0001). Finally, ulceration is significantly lower in LES (Glutamax™)-
treated mice compared to TNBS controls (d; ** P=0.0015). All differences were assessed by 
1-way ANOVA when compared to the TNBS control. All results are the aggregation of at 
least two independent experiments. Treatment groups received 20 μg material per mouse 
via i.p. injection (n=10). 
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Figure 5.11. Pre-treatment with 20μg of LES CM (Glutamax™) per mouse results in 
significant but not complete protection against TNBS induced colitis. Panels a-c show 
longitudinal sections (3-4 μm) of mouse colon stained with haematoxylin & eosin; the white 
bar represents a scale of 200 μm. All pictures are in the same orientation. Panel a) shows a 
typical section from a naïve (no treatment mouse) colon. Panel b) shows a section from a 
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TNBS-treated colon – note the massive destruction of mucosal layer (M), thickening, and 
infiltration of the muscularis externa (ME) due to ulceration. Panel c) shows colon tissue 
from mice pre-treated with 20 μg of LES CM (Glutamax™) via i.p. injection and then 
exposed to TNBS, note the maintenance of mucosal layers and relatively little immune 
infiltration of the tissue. Panel d) shows the aggregate of blinded scoring of histopathology 
slides, where a score of 0 is completely normal tissue and 16 completely degraded. TNBS 
treated mice score highly whereas LES CM (Glutamax™)-treated mice have significant (1 
way ANOVA n=10) protection against colitis (**** P<0.0001). 
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Figure 5.12. Changes in colon cytokine levels induced by treatment with 20 μg LES CM 
(Glutamax™) prior to induction of TNBS colitis in mice. Of the seven cytokines assayed 
here, two are significantly different from the TNBS control (1 way ANOVA). Cytokines 
were measured from colonic tissue cultured for 24 hours in complete media (a-g). LES 
(Glutamax)-treated mice had significantly lower levels of a) IL-1β (* P = 0.0145) and e) IL-
13 (** P = 0.0024. There were no significant differences in the levels of IL-4 (b), IL-5 (c), 
IL-6 (d), TNF (f), and IFN-γ (g). All results are the aggregation of at least two independent 
experiments. Treatment groups received 20 μg material per mouse via i.p. injection (n=10).  
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5.5 Thin layer chromatography (TLC) separation of LES CM (Glutamax™) 
reveals four components that are protective in the TNBS colitis model. 
After establishing that the CM fraction of LES (Glutamax™) can protect against TNBS colitis, 
further separation of components was achieved by TLC. Using a an Analtech-Uniplate silica 
gel plate with a chloroform: methanol (70:30) solvent system, 32.89 mg of LES CM 
(Glutamax™) extract was loaded onto the plate, separated and extracted as per the 
Materials and Methods; Chapter 3. The plate was visualised under both 254 and 365 nm and 
six fluorescent/absorbent bands were identified. In addition to this, five interceding non-
absorbing bands were extracted. A representation of the extracted bands can be found in 
Figure 5.13 along with the extraction solvent and yield. 
Samples were dried and weighed for yield then resuspended for analysis. On preparation, 
band 4 displayed differential solubility and was subsequently divided into two fractions, 
referred to here as Band 4 (precipitate) and Band 4s (supernatant fraction). Each band was 
administered to mice (20 μg per mouse via i.p. injection) prior to administration of TNBS for 
bioactivity assessment as previously described. Bands E1 and E2 were outside the sample 
separation area on the silica gel slide (area below the origin and above the solvent front) but 
were combined for TNBS testing as Band E. Figure 5.14 shows the weight loss curves of mice 
treated with eluate from bands A-E (a) and 1-6 (b).  
 
 
 
 
 
 
 
 
 
133 
 
TLC silica plate (Band) Extraction Solvent Yield (mg) 
E
1
 DCM:Methanol (70:30) 1.4* 
6 DCM:Methanol (70:30) 2.31 
D DCM:Methanol (70:30) 0.98 
5 DCM:Methanol (70:30) 6.64 
C DCM:Methanol (70:30) 1.45 
4 DCM:Methanol (70:30) 14.86 
B DCM:Methanol (70:30) 1.83 
3 DCM:Methanol (70:30) 1.35 
A DCM:Methanol (60:40) 1.44 
2 DCM:Methanol (60:40) 2.12 
1 DCM:Methanol (60:40) 0.44 
E
2
 DCM:Methanol (70:30) 1.4* 
Figure 5.13. The representation of the large TLC silica gel separation plate of LES CM 
(Glutamax™) along with extraction and yield data. Bands A-E (green shading) displayed 
no fluorescence or absorbance at 254/365 nm. Bands 1-6 (grey shading) showed both 
fluorescence and absorbance at 254/365 nm. Bands were extracted in the solvent 
combinations, dichloromethane (DCM): methanol. The yield from each band is indicated; E1 
and E2 were combined for TNBS testing and are indicated by *. 
134 
 
0 1 2 3
8 0
9 0
1 0 0
1 1 0
D a y s
N a i v e
T N B S  +  v e h i c l e
*
*
*
W
e
ig
h
t
 l
o
s
s
 i
n
 %
b
B a n d  4
B a n d  4 s
B a n d  5
B a n d  6
B a n d  1
B a n d  2
B a n d  3
* * * *
* * * *
* * * *
0 1 2 3
8 0
9 0
1 0 0
1 1 0
D a y s
N a i v e
T N B S  +  v e h i c l e
W
e
ig
h
t
 l
o
s
s
 i
n
 %
a
B a n d  A
B a n d  B
B a n d  C
B a n d  D
B a n d  E
 
Figure 5.14. Four bands extracted from LES CM (Glutamax™) via TLC demonstrate 
protection against TNBS colitis weight loss. Here we tested 12 bands extracted from the 
TLC of LES CM (Glutamax™). Mice were treated with 20 μg of material via i.p. injection 
and four bands displayed protection against TNBS-induced weight loss. Band 4, 4s and 6 all 
significantly protect against weight loss (****P <0.0001), Band 5 (*** P = 0.0004) shows 
protection against chemical colitis when compared to the TNBS control. All other bands 
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showed no significant protection (bands A-E and bands 1-3). Band E (a) was combined from 
silica below the origin and above the reagent front of this separation and acts as a control of 
the silica gel TLC components that may be present. All differences were assessed by 1-way 
ANOVA when compared to the TNBS control. All results are the aggregation of at least two 
independent experiments. Treatment groups received 20 μg of material per mouse via i.p. 
injection (panel a; n=6, panel b; n=12).  
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Figure 5.15. Mice treated with 20μg band extracts 4, 4s, 5 and 6 from LES CM 
(Glutamax™) have significantly lower clinical disease scores than the TNBS only 
treated controls. Piloerection score for mice treated with Band 4 from LES CM 
(Glutamax™) is significantly lower than the TNBS control group (a; ** P = 0.0022). The 
mobility score was significantly lower for bands from LES CM (Glutamax™) treatment 
group when compared to the TNBS control (b; bands 4, 4s and 5 (**** P = 0.0001) and band 
6 (** P = 0.0018)). Similarly, stool consistency showed a marked improvement in bands from 
LES CM (Glutamax™)-treated mice when compared to TNBS controls (c; bands 4 and 4s 
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(*** P = 0.0002) and band 5 (** P = 0.0066). Finally, there was a significant difference in 
clinical scores of all bands from LES CM (Glutamax™)-treated mice compared to TNBS 
controls (d; band 4 and 4s (**** P<0.0001), band 5 (*** P = 0.008) and band 6 (* P = 
0.017)). All differences were assessed by 1-way ANOVA when compared to the TNBS 
control. All results are the aggregation of at least two independent experiments. Treatment 
groups received 20 μg material per mouse via i.p. injection (n=12)  
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Figure 5.16. Changes in colon cytokine levels induced by treatment with 20 μg band 
extracts 4, 4s, 5 and 6 prior to the induction of TNBS colitis in mice. Of the five cytokines 
assayed here, four have at least one band that is significantly different from the TNBS control 
(1 way ANOVA). Cytokines were measured from colonic tissue cultured for 24 hours in 
complete media (a-e). Bands 4, 5 isolated from LES CM (Glutamax™)-treated mice had 
significantly lower levels of a) IL-1β; band 4 (** P = 0.0037) and band 5 (** P = 0.0016) 
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whereas levels of IL-1β for band 6 were significantly increased (**** P<0.0001). There were 
no significant changes in levels of b) IL-6 for any of the bands tested here. Only band 4 
showed a significant reduction in c) IL-13 levels (** P = 0.0077) and d) IFN-γ levels (* P = 
0.0209). Bands 4, 5 isolated from LES CM (Glutamax™)-treated mice had significantly 
lower levels of e) TNF; band 4 (*P = 0.0292) and band 5 (*P = 0.0411). All results are the 
aggregation of at least two independent experiments. Treatment groups received 20 μg 
material per mouse via i.p. injection (n=10).  
Since protection was induced by only four bands (bands 4, 4s, 5 and 6), these bands were 
examined in more detail. Bands 4/4s, 5 and 6 are likely separate chemical entities as they 
are separated by interceding bands (bands C and D) which displayed no protection in the 
TNBS colitis bioactivity screen. These four bands have the highest therapeutic potential and 
their clinical indices were examined further (Figure 5.15).  
Overall the most consistent protection was displayed by band 4 followed by bands 4s, 5 and 
finally band 6. While band 6 looked promising based on weight loss data, the clinical indices 
do not reliably reflect this. From these initial screening results, bands 4/4s display the 
greatest protection against TNBS colitis. It is likely that each of bands 4 and 4s have some 
constituent overlap and likely both contain the same active compound. The nature of 
protection of bands 5 and 6 may be distinct. To further understand the nature of protection, 
a limited palette of cytokines was assessed from colon cultures of these treatment groups - 
IL-1β, IL-6, IL-13, IFN-γ, and TNF (Figure 5.16). These cytokines are associated with IBD and 
inflammasome activation, and span the Th1, Th2, and Th17 arms of T helper cell responses. 
Each band generated a distinct cytokine profile. Band 6 showed significant protection 
against weight loss and the clinical symptoms of TNBS induced colitis, yet of the cytokines 
tested only IL-1β was significantly altered, and expression of this pro-inflammatory cytokine 
was, surprisingly, elevated in treated mice, in contrast to the clinical observations. 
Treatment with 20 μg of band 5 resulted in a suppression of IL-1β and TNF in mice after 
administration of TNBS. Despite significant protection in the clinical indices provoked by 
treatment with band 4s, there were no significant changes in any of the five cytokines 
tested. Treatment with 20 μg of band 4 displayed suppression of the pro-inflammatory 
cytokines IL-1β, IL-13, IFN-γ, and TNF. 
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5.6 Results Discussion 
In summary, this chapter demonstrated that the TNBS chemical colitis model is a useful 
bioactivity screen for small molecules. The small molecule techniques routinely adopted in 
phytochemical research are suitable for the separation of hookworm LES components. I 
have also demonstrated that there are a number of small molecule fractions that elicit 
protection against TNBS colitis, possibly via different mechanisms of action (as reflected by 
distinct cytokine profiles). Four of these bands were isolated using the Folch extraction, 
which isolates molecules in the therapeutic window, indicating that there are a number of 
candidates that may be suitable to pursue for the treatment of inflammatory disease. 
One of the major histological findings in LES Glutamax™- and LES CM Glutamax™- treated 
mice was the formation of lymphoid follicles. Lymphoid infiltration of tissues has been 
noted as a feature of A. caninum zoonosis [168]. Interestingly, A. caninum secretes the 
protein Neutrophil Inhibitory Factor (NIF) that blocks adhesion of these lymphocytes [162]. I 
hypothesise that NIF may be an evolutionary consequence of small molecule activation and 
aggregation of lymphocytes initiated by hookworm secreted small molecules. This may be 
one example of a complex and multilayered strategy that hookworms have evolved to 
evade their host. 
One of the key cytokines associated with inflammasome production is IL-1β. The 
inflammasome are receptors and sensors involved in the regulation and the activation of 
inflammation of the innate immune system [401]. Here we show that IL-1β is consistently 
suppressed by all protective fractions tested as demonstrated in figures 5.7, 5.12 and 5.16. 
This indicates that the LES and its fractions may interact with the innate immune system to 
suppress inflammation. The mechanism by which this occurs has not been determined in 
this body of work. 
Interestingly, the LES Glutamax fraction was able to elicit a significant difference in IL-17A 
cytokine levels when compared to the TNBS control (Figure 5.7). The cytokine IL-17A is 
known to play a role with both anti-inflammatory/regulatory responses. The ability to detect 
IL-17A it is perhaps unsurprising given that the parasite secretes a plethora of molecules 
into the surrounding tissues that have the potential to induce both pro- and anti-
inflammatory responses. Inflammatory processes induced by the hookworm’s aggressive 
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feeding behaviour may be partially mopped up by active secretion of anti-inflammatory 
molecules. Recent studies have also emphasised the importance of IL-17F as a target for the 
treatment of colitis [402] and future studies should include this avenue. 
It is apparent from initial screens that culture conditions need to be validated when studying 
small molecules, as previous established methods may not be suitable. There are few 
established screening methods for anti-inflammatory activity for small molecules, and I have 
shown here that the TNBS model is suited to simultaneous profiling of a cross-section of 
immune responses. It is recognised that small molecules can be powerful inhibitors of the 
inflammasome [403, 404], yet I have been able to show here that small molecules may be 
involved in preventing other inflammatory processes. Indeed, two distinct bands of LES CM 
Glutamax™ isolated here are able to supress TNF production. This cytokine is a keystone 
target for many modern anti-inflammatory therapeutics and it is encouraging to highlight 
two possible small molecule candidates here.  
5.7 The next chapter 
The next chapter will present the characterisation of the LES of A. caninum using small 
molecule techniques with emphasis on those fractions that confer protection in TNBS-
induced chemical colitis. 
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Chapter 6 
The characterisation of small molecules 
found in the Excretory/Secretory 
component of adult A. caninum 
Preamble 
In this chapter I detail the molecular characterisation of A. caninum LES. This is the first 
description of the small molecule secretome of any helminth to date. 
I have assembled gas chromatography/mass spectroscopy (GCMS) data from both 
derivatized and underivatized methods. 
I describe these compounds with regards to known (reported in the literature) 
immunomodulatory activity and also in relation to the KEGG pathway maps of the human 
hookworm, N. americanus. 
In addition, I compare the dataset assembled above with one assembled from LES cultured 
on a glucose substrate. This material (LES Glucose) was tested in the TNBS colitis model 
(Figure 5.1, Chapter 5) and mice had significantly poorer outcomes than the TNBS negative 
control (** P=<0.01). From the comparison of protective and a non-protective datasets it 
may be possible to highlight features that are responsible for protection in the TNBS colitis 
model. 
Outputs from this chapter 
The small molecule secretome of Ancylostoma caninum.  
Shepherd C, Wangchuk P., Constantinoiu C., Navarro S., Wilson D., Kouremenos, K. A., De 
Souza, D. P.; Daly N., McConville, M. and A. Loukas  
First Author 
IN DRAFT; Target journal: International Journal for Parasitology 
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*This section was moved from Chapter 2 for brevity and to provide relevant background to 
the following chapter – the section has been framed by (…..) * 
6.1 A. caninum biochemistry – our current state of play 
 
(The dog hookworm has well described physiology and biochemistry which situates it as a 
translational model 
The dog hookworm, A. caninum, was first identified in 1859 (Ercolani), and its physiology, 
morphology, biology and epidemiology have been well described, making it a good 
candidate as a model for translational research. Initial studies focussed on the description, 
harvesting, and optimisation of culture conditions for physiology experiments. It was 
determined that optimal conditions for harvested adult hookworms was a Krebs-Ringer 
solution with the addition of 50% dog serum, allowing adult worms to survive for up to 10 
weeks [61]. These hookworms were able to reproduce and produce viable eggs. The 
addition of whole red blood cells did not have any effect on feeding activity and survival 
[61], and it was shown by other investigators that the majority of red blood cells pass 
through hookworms intact [405]. It was from these observations that it was assumed that 
hookworms get the majority of their nutrition from plasma rather than erythrocytes.  
It is recognised that parasites convert their metabolic processes as they transition from free-
living to parasitic lifestyles. However, little is known about the host cues and parasite 
molecular pathways that govern this process. Metabolic labelling studies in dog hookworm 
have determined that C14-labelled glucose is not converted to glycogen [32], but is diverted 
into amino acid production [406] in a metabolism dominated by fermentative processes 
[407, 408]. Exposure of hookworm L3 to dog sera increases feeding rates [409], and large 
diffusible solutes (protein fraction) stimulate the consumption of glucose [61]. Cyanide 
inhibition studies show that the adult dog hookworm is capable of aerobic metabolism and 
has a tricarboxylic acid (TCA) cycle that is able to oxidize both pyruvic and succinic acids 
[410]. In addition, NADH respiration is not strongly coupled to oxidative phosphorylation, 
with evidence that hookworms lack respiratory control [411]. Adult A. caninum 
succinoxidase activity does not seem to be tightly coupled to the synthesis of ATP, and 
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external NADH oxidation that is not coupled to phosphorylation can occur. The low ratios of 
phosphorylation/oxidation may reflect loosely coupled pathways of respiration or the 
existence of two pathways of respiration - one coupled to the esterification of inorganic 
phosphate and another to the NADH pathway [411].  
Fatty acids produced by A. caninum are major end products of metabolism. Labelling studies 
have shown that glucose is metabolised to produce acetate, propionate, and CO2 while the 
amino acids L-valine and L-leucine are the precursors of isobutyric acid and isovaleric acid, 
respectively [88]. A. caninum adult worms consume larger quantities of oxygen than other 
intestinal nematodes [90], however, they have been shown to fix CO2 to produce propionate 
from amino acids via a CO2 fixation pathway [407, 408]. Adult hookworms display a slowing 
or cessation of metabolic fermentation in the presence of oxygen [411], and the presence of 
oxygen inhibits anaerobic glycolysis. The interactions of the end products of hookworm 
metabolism within the host have never been explored. Similarly, there has been no 
investigation of the role of secondary metabolites produced by hookworms and their roles 
in the host-parasite relationship.) 
To date, very little is known about the small molecules that the hookworm produces in the 
context of the host-parasite interactions. The following results describe the data in terms of 
known biochemical information on A. caninum as well as the immunomodulatory activity 
and the anti-colitic properties of LES fractions described in the previous chapter.  
6.2 Results 
 
Pk # 
Retentio
n time 
(min) 
# of 
car
b-
on 
Kovat
’s 
Index
‡ 
Area % MW NIST Name† 
ID 
matc
h 
Lit Ref 
Bioactivity‡ 
KEGG 
compou
nd 
number 
2 5.04 4 - 0.824 122 1,2,3,4-Butanetetrol, [S-(R*,R*)]- 83 - - 
3 5.17 9 - 0.592 186 Diethyl ethylidenemalonate 72 - - 
4 5.18 9 
- 
1.072 186 Itaconic acid diethyl ester 72 
Immuno-
modulatory, 
Anti-bacterial 
Itaconic 
acid 
(C00490
) 
5 5.18 9 - 0.147 186 Diethyl ethylidenemalonate 73 - - 
6 5.21 4 - 0.125 122 Erythritol 77 - C00503 
7 5.23 8 - 0.187 136 Benzeneacetic acid 94 - C07086 
8 5.25 - - 0.025 - 2(5H)-Thiopenone, 5-methyl- - - - 
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9 5.26 5 844 0.005 114 2-Methyl-3-furanthiol 76 Unknown - 
10 5.26 8 - 0.217 136 Benzeneacetic acid 94 - - 
13 5.38 9 1253 0.094 165 Ethyl-2-pyridulacetate 78 Unknown - 
14 5.38 - - 0.901 - p-Methylbenzeneboronic acid - 
Anti-
spasmodic 
- 
15 5.39 - - 1.687 - Pentaborane 72 - - 
16 5.46 6 1632 0.092 176 Vitamin C 70 Anti-oxidant C00072 
18 5.63 5 - 0.619 115 Methyl cyclopropylcarbamate 73 - - 
19 5.64 7 - 5.426 146 
Butanoic acid, 2-(hydroxymethyl)-
ethyl ester 
70 - - 
20 5.66 13 1753 2.564 229 
3-(2-Ethylhexoxy)propan-1-amine, 
N-acetate 
64 Unknown - 
21 5.68 - - 3.112 - 2H-Thiopyran-tetrahydro-4-methyl 70 - - 
22 5.72 0 - 0.283 66 Pentaborane (11) 68 - - 
23 5.86 8 - 0.035 157 Piperidine, TMS derivative 70 - - 
24 5.87 6 - 0.048 142 
4H-Pyran-4-one, 3,5-dihydroxy-2-
methyl 
64 - - 
25 5.89 3 - 10.55 92 Glycerol 84 - C00116 
26 5.99 13 - 0.022 230 
Methoxyacetic acid, 6-ethyl-3-octyl 
ester 
75 - - 
27 5.99 19 - 0.045 268 5 methyl-Octadecane 75 - - 
29 6.12 35 - 0.005 570 Pentratriacontane, 1-bromo- 76 - - 
30 6.13 12 - 0.043 200 Dodecanoic acid 86 - C02679 
31 6.17 14 - 0.035 206 2,4-Di-tert-butyphenol 84 - - 
32 6.22 15 - 0.032 242 
Dodecanoic acid, 1-methylethyl 
ester 
83 - - 
33 6.27 - - 0.075 - unknown - - - 
34 6.27 17 - 0.008 240 Hexadecane, 2-methyl 80 - - 
35 6.27 17 - 0.040 240 Heptadecane 73 - C01816 
36 6.37 10 - 0.197 161 2-Benzyl-1,3-oxazol-2-ine 88 Unknown - 
37 6.39 16 - 0.226 286 
2,2,4-Trimethyl-1,3-pentanediol 
diisobutyrate 
90 - - 
38 6.48 - - 0.015 - unknown - - - 
39 6.61 13 - 0.015 214 n-Heptyl hexanoate 75 - - 
40 6.81 10 - 0.107 172 Butyl 3-methylpentanoate 77 - - 
41 6.81 5 - 0.057 152 L-Aribinitol 70 - - 
42 6.88 8 - 1.885 135 Benzeneacetamide 92 - - 
44 6.96 11 - 0.431 218 
4-Thia-2,6-diazabicyclo[3.2.0]hept-
2-en-7-one 
80 - - 
46 7.19 8 - 4.341 135 2-Acetyl-4-methyl pyridine 69 - - 
47 7.20 4 1229 13.34 122 Erythriol 76 Unknown - 
48 7.22 13 - 0.477 247 
2-Benzylidene-5-oxooxazolidine-3-
carboxylic acid, ethyl ester 
85 - - 
49 7.23 12 - 8.584 221 
Isoquinoline-4-carboxylic acid, 3-
oxo-2,3,5,6,7,8-hexahydro-, ethyl 
ester 
77 - - 
50 7.34 - - 0.010 - unknown - - - 
51 7.49 20 2000 0.048 282 Eicosane 87 Volatile oil - 
52 7.49 15 - 0.027 212 Tetradecane, 4-methyl- 81 - - 
53 7.49 19 - 0.023 268 5,5 Diethylpentadecane 84 Volatile oil - 
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54 7.58 9 - 0.010 178 Phenacemide 73 
Sodium 
channel 
blocker 
C07428 
55 7.59 14 - 0.018 212 Benzeneacetic acid, phenyl ester 85 - - 
56 7.66 12 - 0.007 222 Ethyl (phenylacetoxy)acetate 78 - - 
57 7.66 12 - 0.003 205 Morpholine, 4-(phenylacetyl) 61 - - 
58 7.6 8 - 0.010 150 Benzeneacetic acid, hydrazide 72 - - 
59 7.70 13 - 0.010 184 Dodecane, 2-methyl- 72 - - 
60 7.71 16 - 0.010 226 4-ethyl-Tetradecane 82 - - 
61 7.78 12 - 0.089 191 Diethyltoluamide 89 DEET C10935 
62 7.84 13 - 0.015 212 Octyl angelate 68 - - 
63 7.84 
 
- 0.018 - 
2-Butenoic acid, 2-methyl-, hexyl 
ester, (Z)- 
- - - 
64 7.85 15 - 0.025 212 Dodecane 2,6,10-trimethyl 62 - - 
65 7.95 4 - 0.020 114 
2,4(1H,3H)-Pyrimidinedione, 
dihydro- 
81 Unknown - 
66 8 10 1371 0.000 161 2-Benzyl 1,3-oxazol-2-ine 84 Unknown - 
67 8.01 - - 0.015 - Hexadecane - - - 
68 8.01 20 2000 0.022 282 Eicosane 87 Volatile oil - 
69 8.02 7 - 0.022 129 N-Ethyl-4-hydroxypiperidine 72 - - 
70 8.02 15 - 0.033 212 Tetradecane, 4-methyl 78 - - 
71 8.05 - - 0.007 - unknown -  - 
72 8.3 6 1335 0.002 123 Niacin 84 
Immuno-
modulatory 
C00253 
73 8.34 - - 0.023 - 
Oxazolidin-4-one, 5-benzylideno-2-
thione- 
- - - 
74 8.35 8 - 0.022 118 Benzofuran 80 - C14512 
75 8.39 9 - 0.054 163 (2-Nitroallyl)-benzene 75 - - 
76 8.40 6 1632 0.070 176 Vitamin C 73 Anti-oxidant C00072 
77 8.40 12 - 0.030 191 Phenylacetimide, N-butyl 80 - - 
78 8.41 5 989 0.000 117 L-Valine 67 
Immuno-
modulatory 
C00183 
80 8.44 - - 0.045 - unknown - - - 
81 8.5 5 962 0.002 117 
3-Hydroxy-N,N-
dimethylpropanamide 
72 Unknown - 
82 8.52 12 1585 0.152 185 1-(Phenylacetyl)pyrrole 92 
Substrate/ 
column 
confounder 
- 
83 8.55 20 2000 0.002 282 Eicosane 85 Volatile oil - 
84 8.57 2 543 0.005 46 Formic Acid 91 
Immuno-
modulatory 
C00058 
85 8.62 5 787 0.002 118 Lactic acid ethyl ester 82 
Immuno-
modulatory 
- 
86 8.80 - - 0.002 - L-alanine ethylamide - Unknown - 
87 8.81 12 - 0.008 189 Benzenacetamide, N-methallyl- 66 - - 
88 8.91 4 987 0.045 114 2,4-Imidazolidinedione, 5-methyl- 93 Unknown - 
89 8.98 - - 0.017 - Isobutyl tricontyl ether - - - 
90 8.99 22 - 0.020 332 
Benzeneacetic acid, 2 tetradecyl 
ester 
78 - - 
91 9.23 8 - 0.114 118 Benzofuran 82 - - 
92 9.42 8 - 0.065 152 Benzeneacetic acid, 4-hydroxy- 84 - - 
93 9.53 7 992 0.008 145 L-Valine, ethyl ester 86 Unknown - 
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94 9.57 - - 0.047 - unknown - - - 
95 9.63 12 1393 0.818 189 N-methallyl-Benzeneacetamide 80 - - 
96 9.68 11 - 0.013 178 
Benzeneacetic acid 1-methylethyl 
ester 
70 - - 
97 9.79 10 - 0.015 172 Pyrimidine, 5-hydroxy-4-phenyl- 66 - - 
98 9.81 10 - 0.308 158 1-(2-Aminophenyl)pyrrole 85 Unknown - 
99 9.95 - - 0.003 - unknown - - - 
100 10.03 16 - 0.005 256 n-Hexadecanoic acid 78 
Substrate/ 
column 
confounder 
C00249 
101 10.13 - - 0.008 - unknown - - - 
102 10.26 4 1046 0.023 114 
2,4(1H,3H)-Pyrimidinedione, 
dihydro- 
92 Unknown - 
103 10.27 10 - 0.033 158 1-(2-Aminophenyl) pyrrole 83 Unknown - 
104 10.38 21 2006 0.002 296 5,5 Diethylheptadecane 79 Volatile oil - 
105 10.39 22 - 0.022 310 Eicosane 2,4-dimethyl- 72 - - 
106 10.39 19 - 0.003 268 5,5-Diethylpentadecane 66 Volatile oil - 
107 10.40 54 - 0.017 758 Tetrapentacontane 82 - - 
108 10.50 10 - 0.704 160 
1H-Imadazole, 4,5-dihydro-2-
(phenylmethyl)- 
84 - - 
109 10.57 8 - 0.130 149 Benzene, (isothiocyanatomethyl)- 84 - - 
110 10.67 9 1253 0.013 152 2-(phenyl methoxy)-Ethanol 81 Unknown - 
111 10.78 - - 0.012 - unknown - - - 
113 10.79 20 2000 0.012 282 Eicosane 76 Volatile oil - 
114 10.80 14 - 0.737 212 
9-Acridinamine, 1,2,3,4-tetrahydro-
2-methyl- 
- - - 
115 10.82 14 - 0.729 212 
1,2,3,4-tetrahydro-2-methyl-9-
Acridinamine 
70 
Substrate/ 
column 
confounder 
- 
117 10.93 - - 0.008 - unknown - - - 
118 11.11 16 1942 0.246 256 n-Hexadecanoic acid 87 
Substrate/ 
column 
confounder 
- 
119 11.12 8 - 0.022 149 Benzene, (isothiocyanatomethyl)- 72 - - 
120 11.15 14 - 0.043 228 
Benzene ethanethioic acid, S-
phenyl ester 
74 - - 
121 11.16 15 - 0.144 229 
N-ethyl-N-(4-methylpenta-2,4-
dienoyl)benzylamine 
77 - - 
122 11.21 9 - 0.010 221 
1-Alanine, N-(5-chlorovaleryl)-
,methyl ester 
68 Unknown - 
123 11.29 11 - 0.023 226 Phenobarbital 84 - - 
124 11.42 20 - 0.015 282 3-Ethyl-3-methylheptadecane 82 - - 
125 11.42 15 - 0.017 212 5-methyl tetradecane 82 - - 
126 11.43 29 - 0.015 408 Nonacosane 72 - C08384 
127 11.60 9 - 0.012 326 
2-Propanol, 1-chloro, 
phosphate(3:1) 
74 - - 
128 11.69 15 - 0.079 212 
1(2H)-Pentalenone, hexahydro-4-
(phenylmethylene)- 
62 - - 
129 11.69 - - 0.040 - unknown - - - 
130 11.71 3 525 0.010 77 Methyl nitrate 81 Unknown - 
131 11.78 13 - 0.333 215 
4-Benzyloxy-2-methylpyridine 1-
oxide 
84 - - 
132 11.79 15 - 0.219 210 2-Propanone, 1,3-diphenyl- 80 - - 
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133 11.79 6 1489 0.048 160 N-L-alanyl-L-Alanine 78 Unknown - 
134 11.80 8 - 0.299 120 Phthalan 77 - - 
135 11.9 14 1923 0.002 246 
Phenyl acetic acid, 2-chlorophenyl 
ester 
80 Unknown - 
136 12.02 10 - 0.298 158 1(2-Aminophenyl) pyrrole 86 Unknown - 
137 12.07 - - 0.085 - unknown - - - 
138 12.08 15 - 0.687 210 2-Propanone, 1,3-diphenyl- 93 - - 
139 12.44  - 0.013 - unknown - - - 
140 12.46 16 - 0.033 278 
1,2 Benzenedicarboxylic acid, (2-
methylpropyl) ester 
91 - - 
141 12.47 16 - 0.018 278 
1,2-Benzenedicarboxylic acid, bis(2-
methypropyl) ester 
86 - - 
142 12.56 15 1736 0.242 210 1,3-diphenyl-2-Propanone 83 
Substrate/ 
column 
confounder 
- 
143 12.63 15 - 0.400 210 2-Propanone, 1,3-diphenyl- 81 - - 
144 12.70 - - 0.010 - unknown - - - 
145 12.75 15 - 0.697 210 1,3-diphenyl-2-Propanone 84 
Substrate/ 
column 
confounder 
- 
146 12.90 11 - 0.030 207 
Glycine, N-(phenylacetyl)-, methyl 
ester 
81 
Substrate/ 
column 
confounder 
- 
147 13.08 7 - 0.015 136 p-methylbenzeneboronic acid 73 
Anti-
spasmodic 
- 
148 13.08 8 - 0.015 135 Benzeneacetamide 95 - - 
150 13.11 8 953 0.072 142 
Acetaldehyde, bis(1-methylethyl) 
hydrazone 
84 Unknown - 
149 13.13 11 1694 1.839 207 
Glycine, N-(phenylacetyl)-, methyl 
ester 
92 
Substrate/ 
column 
confounder 
- 
151 13.17 15 - 0.035 210 1,3-diphenyl-2-Propanone 83 
Substrate/ 
column 
confounder 
- 
152 13.36 20 - 0.152 312 Dodecanoic acid, isoctyl ester 89 - - 
153 13.37 - - 0.027 - unknown - - - 
154 13.56 7 - 0.032 136 p-Methylbenzeneboronic acid 80 
Anti-
spasmodic 
- 
155 13.56 7 794 0.084 92 Toluene 87 
Substrate/ 
column 
confounder 
C01455 
156 13.73 12 - 0.032 186 
1H-Benzo[d]pyrrole[1,2-
a]imidazole, 6,7-dimethyl-2,3-
dihydro 
73 - - 
157 13.77 16 - 0.022 247 Phenylacetamide, N,N-dibutyl- 68 - - 
158 14.04 - - 0.007 - unknown - - - 
159 14.09 - 2054 0.017 - Benzylacetic acid decyl ester 70 - - 
160 14.29 - - 0.008 - unknown - - - 
161 14.41 9 - 0.149 212 
Imidazolo[2,1-b]thiazol-2 
carboxcylic acid 5,6-dihydro-3-
methyl-, ethyl ester 
63 - - 
162 14.55 - - 0.007 - unknown - - - 
163 14.56 8 1292 0.508 137 3-Pyridinepropanol 70 - - 
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164 14.91 15 1736 0.080 210 1,3-diphenyl-2-propanone 81 
Substrate/ 
column 
confounder 
- 
165 15.29 7 - 0.033 136 p-Methylbenzeneboronic acid 81 
Anti-
spasmodic 
- 
166 15.32 - - 0.013 - unknown - - - 
167 15.35 5 - 0.194 129 L-Glutamine 86 - C00064 
168 15.44 7 794 0.010 92 Toluene 82 
Substrate/ 
column 
confounder 
C01455 
169 15.57 18 - 0.234 351 
N-Benzyl-4-(2,4-dichloro-phenoxy)-
N-methyl-butyramide 
63 - - 
170 15.58 11 1358 0.182 205 Mandelonitrile, TMS derivative 66 
Substrate/ 
column 
confounder 
- 
171 16.02 7 - 0.052 154 
2,4(1H,3H)-Pyrimidinedione, 1,3,5-
trimethyl- 
77 - - 
172 16.22 - - 0.018 - Decane, 1-iodo- - - - 
173 16.23 19 1805 0.020 268 5,5-Diethylpentadecane 81 Volatile oil - 
174 16.25 - - 0.010 - unknown - - - 
175 16.40 20 - 0.020 334 
1,2-Benzenedicarboxcylic acid, 
butyl octyl ester 
87 - - 
176 16.41 - - 0.012 - unknown - - - 
177 16.60 13 - 0.094 204 
Phenylacetic acid, 3-methylbut-2-
enyl ester 
77 - - 
178 16.79 5 1180 0.254 129 DL-Pyroglutamic acid 86 
Substrate/ 
column 
confounder 
C01879 
179 16.82 10 - 0.010 163 Phenylacetamide, N-ethyl- 69 - - 
180 17 19 1805 0.002 268 5,5 Diethylpentadecane 76 Volatile oil - 
181 17.00 8 - 0.015 172 Thiourea, N-cyclohexyl-N'-methyl- 62 - - 
182 17.41 18 - 0.010 276 Benzylacetic acid decyl ester 71 - - 
183 17.82 18 2187 0.109 284 Octadecanoic acid 90 - C01530 
184 18.12 20 - 0.107 312 Acetic acid n-octadecyl ester 95 - - 
185 18.18 10 1858 0.005 210 
3-Methyl-1,4-diazabicyclo[4,3,0]-
dione N-acetyl 
75 Unknown - 
186 18.38 20 2000 0.025 282 Eicosane 84 Volatile oil - 
187 18.39 44 - 0.022 618 Tetratetracontane 83 - - 
188 19.53 13 - 0.129 204 
Phenylacetic acid, 3-methylbut-2-
enyl ester 
77 - - 
189 19.58 18 2054 0.010 276 Benzeneacetic acid, decyl ester 74 Unknown - 
190 20.89 7 1795 0.015 154 
Pyrrole[1,2-a]pyrazine-1,4-dione, 
hexahydro- 
83 Antimicrobial - 
191 21.31 14 - 0.025 208 
7,11-Dimethyldodeca-2,6,10-trien-
1-ol 
67 - - 
192 21.63 8 1217 0.022 143 N-hexyl Acetimide 77 Unknown - 
193 21.98 19 1980 0.035 244 Triphenylmethane 90 
Immuno-
modulatory 
- 
194 22.23 - - 0.018 - 2,6,10,14-tetramethyl-Octadecane - - - 
195 22.29 40 - 0.017 562 Octatriacontane, 3,5-dimethyl- 71 - - 
196 22.65 - - 0.144 - unknown - - - 
197 22.69 15 2185 0.010 284 
Benzenesulfonic acid 4 methyl-octyl 
ester 
65 Unknown - 
199 23.01 10 1781 0.038 194 
2,5-cyclohexadiene-1,4-dione 2,5 
methyl-3,6-bis(methylamino) 
72 Unknown - 
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200 23.79 16 - 0.067 276 
1,2-Cyclohexanedicarboxylic acid, 
4-phenyl-, dimethyl ester 
66 - - 
201 23.81 - - 0.062 - unknown - - - 
202 24.27 - - 0.022 - unknown - - - 
203 24.3 10 1781 0.022 194 
2,5-cyclohexadiene 1,4-dione 2,5 
dimethyl-3,6-bis(methylamino) 
72 Unknown - 
204 24.57 10 - 0.007 193 N-(Phenylacetyl)glycine 61 - - 
205 25.10 19 3309 0.054 412 
1,6-Anhydro-4-[2-
(pyrazolidinyl)ethylamino]-2-0-
tosyl-4-deoxy-b-d-glucopyranose 
80 Unknown - 
206 25.65 12 2141 0.048 263 
D-Alanine, N-(5-chlorovaleryl)-butyl 
ester 
78 Unknown - 
207 25.68 14 - 0.047 291 
D-Alanine, N-(5-chlorovaleryl)-, 
hexyl ester 
73 - - 
208 25.80 - - 0.005 - unknown -  - 
209 26.23 6 - 0.090 127 4-Methyleneproline 86 
Substrate/ 
column 
confounder 
- 
210 26.26 14 2141 0.010 291 
D-Alanine, N-(5-chlorovaleryl)-
,hexyl ester 
76 
Substrate/ 
column 
confounder 
- 
211 26.49 15 - 0.084 343 
N-(4-Methylpropyl-glutamyl)-
glycine ethyl ester 
76 - - 
212 26.54 20 - 0.007 282 Eicosane 80 Volatile oil - 
213 26.75 6 1229 0.087 127 4-Methyleneproline 81 
Substrate/ 
column 
confounder 
- 
214 26.97 6 - 0.010 143 L-Proline, 5 oxomethyl ester 77 - - 
215 27.20 20 - 0.054 282 Eicosane 77 Volatile oil - 
216 27.21 24 - 0.050 338 Tetracosane 86 - - 
217 27.29 14 2065 0.015 288 
Benzaldehyde 3-hydroxy-4-benzyl-
oxy- 
76 
β3 adrenergic 
receptor 
agonist 
- 
218 27.62 13 - 0.064 278 
Piperidin-2-thione-6-one, 
5(benzyloxycarbonyl)amino 
65 - - 
219 27.86 14 1898 0.002 250 
5,10-Diethyoxy-2,3,7,8-tetrahydro-
1H,6H-dipyrrolo[1,2-a1'2']pyrazine 
76 Unknown - 
220 27.91 - - 0.003 - unknown - - - 
221 28.17 11 2005 0.003 168 9H-Pyrido[3,4-b]indole 86 Unknown - 
222 28.26 22 - 0.028 340 Eicosyl acetate 87 - - 
223 28.26 20 - 0.043 312 Acetic acid n-octadecyl ester 88 - - 
225 28.42 23 - 0.059 346 
Benzeneacetic acid, 3-pentadecyl 
ester 
79 - - 
224 28.44 19 1805 0.007 268 5,5 Diethylpentadecane 80 Volatile oil - 
226 29 13 2492 0.002 264 L-Glutamine, N2-(phenylacetyl)- 67 Unknown - 
227 29.76 8 - 0.037 165 
Furo[3,4-c]pyridine-3,4(1H,5H)-
dione, 6-methyl 
73 - - 
228 29.77 - - 0.059 - unknown - - - 
229 29.83 16 - 0.254 226 Hexadecane 64 - - 
230 29.96 8 2097 0.059 217 l Alanyl-l-glutamine 79 
Substrate/ 
column 
confounder 
- 
231 30.14 13 - 0.027 219 
Acetamide, N-tetrahydrofurfuryl-2-
phenyl- 
- - - 
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232 30.16 11 - 0.054 236 
Acetamide, 2-phenyl-N1-(2-oxo-4-
mercapto-3-azetidinyl) 
84 - - 
233 30.21 - - 0.017 - unknown - - - 
234 30.34 13 - 0.052 247 
2-Benzylidine-5-oxooxazolidine-3-
carboxcylic acid 
65 - - 
235 30.62 9 1473 0.007 178 Phenacemide - 
Sodium 
channel 
blocker 
- 
236 30.98 9 1125 0.005 135 Amphetamine 73 
Immuno-
modulatory 
- 
237 31.38 17 - 0.008 334 
Piperazine, 1-benzyl-4(4-
fluorophenylsulfonyl)- 
63 - - 
238 31.43 8 - 1.836 175 
1H-Tetrazol-5-amine, 
1(phenylmethyl) 
72 
Kinase 
inhibitor 
- 
239 31.59 - - 0.065 - unknown - - - 
240 31.59 20 - 0.059 282 Eicosane 82 Volatile oil - 
242 31.80 10 1847 0.227 192 
Benzeneacetamide, N-[2-
(hydroxyimino)ethyl]- 
81 Unknown - 
241 31.98 - - 0.032 - 1,3-Propanediol, 2-(phenylmethyl)- - - - 
243 32 8 - 0.002 175 
1H-Tetrazol-5-amine, 1-(phenyl 
methyl)- 
72 
Kinase 
inhibitor 
- 
244 32.04 - - 0.082 - unknown - - - 
245 32.49 - - 0.018 - unknown - - - 
246 32.54 - - 0.062 - unknown - - - 
247 33.05 - - 0.005 - unknown - - - 
248 34.56 - - 0.040 - 
4H-1,2,4-triazolium, 3-mercapto-
1,5-dimethyl-4-(1-methylet 
- - - 
249 34.58 14 - 0.028 227 
4(4-Phenyl-1H-imidazol-zyl) 
piperidine 
65 - - 
250 35.36 11 1552 0.005 172 N-[2-Cyanoethyl]styrenimine 63 Unknown - 
251 35.81 - - 0.052 - unknown - - - 
252 35.83 - - 0.052 - unknown - - - 
253 36.04 13 - 1.049 234 Benzyl ethyl maleate 62 - - 
254 36.19 10 1430 0.003 268 Decane, 1-iodo- 78 Unknown - 
255 36.69 - - 0.032 - unknown - - - 
256 36.71 13 1557 0.025 206 Pentyl phenylacetate 71 Unknown - 
257 37.11 - - 0.114 - unknown - - - 
258 37.13 23 - 0.296 346 
Benzeneacetic acid, 4-pentadecyl 
ester 
74 - - 
259 37.15 36 - 0.104 506 Hexatriacontane 82 - - 
260 37.73 11 1784 0.120 204 Imidazolidin-2-one, 1-phenylacetyl 73 
Kinase 
inhibitor 
- 
261 37.75 13 - 0.042 219 
Acetamide, N-tetrahydrofurfuryl-2-
phenyl 
71 - - 
262 37.76 - - 0.045 - unknown - - - 
263 38.12 19 2097 0.005 290 
Dodecanoic acid, phenylmethyl 
ester 
62 
Anti-
microbial 
- 
264 38.38 8 2097 0.411 217 l-Alanyl-l-glutamine 85 - - 
265 38.68 12 1841 0.030 218 
2,5-Piperazinedione, 3 methyl-6-
(phenylmethyl) 
86 Unknown - 
266 38.83 22 - 0.013 363 L-Cysteine, S-(triphenylmethyl)- 73 - - 
267 39.16 13 1727 0.013 276 
Isobutyl propane-1,3-diyl 
dicarbonate 
73 Unknown - 
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268 39.2 19 - 0.002 441 Folic acid 68 
Immuno-
modulatory 
- 
269 39.21 19 - 0.040 276 
2-Benzyl-8-methyl-1H-
piperidino[4,3-b]indole 
68 - - 
270 39.3 12 1841 0.002 218 
2,5 Piperazinedione, 3-methyl-6-
(phenylmethyl) 
86 
Kinase 
inhibitor 
- 
271 39.4 9 2115 0.226 244 
2-(5-Methyl-3,6-dioxopiperazin-2-yl 
methyl)-malonic acid 
84 Unknown - 
272 39.58 11 1423 0.020 220 Pivalic, 6-chlorohexyl ester 65 Antifungal - 
273 39.80 - - 0.008 - unknown - - - 
274 40.13 - - 0.018 - unknown - - - 
275 40.16 11 - 0.032 176 1-phenyl-2,4-Pentanedione 73 - - 
276 40.45 7 - 0.008 203 Glycyl-l-glutamine 63 - - 
277 40.46 36 - 0.129 506 Hexatriacontane 93 - - 
278 40.46 20 - 0.130 282 Eicosane 
 
Volatile oil - 
279 40.61 - - 0.027 - unknown - - - 
280 40.62 - - 0.018 - unknown - - - 
281 40.75 - - 0.064 - unknown - - - 
282 40.79 - - 0.033 - unknown - - - 
283 40.80 12 1953 0.007 263 
D-Alanine, N-(5-chlorovaleryl)-
,butyl ester 
65 Unknown - 
284 40.80 13 - 0.338 220 
Benzeneacetic acid, 
(tetrahydrofuranyl)methyl ester 
82 Unknown - 
285 41.12 13 1689 0.107 220 
Benzeneacetic acid, 
(tetrahydrofuranyl)methyl ester 
81 Unknown - 
286 41.15 14 - 2.661 291 
3-Diethylamino-1-(3-nitro-phenyl)-
pyrrolidine-2,5-dione 
70 - - 
287 41.33 19 - 0.032 288 
Benzeneacetic acid, 10-undecenyl 
ester 
71 - - 
288 41.39 25 - 0.027 398 Docosyl ethyl carbonate 67 - - 
289 41.4 24 - 0.346 390 Diisooctyl phthalate 94 - - 
290 41.41 11 1780 0.007 204 
2,5 Piperazinedione, 3-
(phenylmethyl)- 
75 Unknown - 
291 41.70 15 - 0.042 233 Phenylacetamide, N-(hept-2-yl)- 67 - - 
292 41.97 25 - 0.025 372 
9-Octadecanoic acid (Z)-, 
phenylmethyl ester 
68 - - 
293 42.20 - - 0.075 - unknown - - - 
294 42.22 - - 0.112 - unknown - - - 
295 42.25 19 1805 0.007 268 5,5 Diethylpentadecane 78 Volatile oil - 
296 42.46 14 - 0.013 246 
2,5-Piperazinedione, 3-benzyl-6-
isopropyl- 
62 - - 
297 42.49 14 - 0.038 246 
3-benzyl-6-isopropyl-2,5-
Piperazinedione 
62 - - 
298 42.56 12 1953 0.079 263 
D-Alanine, N-(5-chlorovaleryl)-
,butyl ester 
71 Unknown - 
299 42.57 36 - 0.254 506 Hexatriacontane 90 - - 
300 42.73 13 - 0.085 219 
Acetamide, N-tetrahydrofurfuryl-2-
phenyl- 
68 - - 
301 42.84 12 2162 0.258 236 dl-Alanyl-l-phenylalanine 65 
Substrate/ 
column 
confounder 
- 
302 42.87 20 - 0.025 310 
Cyclopentanecarboxcylic acid, 
tetradecyl ester 
71 - - 
303 42.90 15 - 0.602 259 
Isoindole-1,3-dione, perhydro-2-
benzyloxy- 
65 - - 
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304 43.01 19 2120 0.022 296 
Cyclopentanecarboxcylic acid, 
tridecyl ester 
75 Unknown - 
305 43.23 18 2517 0.040 261 Benzeneacetamide, N-(2-napthyl)- 87 Unknown - 
306 43.23 - - 0.092 - unknown - - - 
307 43.27 20 - 0.032 338 
cis-Cyclohex-4-en-1,2-dicarboxcylic 
acid, di(isohexyl)ester 
68 - - 
308 43.30 - - 0.117 - unknown - - - 
309 43.50 - - 0.013 - unknown - - - 
310 43.83 - - 0.010 - unknown - - - 
312 43.91 7 1292 0.002 139 Rolziacetam 67 Unknown - 
313 44.02 11 - 0.099 154 2-Heptene, 5-ethyl-2,4-dimethyl- 68 - - 
314 44.09 - - 0.005 - unknown - - - 
315 44.20 30 - 0.070 422 Triacontane 87 - C08389 
316 44.21 15 - 0.040 219 
Benzene methanamine, N-butyl-N-
(2-methylpropyl) 
70 - - 
317 44.21 20 - 0.112 282 Eicosane 91 Volatile oil - 
318 44.34 6 967 0.921 127 Pyridine, 2-chloro-6-methyl- 65 - - 
Table 6.1. The underivatized LES secretome of the helminth A. caninum as determined 
by GCMS and FID. Identity of chromatogram features from LES Glutamax™ determined 
from comparison with the NIST database. ID score match is an algorithm-based index of 
confidence in the identity of the small molecule from each peak. Molecules are colour coded 
on the basis of confidence of identity; xx indicates a very good match of 100-85; xx indicates 
a good match with an ID confidence of 84-70; xx indicates a fair match with an ID 
confidence of 69-60; those molecules with matches below 60 xx are considered tentative ID 
matches. Those molecules with poor confidence or of unknown origin in the NIST database 
are left uncoloured. Molecules that have low ID matches but occur consistently across 
multiple replicates (n=3) are indicated as xx and highlighted in the ID match column. All 
identified molecules were checked against the ChemSpider database for known bioactivity 
and reported Kovat’s index recorded (molecules that had no bioactivity reported were also 
checked by a NCBI journal search - IUPAC name and “anti-inflammatory”). Finally, the 
KEGG compound number is also reported in this table.  
†NIST name from http://webbook.nist.gov/chemistry/ 
‡As sourced from ChemSpider Bioactivity and NCBI PubMed database search 
(https://www.ncbi.nlm.nih.gov/pubmed/) 
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Polar Metabolite 
Relative 
Absorbance 
-/+ SD Pathway* 
KEGG† 
Compound # 
Maltose 0 0  C00208 
Tyrosine 161.3333 76.53569  C00082 
Aspartic acid 193.3333 43.3687  C00049 
Hexadecanoic acid 456.6667 291.4066  C00249 
Histidine 460.3333 120.8709  C00135 
Hypoxanthine 880.5 292.3539  C00262 
Tryptophan 890.1667 602.4303  C00078 
Glutamine 1050.333 307.2001  C00064 
Glucosamine 1068.167 205.134  C00329 
GABA 1187 559.3848 GABA C00334 
D-Galactose-6-phosphate 1198.667 541.3814  C01113 
2-hydroxyisocaproic acid 1268.5 262.3196 BCA C03467 
meso-Erythritol 1800.833 333.2793 
T1R3 
receptor/ligand? 
C00503 
4-hydroxyphenylacetic acid 1999.667 199.1503  C00642 
Lysine 2155 445.4069  C00047 
Isocitric Acid 2327.5 265.5293  C00311 
D-Xylose 2540 394.155  C00181 
Asparagine 2614.167 620.3666  C00152 
3-methyl crotonic acid 3431.833 785.0552 
Branch chain amino 
acid Degeneration 
C01771 
Glycerol-2-phosphate 4206.167 574.3366 Glycolysis C02979 
beta-alanine 5966 983.6092  C00099 
Methionine 6067.833 1084.094  C00073 
Fructose 7195.5 912.4014  C00095 
Isoleucine 8332 1238.951 
Branch chain amino 
acid 
C00407 
Glucose 9335.5 4075.877 Glycolysis C00031 
Talose 9744.333 2788.72  C06467 
Malic acid 13499.83 918.0958 TCA cycle C00149 
Threonine 15477.33 3822.949  C00188 
Citric acid 17206.67 1448.048 TCA cycle C00158 
Phenylalanine 21077.17 6967.139  C00079 
Glucose 6-phosphate 23385 2793.209 Glycolysis C00092 
Succinic acid 24257 1288.725 TCA, GABA C00042 
Fructose 6-phosphate 25961.67 5081.596 Glycolysis C00085 
Ribitol 30008.33 5675.8  C00474 
D-Ribose 50717.83 8421.589  C00121 
Glutamic acid 57999.33 18175.52 
TCA cycle, GABA, 
amino acid 
synthesis 
C00025 
Alanine 98958.83 23616.5  C00041 
Proline 150547.2 31383.81  C00148 
Lactic Acid 203525.3 17522.41 EP C00186 
Urea 204689.8 10672.9  C00086 
Adenine 331455.5 38317.57  C00147 
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Glycerol 1713390 102051.9 GlycoLipid C00116 
Glycolic acid 3133615 318185.7  C00160 
Pyroglutamic acid 7929140 719923  C01879 
Table 6.2. Polar metabolite components of LES Glutamax™ as determined by TMS 
derivatization and GCMS analysis (Bio21 Institute, Melbourne University). The 
metabolites presented in this table are molecules detected and ranked in order of abundance. 
The KEGG compound number is recorded for each molecule as well as the biochemical 
pathway that is commonly associated with that molecule. Abundance is the average of 
number of sample replicates (n=6). 
*Biochemical pathways associated with immune function. 
†KEGG compound number was sourced from http://www.genom.jp/kegg/compound  
6.3 The small molecule secretome of adult A. caninum 
In this section I present both the derivatized and the underivatized GCMS data for A. 
caninum LES harvested from culture in 1 % Glutamax™. Combined, these data provide a first 
sweep characterisation of the small molecule ES component produced by A. caninum. The 
data in Table 6.1 presents the underivatized GCMS data for LES (Glutamax™) and Table 6.2 
presents the derivatized GCMS data for LES (Glutamax™). In Figure 6.1, I present this 
combined data mapped against the KEGG biochemical pathways of the human hookworm 
N. americanus. 
Table 6.1 characterizes shows the underivatized data from LES Glutamax™ using a small 
molecule approach. It was possible to identify 317 features in this dataset with 15.7% being 
completely novel features (unassignable/unidentified). The fragment pattern of each peak 
on the gas chromatogram was compared to the National Institute of Standards and 
Technology (NIST) database (http://webbook.nist.gov/chemistry/). These matches were 
generated automatically using the Shimadzu 2010 data analysis program and then checked 
manually by comparing the 20 top fragment matches with the chromatogram peak 
fragmentation patterns. The chromatogram peaks were then checked in a blinded fashion, 
files were de-identified, and peaks were manually checked against the NIST database. 
Identities were then assigned on the basis of the highest algorithmic and fragmentation 
match. The retention time, the relative amount of each feature (%) and the reported 
molecular weight, number of carbons and Kovat’s index (if reported) were recorded. The 
molecules were then ranked in order of confidence of identification as highlighted in Table 
6.1. Molecules identified were then crosschecked in ChemSpider 
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(http://www.chemspider.com). In addition, a search for these molecules in NCBI PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed/) by their IUPAC (International Union of Pure and 
Applied Chemistry) name and the search term “anti-inflammatory” was recorded in the 
reported bioactivity column. Finally, molecules were searched in the KEGG (Kyoto 
Encyclopaedia of Genes and Genomes) database (http://www.genom.jp/kegg/) and their 
assigned compound numbers recorded. 
The four most abundant features in this database are erythriol (13.34%), glycerol (10.55%), 
isoquinolone-4-carboxcylic acid, 3-oxo-2, 3, 5, 6, 7, 8-hexahydro-ethylester (8.58%) and 
butanoic acid 2-(hydroxymethyl)-ethyl ester (5.43%). None of these molecules have a 
literature reported immunomodulatory activity. The molecule of with the highest 
abundance that has a literature reported immunomodulatory/antibacterial activity in 
ChemSpider (http://www.chemspider.com) is Itaconic acid diethyl ester (1.07%). The ability 
of LES Glutamax™ to protect against TNBS induced colitis in mice suggests that one or 
components are responsible for protection. The low abundance of the majority of features 
could indicate the presence of potent immunomodulatory molecules. 
Table 6.2 presents non-volatile polar metabolites present in LES Glutamax™. This database 
was built using a targeted approach. There is little overlap between the underivatized and 
derivatized LES Glutamax™ data presented. Derivatized methodology allows otherwise non-
volatile small molecules to be analysed by binding to a carrier molecule, trimethylsilane 
(TMS). This analysis was carried out at the Bio21 Institute, University of Melbourne, using a 
targeted approach; that is, only molecules for which standards have been run were 
identified as features of the chromatogram. A list of standards/targets is attached in 
Appendix C, and is a list of commonly encountered polar metabolites. 
Combined, these two tables represent the major detectable components in LES Glutamax™. 
From the previous chapter I was able to establish that LES Glutamax™ is able to protect 
against TNBS-induced colitis. To my knowledge, this is the first time that the secretome of 
any helminth has been described using small molecule techniques. To contextualise the 
findings, those molecules for which KEGG compound numbers have been defined have been 
mapped against the predicted metabolic pathways of the human hookworm N. americanus 
(Figure 6.1). 
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To contextualise this data in terms of parasite metabolism and possible host-parasite 
interactions, I have mapped KEGG compounds to the biochemical pathway of N. americanus 
(Figure 6.1). Since A. caninum is one of the models for N. americanus it is a useful 
comparator for similarities. The N. americanus pathway is based on genomic sequence data 
[175] with the pathway enzymes being identified by homology to similar enzymes. The small 
molecules identified here are the substrates/products of these pathways. 
1
58
 
 
 
Figure 6.1. Small molecules from A. caninum LES Glutamax™ mapped against N. americanus biochemical pathways. Red dots are molecules 
isolated from A. caninum that are matched to known pathways from the N. americanus genome. Coloured lines represent putative pathways based on the 
genome of N. americanus. Greyscale pathways are those not yet described. Glycolysis pathways are poorly represented here, with the greatest 
representation of intermediates in the TCA cycle and amino acid synthesis pathways.  
Mapped against N. americanus using the http://www.kegg.jp/kegg/tool/map_pathway1.html tool (organism code: nai, generated Oct, 2017) 
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6.4 Comparison of A. caninum LES Glutamax™ against LES Glucose database. 
As established in the previous chapter, hookworms cultured in Glutamax™ produce LES that 
is consistently protective against TNBS induced chemical colitis in mice. In contrast, the LES 
produced by hookworms cultured in 2 g/L of glucose produce a significantly greater weight 
loss and poorer clinical outcomes in the TNBS bioactivity screen. This LES Glucose was 
significantly worse than the TNBS control and appeared to induce a pro-inflammatory 
response. Here, I compare the features of the CM LES extracts from both culture conditions 
to identify differences. 
Figure 6.2 shows a heat map comparing all the features apparent in both LES CM 
Glutamax™ and LES CM Glucose (the CM extract of LES cultured on 2 g/L Glucose). This heat 
map reveals distinct differences between the two extracts.  
160 
 
 
Figure 6.2. Comparison of GCMS features of chloroform: methanol extracts of LES 
Glutamax™ and LES Glucose reveal profound differences. Here the 437 detectable 
features of LES CM Glutamax™ (columns 4-7) are compared to those of LES CM Glucose 
(columns 1-3, 8) as determined by GCMS (Agilent 7890A gas chromatograph coupled to an 
Agilent 5975C mass spectrometer) (n=4). Features were compared using XCMS 
(https://xcmsonline.scripps.edu/ ) and reported with their retention time (RT) (ranked from 
lowest (pale) to highest (dark) and the P value (ranked from lowest (pale) to highest (dark). 
The P value expresses the significance of the difference between LES Glutamax™ and LES 
Glucose  
A number of these features are significantly different between the two extracts; in Figure 
6.3, all features that are significantly (* P < 0.05) different between the two samples are 
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visualised; 192 features were determined to be significantly different between the LES CM 
Glutamax™ and LES CM Glucose extracts.  
 
Figure 6.3. The comparison of GCMS features of chloroform: methanol extracts of LES 
Glutamax™ and LES Glucose reveals 192 significant features. This bubble plot shows the 
significant (P <0.05) differences between quantities of individual compounds in LES CM 
Glutamax™ compared to LES CM Glucose. Green bubbles represent an increase relative to 
LES Glucose with the bubble size representing the relative amount of each respective 
component; the deeper the shade of green, the larger the P value (more significantly 
different). Likewise, represented in red scale are those components that are reduced in LES 
CM Glutamax™ relation to LES CM Glucose, with the size of the bubble representing the 
relative amount, and the deeper shading indicating increased significance values. This graph 
was generated using untargeted GCMS data (Agilent 7890A gas chromatograph coupled to 
an Agilent 5975C mass spectrometer). Features were compared using XCMS 
(https://xcmsonline.scripps.edu/ ) [412] 
It was also possible to directly compare the identified polar components in both data sets. 
Due to the constraints of XCMS it was not possible to compare these molecules alone and 
therefore this comparison was carried out in Graphpad prism to see if there were significant 
differences between LES CM Glutamax™ and LES CM Glucose. Figure 6.4 compares the polar 
compounds identified at the Bio21 Institute and highlights the significant differences 
between the extracts compared here.  
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Figure 6.4. Comparison of non-volatile polar components of chloroform: methanol 
extracts of LES CM Glutamax™ and LES CM Glucose. There are significant differences 
in the amount of glucose (**** P <0.0001), fructose (** P = 0.0046), glycolic acid (*** P = 
0.0003) and glycerol (**** P <0.0001) between LES CM Glutamax™ and LES CM Glucose. 
This plot was determined using targeted GCMS data (Agilent 7890A gas chromatograph 
coupled to an Agilent 5975C mass spectrometer). 
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6.5 Discussion 
In this chapter the small molecule secretome of LES Glutamax™ is presented. One of the 
aims of this project was to identify small molecules that may have therapeutic value for the 
treatment of inflammatory disease. I have demonstrated in the previous chapter that 
treatment with LES Glutamax™ protects mice against TNBS-induced chemical colitis. A 
number of molecules with reported immunomodulatory activity were identified (Table 6.1), 
and one or more of these compounds may account for the protection observed in the TNBS 
bioactivity screen. Importantly, there are a number of unknown features identified in the 
LES Glutamax™ secretome, which may present as novel leads for therapeutic development. 
Additionally, it was possible to characterise the volatile polar compounds outlined in Table 
2. Together, these provide a first pass characterisation of the small molecule ES component 
produced by the dog hookworm, A. caninum.  
Only around 12% of the molecules described in Table 6.1 and Table 6.2 can be assigned 
KEGG numbers and can be used to annotate known hookworm biochemical pathways 
(Figure 6.1). These compounds can be assigned to the pathways of fatty acid synthesis, fatty 
acid elongation in the mitochondria, gylcerolphospholipid metabolism, or a partially 
represented tri-carboxcylic acid (TCA) cycle given the predicted genome sequence and 
reconstructed KEGG pathways. In the analysis carried out here there was no detectable 
oxaloacetate, cis-aconitate, 2-oxoglutarate, succinyl coA and fumarate in the TCA cycle 
pathway, the possible significance of this will be explored in the Discussion chapter. There 
were also molecules identified that could be assigned to carbon fixation, amino acid 
biosynthesis, carbon metabolism and 2-oxocarboxcylic acid metabolism, although 
representation of LES compounds in these pathways was sporadic and incomplete. Of the 
molecules that were assigned KEGG numbers, 19 were identified as ABC transporters 
(mineral and organic ion transporters); the significance of this is unknown. 
The overwhelming majority of molecules identified in this study are novel. Of the 318 
features identified in Table 6.1, a number could be eliminated on the basis that they are 
confounding agents (for example the silyl molecules are associated with GCMS column 
leaching). Yet others are from the supportive media. The Glutamax™ media contains PBS 
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and an anti-mycotic and antibiotic, the breakdown products of which account for some of 
the compounds identified herein. The breakdown products of both penicillin and 
streptomycin are poorly described so it is difficult to unpick their contribution to this 
dataset. The dimer glutamine-alanine was detected, and is the primary component of 
Glutamax™. Other molecules like DEET (insecticide) and phenobarbital (euthanasia drug) are 
presumed to be from the dog host and highlight the sensitivity of the GCMS method. It is 
also noteworthy that there is a high incidence of esters, possibly resulting from 
lyophilisation of phosphate buffered solutions [413]. 
The primary aim of this project was to identify molecules from A. caninum LES that may 
have therapeutic value. If the focus is to remain on drug discovery, the post-collection 
modification of small molecules is less important, as long as these collection procedures are 
reproducible and the molecules maintain protective bioactivity. However, this issue should 
be addressed if the primary interest is the molecular basis of host-parasite interactions. The 
removal of PBS could be achieved simply by running the LES collected through a preparative 
HPLC column to desalt the solution prior to lyophilisation.  
During the course of this research it became evident that when hookworms were cultured in 
a media where the primary carbon source is glucose, the resulting LES generated very 
different bioactivity results compared to those of LES Glutamax™. From previous studies it 
was known that hookworms prefer not to metabolise glucose for energy but instead to 
divert it into amino acid production [406]. It possible to identify profound differences in the 
features of LES CM Glutamax™ (shown to be protective in TNBS colitis) and LES CM Glucose 
(Figures 6.2 and 6.3), with 192 features significantly different between the two culture 
methods. Using targeted GCMS it was possible to identify four molecules with significant 
differences between the two extracts. The possible implications of this will be discussed in 
the Discussion chapter. 
Currently, proteaceous therapeutics targeting cytokines have serious potential side effects 
due to anti-protein responses. The ability to suppress inflammatory effects using small 
molecules is promising because it has the potential to overcome the limitations of modern 
IBD treatments. From the results above multicomponent fractions have the ability to 
suppress inflammatory effects of the TNBS colitis model. The identification of small 
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molecules that are stable, with targeted modes of action and relatively economical to 
manufacture would be the ultimate goal of future research. The findings here are an 
exciting step towards this goal. 
6.6 The Next Chapter 
Small molecules had not previously been screened by the Loukas laboratory. While other 
researchers had successfully used the TNBS colitis model for assessing anti-inflammatory 
small molecules [414] it was important to show that the model could be used as a 
bioactivity screen in our hands. The next chapter shows that the TNBS colitis model was able 
to highlight the anti-inflammatory potential of the small molecule; capnoidine.  
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Chapter 7 
Proof of Concept 
Identification of a small molecule 
therapeutic candidate using the TNBS 
colitis model 
Preamble 
This chapter I focus on the workup of the small molecule capnoidine as a therapeutic 
candidate using TNBS colitis as a bioactivity screen. 
This work is important as it shows that in principle the TNBS colitis screen can be used down 
to the individual molecule level as a bioactivity screen for anti-inflammatory potential. 
Here I investigated capnoidine as an agent to reduce inflammatory markers in the TNBS 
colitis screen and was able to show that it could protect against the key markers of chemical 
colitis. 
This work validates the use of the TNBS chemical colitis model as a screen for small 
molecule bioactivity. 
Out puts from this Chapter: 
Capnoidine, an isoquinoline alkaloid of a medicinal plant, protects mice against acute 
experimental colitis. Shepherd C, Giacomin P, Miller C, Navarro S, Loukas A, and Wangchuk 
P.  
PUBLISHED WORK Published here with permission. 
Please note: This work has been edited for brevity. 
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Materials and Methods presented here are solely the work of P Wangchuk. All other 
laboratory work was performed by myself, C Shepherd and is included in the Materials and 
Methods (Chapter 3). 
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7.1 Introduction 
Despite recent enthusiasm for the concept of computationally- and synthetically-derived 
drugs, there has been a decline in recent interest due to the relatively low number of drugs 
from these sources that have reached the marketplace [415]. Computationally-optimised 
drugs have relatively low chemical diversity compared with those sourced from natural 
products [28]. Natural products hold appeal for therapeutic drug discovery because they 
display superior chemical diversity and are considered evolutionarily optimised for biological 
function [28]. Long used herbal medicines have the potential to contain compounds that are 
beneficial [416]. Drugs such as aspirin, taxol, and vinblastine are all examples of currently 
used therapeutics derived from plants originating from traditional medicine [417-419]. 
Natural therapies, often known as complementary and alternative medicine (CAM), have 
the potential to be low cost and are well accepted by patients due to their “natural” origins. 
Patients with IBD rank among the highest users of CAM, with current or past use of CAM 
ranging from 21-60% [420-423]. Despite their increasing use by IBD patients, a lack of 
understanding of the bioactive chemical components and mechanisms of anti-inflammatory 
action are obstacles to the incorporation of many CAM or dietary treatments into 
mainstream medicine [392]. 
Recently, a systematic review of CAM treatments in IBD showed that 29 trials including 
phytotherapy, psychological therapy, acupuncture, and helminth therapy have been 
conducted to date [424]. Even though many studies showed promising results - particularly 
those involving poly-ingredient phytotherapy - most trials required additional substantiation 
[424]. Poly-ingredient herbal medicines are complex mixtures, so their mechanisms of 
action are, therefore, difficult to determine. Isolated bioactive molecules from medicinal 
plants or natural product compounds are, therefore, the ideal targets for drug discovery. 
Pre-clinical studies of medicinal plant extracts [414, 420, 425-428] have demonstrated anti-
colitic properties. Similarly, crude extracts of the medicinal plants, Corydalis dubia, Ajania 
nubigena and Pleurospermum amabile, which are used in Bhutanese traditional medicine 
(BTM) as febrifuge and for treating infections related to inflammatory conditions [416], 
significantly reduced the production of TNF in LPS-activated human monocytic cells (THP-1) 
[429]. 
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Following on from our previous work with crude extracts [429], we set out to isolate and 
test the anti-colitic properties of purified compounds from these medicinal plants. Of 25 
compounds that were isolated and whose structures were determined from these three 
plant species [430-432], we assessed four of the most abundant compounds for their anti-
colitic properties in a TNBS-mouse model of colitis. These four compounds (capnoidine (1), 
scoulerine (2) linalool oxide acetate (3) and isomyristicin (4) have not been explored for 
anticolitic potential until now. Since capnoidine (1) imparted the best protection of mice 
against colitis-induced weight loss, we conducted a detailed assessment of this compound 
as a novel lead therapeutic agent. 
7.2 Results 
Encouraged by the preliminary anti-inflammatory activities of the crude extracts of C. dubia 
(Figure 7.1a), A. nubigena (Figure 1b) and P. amabile (Figure 1c) against TNF in LPS-activated 
THP-1 monocytic cells [429], we isolated 25 compounds from these crude extracts as 
described previously[430-432].  
 
Figure 7.1. The structures of the compounds isolated from three plant species and 
screened in the TNBS model of acute colitis. Capnoidine (1) and scoulerine (2) were 
isolated from Corydalis dubia (a) [432], linalool oxide acetate (3) was isolated from Ajania 
nubigena (b) [430], and isomyristicin (4) was isolated from Pleurospermum amabile (c) 
[431]. 
 
1 2 3 4 
b a c 
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Four of the compounds (Figure 7.1, 1-4) were obtained in sufficient quantities to enable 
further assessment of their anti-inflammatory properties against TNBS-induced colitis in 
mice.  
 
7.2 Preliminary assessment of compounds against TNBS-induced colitis 
Body weight loss over time after administration of TNBS was monitored as a preliminary 
indicator of colitis (Figure7.2). Amongst the four compounds investigated, capnoidine (1) 
was the only one to confer protection of mice against TNBS-induced body weight loss (**P = 
0.0037; 2-way ANOVA). Linalool oxide acetate, isomyristicin and scoulerine did not confer 
any protection against weight loss compared with weight loss in mice given TNBS only. 
Further studies on the anti-colitic properties of these natural products were, therefore, 
restricted to capnoidine (1).  
Figure 7.2. Levels of protection of mice conferred by four selected compounds (1-4) (50 
μg/mouse dose) against the TNBS-induced ulcerative colitis. (a) Percent weight loss of 
mice. Capnoidine provided significant protection ((**P = 0.0037; 2-way ANOVA) to the 
mice against the TNBS-induced percent weight loss compared with the TNBS control group 
that received vehicle alone. (b) Colon length of each group of mice. Although a trend in 
improved colon length was observed in a group of mice treated with capnoidine, it was not 
statistically significant. Error bars represent ± SEM. The results were pooled from two 
independent studies (total n = 10 mice) performed using 5 mice in each experiment. 
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7.3 Detailed investigation of capnoidine as a lead compound against TNBS-
induced colitis 
To examine the effect of capnoidine in more detail in the TNBS colitis model, the 
experiment was repeated with additional pathological and clinical parameters being 
measured. Mice were treated with capnoidine (50 μg/mouse) and then 4-6 hr later received 
intra-rectal administration of TNBS. Mice were monitored for their general wellbeing and 
clinical symptoms for three days. Confirming previous preliminary observations capnoidine-
treated mice showed a highly significant reduction (****P = 0.0001) in body weight loss 
when compared with the TNBS only group (Figure 7.3a).  
Capnoidine-treated mice also had significantly reduced clinical scores compared with TNBS 
only mice, including mobility (Figure 7.3b), piloerection (Figure 7.3c) and faecal consistency 
(Figure 7.3d). The overall clinical score of capnoidine-treated mice showed significant (**P = 
0.006) improvement when assessed by 2-way ANOVA (Figure 7.3e). 
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Figure 7.3. Capnoidine (Cap 50, 50 μg/mouse) treated mice showed significant 
improvements in clinical score compared with TNBS only mice. (a) Percent weight loss 
compared with original starting weight (****P = 0.0001), (b) Piloerection (****P = 0.0001), 
(c) Mobility (****P = 0.0001), (d) Faecal consistency (****P = 0.0001) and (e) overall 
clinical score (**P = 0.0060). Statistical analyses were performed by pooling data from 
groups of mice from two independent and reproducible experiments (Total n = 15). Error bars 
represent mean ± SEM. The results were pooled from two independent studies performed 
using 5 mice in each experiment. 
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7.4 Capnoidine treatment resulted in reduced intestinal pathology in mice  
On day three post TNBS administration mice were euthanized and the colons were removed 
(Figure 7.4a). Colons were assessed for changes in macroscopic appearances including 
length, adhesions, colon wall thickening, mucosal oedema, ulceration and necrosis (Figure 
7.4f). Compared with mice that were administered TNBS only, mice treated with 50 μg 
capnoidine had significantly longer colons (Figure7. 4b, **P = 0.0030), and showed 
significantly reduced pathology scores (0-2 scoring matrix), including a reduced number of 
adhesions (Figure 7.4c, **P = 0.0055), thinner walls (Figure 7.4d) (*P = 0.0112), and less 
ulceration (Figure 4f, **P = 0.0032). There was no significant difference in oedema between 
the two groups (Figure 7.4e). 
Overall, the macroscopic pathology score was significantly reduced in capnoidine-treated 
mice compared with mice administered TNBS only (Figure 7.4g, *P = 0.0205). 
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Figure 7.4. Capnoidine (Cap 50 + TNBS) treated mice (50 μg/mouse) showed reduced 
colon pathology after administration of TNBS compared with mice given TNBS only. 
Mice treated with capnoidine (Cap 50) presented with healthier looking colons (a) compared 
with mice treated with TNBS alone. (b) Colon length (**P = 0.0030), (c) Adhesion of colon 
(**P = 0.0055), (d) Colon wall thickening (**P = 0.0112), (e) Oedema (n.s.), (f) Ulceration 
(**P = 0.0032) and (g) Overall combined macroscopic pathology score (*P = 0.0205). 
Statistical analyses were performed by pooling data from groups of mice from two 
independent but reproducible experiments (Total n=15 mice). Error bars represent mean ± 
SEM. 
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7.5 Capnoidine-treated mice had significantly reduced histopathology  
The H&E-stained distal colon sections were observed for histological changes induced by 
TNBS administration and were scored as described by Hong et al.[392]. Untreated mice 
showed normal colon tissue architecture including gastric mucosa, lamina propria, epithelial 
compartments, goblet cell content, and colonic wall/musculature (Figure 7.5a). 
Colons of TNBS only mice exhibited severe lesions and extensive histological damage, 
including thickening of the lamina propria and colon wall, evidence of oedema and mucosal 
erosion with destruction of healthy goblet cells (Figure 7.5b). In addition, increased numbers 
of leukocytes and polymorphonuclear and inflammatory cell infiltrates were evident in the 
lamina propria, intraepithelial compartments, and colon wall. Colons of capnoidine-treated 
mice showed no signs of acute colitis, including having healthy colon architecture with 
normal crypts and goblet cells, good mucosal integrity and no ulceration (Figure 5c). Scoring 
of histological sections for overall pathology showed that capnoidine-treated mice had 
significantly reduced histopathology (****P = 0.0001) compared with TNBS only mice 
(Figure 7.5d).  
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Figure 7.5. Capnoidine-treated mice had significant protection against TNBS-induced 
histopathology. Representative photomicrographs of H&E stained colonic tissue 
sections. (a) healthy naive control mice, (b) vehicle-treated TNBS treated mice, (c) 
Capnoidine-treated TNBS mice, (d) Blinded histological scoring of colonic pathology 
(****P = 0.0001). Statistical analyses were performed by pooling data from groups of mice 
from two independent but reproducible experiments (Total n=15 mice). Error bars represent 
mean ± SEM. Goblet cell destruction (as indicated by arrows) is demonstrated in Periodic 
acid–Schiff (PAS) staining of colon sections (e) healthy naive control mice, (f) vehicle-
treated TNBS treated mice, (g) Capnoidine-treated TNBS mice 
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7.6 Cytokine responses indicate anticolitic effect of capnoidine 
We next assessed the expression of the key cytokines IL-1β, IL-4, IL-5, IL-6, IL-13, IL-17A, 
TGF-β IFN-γ and TNF within the colons of mice following treatment with capnoidine. We also 
carried out RT-PCR on colons for cytokine IL-10 expression. Mice treated with capnoidine 
prior to administration of TNBS showed a significant reduction in the levels of IL-1β, IL-6, IL-
13 (P values < 0.05) and TNF (P < 0.01), and an increase in IL-4 (P = 0.0355) in colon culture 
media when compared with the TNBS only group (Figure 7.6a-g). There was no observable 
difference in IL-5 levels between treatment groups. There was an observable trend for 
reduced levels of IFN-γ in the capnoidine-treated group, but the difference was not 
statistically significant. Levels of IL-17A, TGF-β and IFN-γ in colon tissue homogenate (Figure 
6h) of capnoidine-treated mice were lower than levels in TNBS only mice but the difference 
was not significant (P>0.05). We also determined the levels of the cytokine IL-10 RNA 
transcripts (Figure 7.7) however, there was no significant difference between IL-10 
transcription levels .of the TNBS only and capnoidine treated mice.  
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Figure 7.6. Capnoidine-treated mice have cytokine profiles that indicate protection 
against TNBS-induced colitis. Mice treated with capnoidine (Cap 50 + TNBS) showed 
cytokine profiles indicative of anti-colitic effects with significant reductions in levels of: (a) 
IL-1β (*P =0.0441), (d) IL-6 (*P =0.0413), (e) IL-13 (*P =0.0462) and (g) TNF (**P 
=0.0041) compared with levels in the TNBS only mice. There was an observable increase in 
the level of IL-4 (*P =0.0355) (b) but there was no difference in the amount of IL-5 
production (c) between the two groups. While there was a trend for a decrease in IFN-γ levels 
(f), this was not significant. A comparison of IL-17A, TGF-β and IFN-γ levels from colon 
homogenates (h) showed no statistically significant difference between TNBS only mice and 
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those treated with capnoidine + TNBS. Statistical analyses were performed by pooling data 
from groups of mice from two independent but reproducible experiments (Total n=15 mice). 
Error bars represent mean ± SEM. 
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Figure 7.7 Capnoidine treatment does not significantly alter IL-10 tRNA levels when 
compared to TNBS only treated mice. Mice treated with capnoidine (Cap 50 + TNBS) 
showed tRNA levels that are not significantly different to TNBS only treated mice. PCR 
assays were performed in triplicate and assay efficiency for RT-PCR was determined to 
average 80-110% as calculated by LinRegPCR program. PCR was performed by pooling 
samples from groups of mice from two independent but reproducible experiments (Total 
n=15 mice). Error bars represent mean ± SEM. 
 
7.7 Tissue p-IκB-α (Ser32) and p-NF-κB p65 (Ser536) levels of capnoidine 
treated mice were significantly reduced compared with TNBS treated mice 
Molecules that are able to block the nuclear factor NF-κβ pathway signal transduction are 
attractive therapeutic targets in the treatment for IBD. This is because this signal pathway is 
thought to facilitate crosstalk between inflammatory pathways and promotion of intestinal 
inflammation associated pathology [433]. Transcription of pro-inflammatory cytokines such 
as IL-1β, IL-6 and TNFα is regulated through the phosphorylation status of the transcription 
factor nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB). Translocation of 
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NFĸB from the cytoplasm to the nucleus is, in turn, regulated by the phosphorylation status 
of inhibitor of ĸB-α (IĸB-α). We determined the levels of p-IκB-α (Ser32) and p-NF-κB p65 
(Ser536) in the colon tissue homogenates (Figure 7.8). Mice treated with capnoidine prior to 
administration of TNBS showed a significant reduction in the amounts of the p-IκB-α (Ser32) 
(P = 0.0259) and p-NF-κB p65 (Ser536) (P = 0.0466) respectively compared with TNBS only 
mice.  
 
Figure 7.8. Levels of transcription factors (phosphorylation) in the colon tissue 
homogenates. Capnoidine-treated (Cap 50 + TNBS) mice have significantly lower levels of:  
(a) p-IκB-α (Ser32) (*P = 0.0259) and (b) p-NF-κB p65 (Ser536) (*P = 0.0466) compared 
with levels in TNBS only mice. Results were normalised to amount of colon tissue for each 
experiment. Statistical analyses were performed by pooling data from groups of mice from 
two independent but reproducible experiments (Total n=15 mice). Error bars represent ± 
SEM. 
7.8 Discussion 
The treatment regimen for IBD, especially UC, is limited and current therapies are 
associated with adverse side effects [434] and considerable socio-economic cost [435, 436]. 
Since the causes of IBD are complex, it is challenging to develop an appropriate treatment 
strategy. Current IBD drugs, especially the biologics, can have severe side effects [20], are 
expensive and difficult to administer [437]. As a result, a surge in interest in alternative 
medicine, especially naturally derived herbs and plant extracts, has emerged [438]. 
Nonetheless, the challenge with crude herbal extracts is the difficulty in elucidating 
mechanisms of action, and, therefore, emphasis is placed on isolation of bioactive chemical 
components as scaffolds for lead optimisation and therapeutic application. Due to their 
simple structures and anti-inflammatory properties [439], chemical entities including 
terpenoids, polyphenols, flavonoids and isoquinoline alkaloids have received attention as 
181 
 
alternative candidates for IBD therapy. These phytochemicals confer anti-inflammatory 
activity by reducing cytokine production and altering the expression of transcription factors 
associated with inflammatory pathways [440, 441]. For example, the quaternary coptisine, 
an alkaloid found in Chinese goldthread (Coptis chinensis), displays protection in colitis 
[442]. Similarly, noscapine, a phthalideisoquinoline alkaloid derived from Papaver 
somniferum, has exhibited anti-inflammatory activity through cytokine regulation [443] and 
this compound is currently under clinical trials for cancer therapy [444].  
The genus Corydalis is not only well represented as a component of traditional medicines 
but also produces a number of small molecule isoquinoline alkaloids that display anti-
inflammatory properties [445]. Interestingly, the isoquinolone alkaloids from Corydalis 
plants that display anti-inflammatory activity show little structural similarity [445, 446]. This 
reflects the difficulty in establishing Structure Activity Relationships (SAR) between 
phytochemicals and mechanisms of suppressing inflammation [447].  
In this study, we have investigated the anti-colitic properties of 4 compounds (Figure 7.1), 
which were isolated from C. dubia, A. nubigena and P. amabile - in a mouse model of acute 
TNBS colitis. TNBS-induced colitis shares many clinical, histological and biochemical features 
with human UC and is a widely utilised in vivo protocol for screening of anti-colitic 
compounds [6, 426]. Questions arise as to whether an acute TNBS-induced model could 
perfectly represent a human IBD, which is chronic inflammatory in nature. It must be 
acknowledged that human IBD - CD and UC- while chronic, are well documented to be 
episodic in nature. The aetiologies of both acute and chronic intestinal inflammatory disease 
is often enigmatic and are often linked to prior acute inflammatory disease incited by 
pathogens including viruses, bacteria, parasites, dysregulation of the intestinal immune 
response, or autoimmune disorders. Presently, there is no ‘perfect’ animal model that can 
address all the mechanisms involved in intestinal inflammation of IBD. Each animal model 
has an array of advantages and disadvantages to its use and therefore a comprehensive 
study examining multiple aspects of intestinal inflammation requires multiple models. We 
are aware of the relative strengths and limitations of each model of colitis used to study 
acute and chronic inflammatory diseases of the mammalian intestine, and the scope and 
relevance of outcomes achievable based on this knowledge. The ability to induce 
inflammation to mimic common human diseases is an important factor of a successful 
animal model and a review by Jiminez et al. [448] highlighted the suitability of TNBS as an 
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incitant of both acute and chronic inflammation. TNBS elicits cell-mediated mixed Th1 and 
Th2 cytokine-based immune responses and induces transmural inflammation in the gut with 
clinical, morphological and histopathological features similar to those of human IBD. 
Clinically, IBD is characterized by severe diarrhoea, bleeding, abdominal pain, fluid and 
electrolyte loss, which underlines the initial acute nature of IBD. Similarly, patients with 
ulcerative colitis experience significant colonic thickening and dense infiltration of 
neutrophils, monocytes, macrophages and T cells typically on the mucosal layer of the 
bowel wall. All these clinical and histological signs are exhibited in the TNBS colitis model, 
which we have employed here for screening the anti-colitis properties of four compounds 
isolated from three Bhutanese medicinal plants. These three medicinal plants, which grow 
in the high mountain ranges of the Himalayas in Bhutan, have been used in BTM for 
hundreds of years for treating various diseases including symptoms related to inflammation.  
Of the four compounds tested, capnoidine (1) (isolated from C. dubia) showed the best and 
significant anticolitic properties. We have demonstrated here that treatment of mice with 
capnoidine prior to administration of TNBS resulted in a reduction in severity of clinical 
symptoms (Figure 7.3) accompanied by a reduction in colon pathology (Figure 4) and 
histopathology (Figure 7.5). This was associated with a significant reduction in the 
production of IL-1β, IL-6, IL-13 and TNF (Figure 7.6), which are the signature cytokines of 
human UC. The ability of this compound to significantly reduce expression of TNF in the 
colon of mice after TNBS administration supports previous observations on its parent C. 
dubia crude extract [429]. Indeed, TNF is a major target of monoclonal antibody-based 
biologics for treating IBD and other inflammatory diseases, including rheumatoid arthritis 
and psoriasis [437, 449-451]. Generally, the production of IL-1β and TNF is associated with 
the severity of disease in human UC, possibly due to persistent activation of NF-kB [452]. 
Capnoidine treatment resulted in significantly reduced levels of IL-6 in the colon compared 
with TNBS only mice. IL-6 is a multi-functional cytokine produced by a wide range of 
immune cells, and plays a role in the differentiation of Th17 cells. IL-6 is highly expressed in 
flaring IBD, and is, therefore, a target for monoclonal antibody-based treatment of IBD 
patients who failed to respond to anti-TNF therapy [453]. 
Transcription of pro-inflammatory cytokines is regulated through the activities of NFĸB49. 
Our results showed significantly lower levels of phosphorylated IĸB and phosphorylated 
NFĸB in mice pre-treated with capnoidine compared with mice given TNBS only (Figure 7.8) 
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suggesting that capnoidine is able to reduce cytokine production possibly via inactivation of 
the NFĸB pathway. However, the precise mode of action of capnoidine remains unknown. 
Our study was curtailed by the amount of capnoidine available, a common limitation 
encountered when working with natural products and validation of ethnomedicines [441]. 
Capnoidine treatment also suppressed expression of the Th2 cytokine, IL-13, which has been 
attributed to driving pathogenesis in UC and is the focus of efforts to develop new biologics 
[454]. On the other hand, capnoidine treatment resulted in increased expression of the Th2 
cytokine IL-4 when compared with levels in the TNBS only group, resulting in similar levels 
to those found in healthy control animals, and likely reflected the absence of inflammation 
in the gut. The cytokine IL-10 is implicated as an anti-inflammatory cytokine in colitis [455] 
however we found no significant difference in tRNA levels between TNBS only and 
capnoidine treated mice. Thus, thorough investigation of capnoidine highlighted its highly 
significant anticolitic properties including protection of mice against clinical signs 
(bodyweight loss, diarrhoea, and piloerection), pathological features (colon shortening, 
adhesion, thickening, oedema and ulceration), dysregulated cytokine production (decreased 
TNF, IL-1β, IL-6 and IL-13, and elevated IL-4), and histological changes (mucosal layer, goblet 
cells, lamina propria, and infiltration of inflammatory leukocytes and polymorphonuclear 
cells). 
While the exact mechanism of action remains unknown, the ability of capnoidine to 
significantly reduce the inflammasome signalling pathway 1 molecules implicates the 
possible disruption of inflammasome formation and the prevention of the inflammatory 
process. The ability of capnoidine to protect mice against these hallmark features of murine 
colitis, which are translatable clinical symptoms and pathology in human UC, is a strong 
indication that this compound is a potential candidate as a new anticolitic compound. This 
study also shows that capnoidine is at least one of the bioactive components that are 
responsible for the anti-inflammatory properties of its parent crude extracts of C. dubia. C. 
dubia has been harvested historically for the treatment of symptoms and diseases that bear 
relevance to inflammatory conditions. Our findings highlighted the value of exploring 
traditionally used herbal medicines as a source of novel anti-IBD therapeutics.  
Capnoidine is a simple small molecule that shares close structural similarity with noscapine 
(Figure 7.9), which is currently used as an antitussive and antimitotic drug in many countries 
and is also in clinical trials for treating many cancers[444]. Like noscapine, capnoidine (logP 
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= 3.38) also met the criteria of the ‘Lipinski Rule of 5[24], which predicts the drug-likeliness 
of a compound.  
 
Figure 7.9. Noscapine structure has scaffold similar to capnoidine (1) 
 
In addition, our previous cytotoxicity study of capnoidine against normal Vero cells (kidney 
epithelial cells of African green monkey, Cecopithecus aethiops) found that it is non-toxic 
[432]. These chemical and biological properties of capnoidine underscore its potential as a 
lead scaffold upon which to develop newly derivatized anticolitic small molecule drugs and 
opens up new avenues for other therapeutic studies and applications. With further future 
medicinal chemistry works on lead optimisation, derivatization, appropriate dose response 
analysis, cytotoxicity, bioavailability, stability and mechanism of action of capnoidine; this 
compound, as a natural product anti-inflammatory agent, presents potential to inspire new 
treatment strategies in an area of care where mainstream medication often fails or 
emancipates major side effects.  
 
 
 
7.9 Materials and methods 
These methods were performed by P Wangchuk and included here for completeness. 
Essentially, they describe the methods used to extract and identify the capnoidine 
molecule prior to testing in the colitis model. All other work as described in the results 
was performed by C Shepherd. 
Plant materials  
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The selected plant materials – Corydalis dubia (Fumariaceae, herbarium voucher specimen 
number (HVSN) 78)), Ajania nubigena (Asteraceae, HVSN 73), Pleurospermum amabile 
(Umbelliferae, HVSN 29) – were collected from the Himalayan mountains of Lingzhi in 
Bhutan in July-August 2009 and the herbarium specimens were preserved at Menjong Sorig 
Pharmaceuticals (MSP), Ministry of Health, Thimphu, Bhutan. Although the whole plant of C. 
dubia is used in BTM, only the aerial parts of A. nubigena and P. amabile were used in this 
study. We collected those parts of plants from their natural habitats and dried them in the 
shade/sun in accordance with prescribed BTM traditional methods of drying. 
 
7.10 Preparation of compounds for the TNBS experiment  
The extraction, fractionation, isolation and characterisation of compounds from these three 
plant species were reported earlier[430-432]. Briefly, the air-dried plant materials (2 kg) 
were chopped into small pieces and were repeatedly extracted with analytical grade or 
HPLC grade methanol (MeOH) (5 x 3 L over 48 h). The extracts were filtered and then 
concentrated using a rotary evaporator at 35-50°C to produce the crude MeOH extracts of 
each of the three medicinal plants. The MeOH extracts were dissolved in MeOH:H2O (200 
mL, 1:9), then fractionated with different solvents (3 × 100 mL) including hexane, CH2Cl2, 
CHCl3, EtOAc, n-BuOH to obtain the respective solvent extracts, and purified repeatedly 
using flash column chromatography packed with Merck Kieselgel 60 PF254. Aluminium-
backed silica plates (0.2 mm silica thickness, Merck, normal and reverse phase) were used 
for separating isolates of smaller quantities. Solid compounds were crystallized from a 
mixed solvent system of chloroform/methanol. UV light (short wavelength of 254 nm, long 
wavelength of 366 nm) was used for visualization of the separated bands on TLC. 
Dragendorff’s reagent was used for visualising alkaloids on TLC plates. Ceric ammonium 
molybdate solution was used for staining non-alkaloid compounds spotted on TLC plates. A 
Reichert hot-stage apparatus was used for determining the melting point of the compounds 
and was not corrected. IR spectra were obtained on neat samples using a Smart Omni-
Sampler Avator ESP Nicolet spectrometer. While LR-ESI-MS of the compounds were 
obtained using Micromass Waters Platform LCZ (single quadrupole, MeOH as solvent), the 
LR-EI-MS and HR-ESI-MS were acquired using Shimadzu GCMS-QP-5050 (DIT at 70 eV) and 
Micromass Waters Q-ToF Ultima (quadrupole time-of-flight) mass spectrometers, 
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respectively. The GC-FID was obtained using a Shimadzu GC-2010 Plus gas chromatograph 
with hydrogen as carrier gas (1.5 mL/min at 40 °C in a constant total flow mode) and the GC-
MS spectra was acquired using Shimadzu QP5050A GC-MS system (electron impact (EI) 
mode at 70 eV) with helium as a carrier gas. Separation was achieved using a Restek fused 
silica capillary column (Rxi-5MS: 30 m × 0.25 mm i.d., 0.25 μm film thickness). The 
compounds were identified by comparing their mass spectra with the NIST and NISTREP 
mass spectra library of GC-MS data system and further confirmed by comparing the NMR 
chemical shifts of the spectra. 1H-NMR, gCOSY, 13C-NMR, APT, gHMBC, gHSQC, TOCSY and 
gNOESY spectra of the compounds were acquired by a 500 MHz Varian Unity Inova, 500 
MHz Varian Premium Shield (VNMRS PS 54), and 300 MHz Varian Mercury spectrometers (in 
deuterated solvents, CD3OD or CDCl3)21-23. Other chemicals and solvents used for natural 
product isolation and characterisation were described previously [430-432]. 
Twenty-five compounds in total were isolated from these three plant species. We selected - 
on the basis of abundance - four major compounds (1-4, Figure 1) for investigation of their 
anti-colitic properties in a mouse model of TNBS colitis. As described previously [432], 
capnoidine (1) (8 mg) and scoulerine (2) (9.4 mg) along with other six isoquinoline alkaloids 
were obtained from the crude MeOH extract of C. dubia [432]. Capnoidine (1) was obtained 
as colourless crystals and had a molecular weight (Mol. Wt.) of 367 and the formula 
C20H17NO6. Scoulerine (2) was isolated as a reddish brown solid with a Mol. Wt. of 327 and 
the formula C19H21NO4. Linalool oxide acetate (3) (1.2 g), along with 7 other compounds, 
was isolated as colorless oil (Mol. Wt. 212, formula C12H20O3) from the crude MeOH extract 
and essential oil of A. nubigena [430]. Isomyristicin (4) (185.3 mg), along with 9 other 
compounds, was isolated as colorless oil (with Mol. Wt. 192 and the formula C11H12O3) from 
the MeOH extract and essential oil of P. amabile [431]. Stock solutions of these four 
compounds (1-4) were prepared by dissolving one milligram of each of compound in 1% 
DMSO/PBS (0.22 μm filtered) to obtain 1 mg/mL stock concentrations. Each mouse was 
administered 50 g of this stock solution.  
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Chapter 8 
Discussion 
Preamble 
In this chapter, I bring together my research findings and discuss: 
• The value of the TNBS colitis model as a bioactivity screen for anti-inflammatory 
small molecules, and its successful application herein using a range of complex 
mixtures down to individual molecules.  
• The possible therapeutic value of these molecules is explored in the context of our 
search for novel anti-inflammatories. 
• The possible roles of small molecules produced by hookworms in host-parasite 
interactions. 
• The small molecule milieu characterised herein and how it fits with our 
understanding of parasite metabolomics.  
Finally, I will look at the limitations and the questions raised by this study. I will touch on 
future research directions that my research presents and avenues of endeavour that may be 
explored. 
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8.1 Long friendships run deep 
For eons humans have collected, foraged and harvested medicinal herbs. They have climbed 
precarious peaks, waited for the right season and picked at just the right stage. They have 
processed, stored, and administered in particular ways. It turns out that this is for good 
reason, with a significant proportion of modern drugs being sourced from ethnobotanicals 
[28]. These traditional medicines through their long associations have proved a rich source 
of drug discovery. However, in the last 50 years there has been a dramatic increase in 
inflammatory disease such as asthma, diabetes, multiple sclerosis and inflammatory bowel 
diseases in modernised populations [37]. These modern diseases are chronic, seemingly 
have no cure and the modern drug cabinet appears to be bare for treatments. New 
medicines are clearly needed for these ailments. 
The search for drugs to treat inflammatory diseases has cast a wide net but is restricted by 
our lack of understanding of the diseases themselves and the limitations of modern drug 
discovery. Breakthrough medications such as the anti-TNF biologics are expensive, have 
serious complications and patients can be resistant to treatment [16, 451]. Turning back to 
long-term and natural biological associations seems a rational approach to modern drug 
discovery [456]. The association of human and hookworm is one of the most ancient and 
enduring. Parasites, as outlined by the “Old Friend’s Theory” may be integral to human 
immune system maturation [38], with hookworms being one of the most co-dependent of 
these relationships [280]. 
The human hookworm, in its gut dwelling stage, can evade ejection by the host for up to a 
decade. And, as evidenced by worm burdens in adults, the host fails to develop any sort of 
meaningful protective immunity against this parasite [50]. This evasion is an active process; 
parasites produce molecules that interact with the host immune system to prevent their 
expulsion, but at the same time, immune effector mechanisms maintain worm burdens at 
levels that the host can usually tolerate. The ancient association of human and hookworm 
has meant that the human immune system has evolved to expect the input of these 
molecules. It is speculated that the lack of exposure to pathogen (and particularly helminth) 
molecules may be one of the underlying causes of inflammatory disease. So what are these 
molecules? How do they interact with the immune system? Moreover, can they be used to 
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treat inflammatory disease? All of these questions are difficult to answer in the setting of 
the human hookworm. Study is ethically constrained and there are restrictions on the 
usefulness of many animal model equivalents. 
The dog hookworm is one of the models studied to understand the human-hookworm 
relationship. Proteomic study of the ES products produced by the gut dwelling adult 
hookworm has revealed a number of proteins that are immunomodulatory. For example, 
the 41 kDa protein Neutrophil Inhibitory Factor (NIF) prevents the adhesion and aggregation 
of neutrophils and ultimately prevents their activation [162]. In addition, homologues of 
tissue inhibitors of metalloproteases (TIMPs) have been shown to prevent dendritic cell 
activation [246] and have been successfully used to treat inflammatory disease in mouse 
models [164, 457]. There is also evidence of hookworms being able to induce crosstalk 
between the innate and adaptive immune system by inducing the production of IL-4 [256]. 
In an apparent theme of parasitism, evasion of the host is no one-trick pony, with multiple 
proteins (and possibly other molecules) acting at different sites in different ways [39, 329]. 
There has been very little work carried out on the small molecules that hookworms produce 
within their suite of ES molecules. This low molecular weight ES complement (LES) and how 
it contributes to host tolerance has not been explored [39]. In addition, there has been no 
investigation of the therapeutic potential of LES from any helminth, despite small molecules 
being a much more attractive proposition than peptides or proteins from a therapeutic 
standpoint due to their potential ease of administration and increased stability and 
bioavailability. 
8.2 A small molecule bioactivity screen: Is the TNBS chemical colitis model 
suitable? 
One of the difficulties of studying the immunomodulatory effects of small molecules is that 
the targets can be either poorly defined or extraordinarily narrow, and therefore it is 
difficult to screen a broad range of components. What is apparent is that small molecule 
interactions can occur in surprising ways and there are literally catalogues full of small 
molecules that interact with the immune system [458]. Since there was no existing 
literature to guide the selection of a screening model for helminth products, I have used the 
TNBS chemical colitis mouse model as a broad-based bioactivity screen for anti-
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inflammatory activity. This model is known to induce Th1/Th17 type inflammation with Th2 
hyperplasia, as well as activation of the innate inflammatory processes. The TNBS model has 
the additional advantages of only needing minimal amounts of screening material and 
having a relatively short experimental window. 
While the TNBS mouse colitis model was well established in our laboratory [5], it had never 
been used to screen small molecules for anti-inflammatory activity in this setting. To 
validate the TNBS colitis model, I administered the small molecule, capnoidine, to mice (50 
μg/mouse) and assessed its protection against TNBS induced colitis. Capnoidine is a small 
molecule sourced from plant material and extracted in part using small molecule techniques 
that were proposed for use in this project with hookworm LES. I was able to show reduced 
clinical, macroscopic, and histological disease in capnoidine-treated mice compared to the 
TNBS only treated mice. I was also able to show that there was a decrease in the 
inflammation-associated cytokines IL-1β, IL-6, IL-13 and TNF in capnoidine treated mice. This 
series of experiments was able to establish that small molecules can be screened 
successfully using the TNBS colitis model. 
8.3 Small molecules from A. caninum ES can protect against TNBS chemical 
colitis – LES Glutamax™ is complex 
In a number of experiments presented in this body of work, it is possible to show that the 
low molecular weight component produced by adult A. caninum can protect against TNBS-
induced colitis. Treating mice with LES Glutamax™ (50 μg/mouse) prior to administration of 
the TNBS chemical confers significant protection against the clinical, histological and 
macroscopic parameters of TNBS chemical colitis [31]. Cytokine responses of mice pre-
treated with LES Glutamax™ revealed a significant reduction in the pro-inflammatory 
associated cytokines IL-1β, IL-13, and TNF. However, there was an increase in the levels of 
INF-γ and IL-17A, which are associated with inflammation. This is the first time it has been 
demonstrated that hookworm LES has immunomodulatory potential. 
Characterisation of LES Glutamax™ by GCMS revealed over 300 features. Of these features, 
only a handful were identified and attributed immunomodulatory activity (Table 6.1) based 
on prior reports in the literature. From a therapeutic discovery standpoint, these results are 
encouraging. The molecules present in A. caninum LES (Ac LES) have not been defined in the 
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context of their anti-inflammatory activity and a number of undescribed molecules have 
been identified. Given that many of the current drugs used to treat IBD rely on their ability 
to reduce TNF levels, the suppression of TNF by Ac LES is encouraging. Due to the 
complexity of LES Glutamax™, separation of components using small molecule techniques 
was carried out. 
8.4 Small molecule techniques – purifying therapeutic candidates from 
crude Ac LES 
A small molecule technique is a term used to describe the organic chemistry methods used 
to separate molecules based on their physical and chemical properties. They are a 
commonly utilised approach in ethnobotanical research. The research described herein is 
the first report of such techniques being applied to helminth ES components. Using a simple 
extraction method - the Folch extraction [400] - it was possible to separate LES Glutamax™ 
into three components. A polar salt extract, which showed no protection in the TNBS 
bioactivity screen, chloroform: methanol extract and an ethyl acetate extract. 
Both the LES Glutamax™ chloroform: methanol (LES CM Glutamax™) and the ethyl acetate 
(LES EA Glutamax™) fractions were protective in the TNBS colitis screen. It was decided that 
only the LES CM Glutamax™ fraction would be pursued in this study since it had the greatest 
therapeutic potential. LES CM Glutamax™ prevented the onset of inflammation in the TNBS 
chemical colitis model. However, of the cytokines assessed in this model, only IL-1β was 
significantly suppressed when compared to the TNBS control. Because of the strong 
protection against weight loss, low clinical disease scores, and preservation of histological 
structure, I decided to further investigate LES CM Glutamax™. 
Using a preparative thin layer chromatography plate, LES CM Glutamax™ was separated into 
11 bands that were extracted and tested in the TNBS bioactivity screen. Of these bands, 
only four showed comprehensive protection against weight loss, clinical presentation, and 
macroscopic score. Analysis of colon cytokines from mice treated with these four bands in 
the TNBS colitis model revealed distinct differences. Band 4 induced significantly lower IL-
1β, IL-13, INF-γ and TNF levels when compared to the TNBS only treated mice. As a result, 
this band presents as the most promising for further investigation and has the highest 
192 
 
therapeutic potential. Identifying the individual components of band 4 is beyond the scope 
of this thesis, but this work is ongoing in our lab. 
It is possible to demonstrate here that small molecule techniques can be used systematically 
to identify molecules of therapeutic interest when guided by a suitable bioactivity screen. 
8.5 LES Glutamax™ - small molecule description – big picture implications 
The characterisation of the LES produced by A. caninum represents the first time that the 
small molecule secretome has been described for any helminth. Analyses reveal a complex 
mix of components, many of which have not been annotated. It was possible to map 43 of 
these molecules to the putative biochemical pathways of the human hookworm, N. 
americanus. The observations here agree with what is already known about parasite 
metabolism. 
A common pattern in parasite metabolism is a functionally incomplete TCA cycle [459, 460], 
which is what we observe here. It is also known that parasites rely on the host for glucose 
and subsequently use this in anaerobic glycolysis rather than classical glycolysis [407]. 
Parasitic helminths are known to favour lipids and amino acids over carbohydrates as a 
source of energy [461]. These parasites utilise the TCA cycle and fatty acid degradation for 
amino acid metabolism and not for ATP production [462]. Of the molecules identified 
herein, the majority map to the TCA cycle, amino acid synthesis, and fatty acid metabolism. 
It has been noted by others that successful parasites without exception utilise anaerobic 
metabolism during active parasitism. The advantages of this metabolism are three-fold: the 
end products are short chain fatty acids which are well established as anti-inflammatory 
agents; short chain fatty acids are molecules produced by commensal bacteria and may aid 
to mask the presence of hookworms; finally, the actual metabolomics pattern may signal to 
surrounding cells a general “health and well-being” pattern.  
It is intriguing that these 43 molecules are readily detectable in the secretome of 
hookworms, as opposed to just their somatic tissues. Parasites are known to be fermentive 
metabolisers; that is the end products of metabolism are molecules like short chain fatty 
acids. Yet here, the cellular intermediates of biochemical pathways are easily discernible. 
There is an argument to be made that these molecules may be released from dying cells or 
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the worm itself, but given the relative impermeability of the hookworm’s outer cuticle, I 
propose that the hookworm is actively secreting these molecules to reinforce an 
environment of tolerance and immune homeostasis around its site of attachment. 
There has been much recent interest in immunometabolism - the metabolism profiles of 
activated immune cells - and profiles that are associated with immune homeostasis [463]. 
There are six pathways that are strongly associated with immune function; glycolysis (pro-
inflammatory), the TCA cycle, the pentose phosphate pathway, fatty acid oxidation, fatty 
acid synthesis and amino acid metabolism. For example, high levels of fatty acids and amino 
acids can inhibit activation of the mTOR pathway in cells, and is considered anti-
inflammatory [463]. It would be interesting to know the levels of mTOR expression at the 
site of hookworm attachment in the gut to see if this is one of the mechanisms of immune 
tolerance. It is also known that M1 and M2 macrophages have distinct differences in their 
TCA cycles; M2 macrophages have a complete TCA cycle whereas M1 macrophages have a 
TCA cycle that is broken in two places (after citrate and succinate) [463]. Noteworthy is that 
M2 macrophages are associated with helminth expulsion, yet we see here that A. caninum 
has adopted the broken TCA cycle pattern associated with M1 macrophages.  
It is notable that hookworms when cultured in 2 g/L of glucose produce a LES that drives 
pro-inflammatory responses in mice, as evidenced by the TNBS bioactivity screen (Figure 
5.1). It is well established that glycolysis is employed by many activated immune cells; in 
macrophages glucose utilisation drives the production of IFN-γ and inflammatory processes 
[463]. The results herein suggest that other molecules associated with glucose metabolism 
may help to drive or reinforce inflammatory processes. It may be possible by comparison 
with the protective LES CM Glutamax™ to determine what these features may be. 
8.6 Limitations and Future work 
The primary limitation of this study was supply and access to dog hookworm for culture and 
study. Access to cadaver dogs for the harvesting of hookworms can be restricted on an 
ethical and social level, and this proved to be a significant barrier for this project. Raising 
dogs in an experimental setting for experimental infection and harvesting of hookworms 
was not an appropriate option for this project for ethical, logistical, and financial reasons. 
Hookworm infections in dogs display a distinct seasonality in its pattern. During the course 
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of this study, I found that high- to medium-intensity hookworm infections in dogs occurred 
in the May-June period coinciding with the last rains of the monsoon season. Harvests 
outside of this time invariably failed to yield appreciable numbers of hookworms; one 
collection event memorably gave a total of 50 hookworms from a total of eight dogs. While 
in the latter stages of this study, we were able to negotiate access to cadavers supplied to 
the vet school, which allowed for a more consistent supply of hookworm material to 
continue studies. This required travel to Townsville from Cairns to collect material and 
transport it back to the laboratory and all the complications that entails. 
In the introduction of this thesis, evidence was presented that helminths actively produce 
proteins that interact with the host immune system to induce immune tolerance. The 
themes of immunomodulation show that helminths have produced a complex array of 
proteins that could not be predicted by bioinformatics alone. These ICH are pleiotropic but 
act to induce modified Th2 response in the host [39]. The findings here suggest that the 
protein component produced by helminths is not the complete story of immunomodulation 
by helminths. There are small molecules are present in the ES that are associated with 
intracellular processes yet they are found in relatively abundant quantities. If viewed 
through an immunometabolism lens these molecules may well prove to be a strategy by A. 
caninum to provide a further layer to the immunomodulatory environment around the site 
of attachment by molecular signalling to epithelial cells, macrophages and DCs that the 
“status quo” is being maintained. By bathing the area in molecules that indicate immune 
homeostasis it may be possible for the helminth to evade expulsion. Not only do these 
molecules act as anti-inflammatory signals to surrounding cells but also helminths are 
known to produce molecules that are foodstuffs for commensal bacteria of the gut. By 
adopting this strategy it promotes an immune-tolerogenic environment by proxy. To this 
researcher it would not be surprising to find that in addition these helminths are producing 
a number of small molecules that directly disrupt inflammatory processes like the formation 
of inflammasome. One possible experimental technique to explore these questions could be 
the application of NMR-metabolomics, where the metabolomic profiles of individual cells 
can be profiled. It may be possible to discern the immune-metabolomic profile of buccal 
cells and the cells of the host at the site of the hookworm attachment. 
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Curtailed access to material meant that projects such as re-investigating peptide 
components using modified collection techniques was not possible. With the increasing 
sensitivity of new mass spectrometry technologies, these limitations may be countered to 
some degree. Moreover, the ability to perform in situ proteomic MS/MS analysis of tissues 
and cellular level NMR metabolomics means that some of the interesting questions around 
the roles of hookworm small molecules in host-parasite interactions that were raised as a 
result of this thesis might be answered. Are peptides involved in host-parasite interactions? 
Are exosomes involved in small molecule cross talk? Do hookworms produce molecules that 
block pro-inflammatory metabolism/pathways? Do hookworm small molecules directly 
interact with host immune cells? Is it possible for these molecules to be developed as 
treatments for inflammatory disease? 
This project has hinted at both the biological and therapeutic potential of the small 
molecules present in LES. However, for any molecule identified to garner interest for 
therapeutic development establishing anti-inflammatory results in more than one animal 
model is desirable [464]. Ultimately, identifying small molecules for the treatment of human 
disease requires the transition to human models. One way to do this is cell proliferation 
studies of human PBMCs. Cells are labelled with CFSE and incubated in the presence of the 
small molecule of interest  to assess activation via proliferation of human lymphocytes in 
vitro [465]. Using this method would be possible to identify cells are activated by the small 
molecule of interest. Another technique that could be valuable it that once the identity of 
specific small molecule candidates is carried out binding assays to human arrays could be 
performed. It is important to do this, as many examples of encouraging results in mouse 
models do not translate into clinical trial efficacy. This can be due to the differences 
between murine and human immune systems. One way to mitigate this is the use of 
humanised mice models as suggested above. 
Finally, there are many features highlighted in LES Glutamax™ that have never before been 
described; they are either completely unknown or have no recorded bioactivity; this 
presents itself as an exciting field for therapeutic discovery. I have been able to demonstrate 
reproducible protection with hookworm LES in the TNBS chemical colitis model, and using 
small molecule techniques, shown that it is possible to narrow the focus to a small number 
of candidate molecules that suppress inflammation and associated production of pro-
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inflammatory cytokines. While the mechanism or the exact molecule(s) by which protection 
is induced at this stage is not known it is exciting to think that hookworms are producing a 
small molecule secretome that may enhance host tolerance. As mentioned previously, final 
characterisation of the bioactive compounds is ongoing, with the ultimate aim of identifying 
suitable therapeutic candidates.  
8.7 Final Summary 
I have established that the small molecule complement produced by the dog hookworm A. 
caninum has anti-inflammatory activity. Through small molecule purification techniques, I 
have isolated molecules that fall within the therapeutic window.  
In addition to this, I have characterised using GCMS the small molecule secretome of A. 
caninum. This is the first time that a helminth has been described in this way. From my 
results, I speculate that hookworms employ similar strategies to suppress inflammation at 
the small molecule level as they do at the protein level. Hookworms likely produce multiple 
small molecules with distinct anti-inflammatory mechanisms of action, and these 
compounds probably act in synergy to induce immune tolerance and protect the worm 
against expulsion from its mammalian host.  
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LCMS 5600 Putative Peptide sequencing data 
Putative amino acid sequence† ID Match in NCBIprot 
and Swissprot 
databases 
Match against Ancylostoma caninum genome 
(ORF 50) 
VPLGGPDGGNGGH No significant match No significant match 
DGTNVGGSSGTI No significant match No significant match 
PHGKVFGMFLYEYAR No significant match No significant match 
SSGPATLM No significant match No significant match 
SYSMTGSTT No significant match No significant match 
LGGGVGCPF No significant match No significant match 
AHTETESKKFTTA No significant match No significant match 
NGGGVGGAAHPSP No significant match No significant match 
QHGEGPPPFLK No significant match No significant match 
HSHHDHYDMPYAGNM No significant match No significant match 
PGLGTGHGPATT No significant match No significant match 
NPGLFTGKG No significant match No significant match 
PDAGGGLTPSGPM No significant match No significant match 
PGLGPGSGSGNPAV No significant match No significant match 
CGHAAPF No significant match No significant match 
YGNGT No significant match No significant match 
HGGGSP No significant match No significant match 
VAGGPGSSGML No significant match No significant match 
LAPSAPAPTTNSPGK No significant match No significant match 
EMMEAEDDEVDE No significant match No significant match 
NPGLFTGKG No significant match No significant match 
HASPDGPNLPPMSASMTT No significant match No significant match 
PTYLGMGLHTGAQST No significant match No significant match 
VPLGGDGGNCGH No significant match No significant match 
GGLLKPLL No significant match No significant match 
ALNHCSVQ No significant match No significant match 
MIIKPQP No significant match No significant match 
DKPKLIL No significant match No significant match 
DVFLGMFLYEYAR No significant match No significant match 
   
   
   
GGPEGPPPFLK 100% match to 
immune-dominant 
hypodermal antigen 
100% match to immune-dominant 
hypodermal antigen 
   
†Where Alanine=A, Cysteine=C, Aspartic Acid=D, Glutamic Acid=E, Phenylalanine=F, Glycine=G, 
Histidine=H, Isoleucine=I, Lysine=K, Leucine=L, Methionine=M, Asparagine=N, Proline=P, Glutamine=Q, 
Arginine=R, Serine=S, Threonine=T, Valine=V, Tryptophan=W, Tyrosine=Y 
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Bio21 Institute – Polar Metabolite Standards 
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